losartan has been researched along with Disease Models, Animal in 532 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This focused review emphasizes the results of clinical trials using β-blocker, losartan potassium, and irbesartan in patients with Marfan syndrome and comments briefly on mechanisms of aortic remodeling, including fibrosis and transforming growth factor β signaling." | 9.01 | Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review. ( Eagle, KA; Hofmann Bowman, MA; Milewicz, DM, 2019) |
| "There are indicators that losartan, a drug widely used to treat arterial hypertension in humans, offers the first potential for primary prevention of clinical manifestations in Marfan syndrome." | 8.84 | Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? ( Cameron, DE; Carrel, T; Dietz, HC; Habashi, J; Matt, P; Van Eyk, JE, 2008) |
| "Topical Losartan1% significantly alleviates psoriasis by reducing AT1R and IL-17a expression." | 8.02 | Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation. ( Abdollahifar, MA; Dehpour, AR; Haddadi, NS; Hedayatyanfard, K; Kazemi, K; Shayan, M; Shokrian Zeini, M; Solaimanian, S, 2021) |
| "To investigate the effect of losartan on preventing bladder fibrosis and protecting renal function in rats with neurogenic paralysis bladder (NPB)." | 8.02 | Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. ( Bauer, SB; Chen, Y; He, YL; Ji, FP; Liu, EP; Ma, Y; Pu, QS; Wang, QW; Wang, Y; Wen, JG; Wen, YB; Xing, D; Yang, XH; Zhai, RQ, 2021) |
| "In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)." | 8.02 | Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021) |
| "To study the pro-apoptotic effect of Losartan on myocardial cells after acute myocardial infarction (AMI) in rats." | 7.96 | Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. ( Liu, R; Xin, LH; Yang, XW, 2020) |
| "Losartan prevented visceral allodynia and colonic hyperpermeability in rat IBS models." | 7.96 | Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. ( Miyagishi, S; Nozu, R; Nozu, T; Okumura, T; Takakusaki, K, 2020) |
| "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)." | 7.91 | Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019) |
| "We assessed the ability of poststroke losartan and captopril treatment to attenuate hematoma expansion and plasma extravasation after intracerebral hemorrhagic stroke in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 7.88 | Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. ( Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018) |
| "Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased." | 7.88 | Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion. ( Bie, P; Fialla, AD; Schaffalitzky de Muckadell, OB; Thiesson, HC, 2018) |
| " Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg-1·day-1) intraperitoneally for 2 weeks." | 7.85 | Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. ( Ali, SS; Gazzaz, ZJ; Ibraheem, MS; Murad, HA, 2017) |
| " Besides its antihypertensive effects, losartan can modulate inflammation in cardiovascular disease." | 7.85 | Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease. ( Aiba, Y; Hayashi, K; Kato, M; Koga, Y; Matsuda, S; Mochizuki, H; Nakamura, H; Niimura, F; Sekine, K; Suganuma, E; Takahashi, O; Ukawa, T, 2017) |
| "Stroke-prone spontaneously hypertensive (SHRSP) rats were administered losartan, amlodipine or saline for 6 or 16weeks at the onset of prehypertension." | 7.85 | Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model. ( He, DH; Lin, JX; Xie, Q; Xu, CS; Zhang, LM, 2017) |
| "Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension." | 7.83 | Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension. ( Morgan, DA; Peotta, V; Pitz, KM; Rahmouni, K; Rice, OM; Roghair, RD; Segar, JL, 2016) |
| "To investigate the potential protective effects of losartan on varicocele-induced germ cell apoptosis, 24 adult male Sprague Dawley rats were divided into three groups: a sham operation was performed in SHAM group, and experimental left varicocele was created in VAR and VAR + LOS groups." | 7.83 | Effects of losartan on experimental varicocele-induced testicular germ cell apoptosis. ( Bolat, D; Gunlusoy, B; Kose, T; Oltulu, F; Turan, T; Turk, NS; Uysal, A; Yigitturk, G, 2016) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "The neuroprotective effect of losartan in mouse glaucoma is associated with adaptive changes in the sclera expressed at the optic nerve head." | 7.81 | Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma. ( Berlinicke, CA; Jefferys, JJ; Kim, J; Kimball, EC; Mitchell, KL; Nguyen, C; Nguyen, TD; Oglesby, EN; Pease, ME; Pitha, IF; Quigley, HA; Steinhart, MR; Welsbie, DS, 2015) |
| "To investigate the mechanisms underlying the therapeutic effects of losartan on hyperuricemia-induced aortic atherosclerosis, in an experimental rabbit model." | 7.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| " We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 7.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 7.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "To assess the effect of losartan, angiotensin II receptor type 1 (AT1) receptor antagonist, on the pulmonary T helper (Th) cell polarization response in acute lung injury (ALI) mice." | 7.80 | [Losartan modulates T helper type 1 cells and T helper type 17 cells-mediated responses in a mouse model of lipopolysaccharide-induced acute lung injury]. ( Guo, F; He, H; Huang, Y; Liu, J; Liu, L; Qiu, H; Yang, Y; Yu, T; Zhang, P, 2014) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 7.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| "To investigate the mechanisms of losartan- and exercise training-induced improvements on endothelial dysfunction in heart failure." | 7.79 | Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms. ( Ellingsen, Ø; Haram, PM; Høydal, MA; Kemi, OJ; Wisløff, U, 2013) |
| "To evaluate the in vivo effect of losartan - an angiotensin II receptor antagonist - on the course of chronic colitis-associated fibrosis and on TGF-b1 expression." | 7.78 | Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012) |
| "Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model." | 7.78 | The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012) |
| "Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown." | 7.77 | Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. ( Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F, 2011) |
| " The AT(1) receptor for angiotensin II (Ang II) is involved in the renal expression of the nuclear factor-kappa B (NF-ΚB) during this nephrosis." | 7.77 | Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. ( Hernández-Fonseca, JP; Mosquera, J; Muñoz, M; Pedreañez, A; Rincón, J; Viera, N, 2011) |
| "Losartan potassium (INN losartan), an antihypertensive drug, has been shown to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of transforming growth factor beta." | 7.76 | Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. ( Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2010) |
| " This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels." | 7.76 | Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z, 2010) |
| "The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments." | 7.76 | Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| "To evaluate the effect of losartan-an angiotensin II type 1 receptor (AT1R) antagonist- and telmisartan-an AT1R blocker with insulin-sensitizing properties-, on the hepatic expression of plasminogen activator inhibitor-1 (PAI-1) in a rat model of nonalcoholic fatty liver disease (NAFLD)." | 7.75 | Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. ( Burgueño, AL; Carabelli, J; Pirola, CJ; Rosselli, MS; Schuman, M; Sookoian, S, 2009) |
| "The effect of centrally administered losartan, an AT(1) receptor antagonist, on gastric acid secretion and gastric cytoprotection was studied using different models of gastric ulcers, such as acetic acid-induced chronic gastric ulcers, pylorus ligation, ethanol-induced and stress-induced acute gastric ulcers and cysteamine hydrochloride-induced duodenal ulcer." | 7.75 | Effect of centrally administered losartan on gastric and duodenal ulcers in rats. ( Asad, M; Merai, AH; Prasad, VS, 2009) |
| "To investigate the effects of angiotensin-converting enzyme inhibitor (cilazapril) and angiotensin II type I receptor antagonist (losartan) on tubular and interstitial cell apoptosis and caspase-3 activity in rats with obstructive nephropathy after unilateral ureteral obstruction." | 7.74 | Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats. ( Cuzić, S; Knotek, M; Radović, N, 2008) |
| "To study the effect of angiotensin II (Ang II) and losartan, which is an angiotensin II type 1 receptor (AT1R) antagonist, on expression of AT2R in rat lung and the relationship between AT2R with acute lung injury (ALI)." | 7.74 | [Angiotensin II type 2 receptor expression and its modulation in angiotensin II induced acute lung injury in rat]. ( Chen, QH; Guo, T; Liu, L; Qiu, HB; Yang, Y; Zhao, MM; Zhu, Y, 2008) |
| " Rats with congestive heart failure (CHF) have increased protein level of NKCC2, which can be normalized by angiotensin II receptor type-1 (AT(1)) blockade with losartan." | 7.74 | Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. ( Brønd, L; Christensen, S; Hadrup, N; Jonassen, TE; Nielsen, JB; Nielsen, S; Praetorius, J; Torp, M, 2007) |
| " Angiotensin II (Ang II), one of the main vasoactive hormones of the renin-angiotensin system, has been associated with the development and progression of atherosclerosis." | 7.74 | Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. ( Badimon, L; Costales, P; Huesca-Gómez, C; Llorente-Cortés, V; Sendra, J, 2008) |
| " We examined the modulatory effect of the type 1 angiotensin II receptor blocker losartan on the ability of metabolic acidosis to stimulate ammonia production and secretion by mouse S2 proximal tubule segments." | 7.74 | Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis. ( Nagami, GT, 2008) |
| "Losartan attenuates BSO-induced hypertension, which appears to be mediated, in part, by angiotensin II and the prostanoid endothelium-derived factors." | 7.72 | Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. ( Abukhalaf, IK; Bayorh, MA; Eatman, D; Ganafa, AA; Silvestrov, N; Socci, RR, 2003) |
| "The aims of the present study were to determine the effects and mechanisms of angiotensin II (Ang II) on leukocyte-endothelium interactions and the role of Ang II in a novel model of ischemia/reperfusion (I/R) in the mouse colon." | 7.72 | Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. ( Jeppsson, B; Menger, MD; Riaz, AA; Sato, T; Schramm, R; Thorlacius, H; Wang, Y, 2004) |
| "We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT1a-R) 28 days after myocardial infarction." | 7.72 | Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. ( Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA, 2004) |
| "This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)." | 7.72 | [Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004) |
| "Losartan prevents apoptosis of pancreatic acinar cell by blocking AT1R during the development of pancreatic fibrosis." | 7.72 | Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. ( Dong, Y; Wang, XP; Wu, K; Wu, L; Zhang, R, 2004) |
| "Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II." | 7.71 | Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002) |
| "Cardiac hypertrophy is common in hypertension but its development is influenced by angiotensin II, sodium intake aldosterone, and the time of day blood pressure (BP) is elevated." | 7.71 | Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. ( Aubert, JF; Brunner, H; Morgan, T, 2001) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 7.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 7.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors." | 7.69 | Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995) |
| " In a single dose study in patients with heart failure, the AT1 antagonist losartan decreased mean arterial pressure and pulmonary arterial pressure and increased the cardiac index, with maximal effects at 25 mg/day." | 7.69 | Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. ( Fleck, E; Holzmeister, J; Neuss, M; Regitz-Zagrosek, V, 1995) |
| "We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats." | 7.69 | Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. ( Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC, 1994) |
| "Rats with a moderate to large myocardial infarction were treated with captopril (2 g/liter drinking water, n = 87) or losartan (2 g/liter drinking water, n = 96)." | 7.69 | Survival after myocardial infarction in rats: captopril versus losartan. ( Goldman, S; Johnson, CS; Milavetz, JJ; Morkin, E; Raya, TE, 1996) |
| " Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group." | 7.69 | Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996) |
| "Pleural fibrosis is associated with various inflammatory processes such as tuberculous pleurisy and bacterial empyema." | 5.48 | Inhibition of angiotensin II and calpain attenuates pleural fibrosis. ( Greer, PA; Huang, H; Ma, WL; Shi, HZ; Song, LJ; Su, Y; Xiang, F; Xin, JB; Xiong, L; Xu, JJ; Yang, J; Ye, H; Yu, F, 2018) |
| "Spontaneous seizures were video- and EEG-monitored in spontaneously hypertensive rats (SHRs) for a 16-week period after SE." | 5.43 | Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy. ( Atanasova, D; Ivanova, N; Kortenska, L; Lazarov, N; Lozanov, V; Mitreva, R; Pechlivanova, DM; Stoynev, A; Tchekalarova, JD, 2016) |
| " We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)." | 5.43 | Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. ( Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016) |
| "Losartan treatment partially attenuated these responses." | 5.40 | Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014) |
| "Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0." | 5.40 | Losartan improves measures of activity, inflammation, and oxidative stress in older mice. ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014) |
| "Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy." | 5.40 | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 5.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 5.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Cotreatment with GW9662 partly blunted the normalization of vascular dysfunction and inflammation." | 5.38 | Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat. ( Kobara, M; Nakata, T; Noda, K; Toba, H; Tojo, C; Wang, J, 2012) |
| "Losartan treatment was associated with significant impressive improvement in muscle strength and amelioration of fibrosis." | 5.38 | Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. ( Aga-Mizrachi, S; Barak, V; Brunschwig, Z; Elbaz, M; Ettinger, K; Kassis, I; Nevo, Y; Yanay, N, 2012) |
| "Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin." | 5.36 | Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010) |
| "Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0." | 5.36 | Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010) |
| "Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease." | 5.36 | Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010) |
| "Losartan has been proposed for the prevention of thoracic aortic aneurysm." | 5.35 | Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. ( Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2009) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 5.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Intimal hyperplasia is a serious problem after percutaneous transluminal coronary angioplasty (PTCA)." | 5.29 | Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Miyazawa, K; Shibata, N; Ujiie, A, 1996) |
| "Recent studies have demonstrated that blockade of the angiotensin II type 1 receptor with losartan decreases aortic damage in an animal model of Marfan syndrome (a KI mouse model with a pathogenic mutation in the gene coding for fibrillin-1)." | 5.14 | Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. ( Aegerter, P; Arnoult, F; Boileau, C; Bouffard, C; Collignon, P; Delrue, MA; Detaint, D; Dulac, Y; Faivre, LO; Gautier, M; Hoffman, I; Jondeau, G; Odent, S; Plauchu, H; Tchitchinadze, M; Tubach, F, 2010) |
| " This focused review emphasizes the results of clinical trials using β-blocker, losartan potassium, and irbesartan in patients with Marfan syndrome and comments briefly on mechanisms of aortic remodeling, including fibrosis and transforming growth factor β signaling." | 5.01 | Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review. ( Eagle, KA; Hofmann Bowman, MA; Milewicz, DM, 2019) |
| " Inhibition of TGFβ signaling by Losartan treatment greatly improved the phenotype of myopathies associated with laminin-α2-deficient congenital muscular dystrophy." | 4.88 | TGFβ signaling: its role in fibrosis formation and myopathies. ( Cohn, RD; MacDonald, EM, 2012) |
| "There are indicators that losartan, a drug widely used to treat arterial hypertension in humans, offers the first potential for primary prevention of clinical manifestations in Marfan syndrome." | 4.84 | Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? ( Cameron, DE; Carrel, T; Dietz, HC; Habashi, J; Matt, P; Van Eyk, JE, 2008) |
| "Losartan, the first potent and specific AT1 receptor antagonist, is orally active with a long duration of action and therefore has potential for treatment of chronic diseases, such as hypertension and heart failure." | 4.79 | The preclinical basis of the therapeutic evaluation of losartan. ( Chiu, AT; Smith, RD; Timmermans, PB; Wong, PC, 1995) |
| "Topical Losartan1% significantly alleviates psoriasis by reducing AT1R and IL-17a expression." | 4.02 | Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation. ( Abdollahifar, MA; Dehpour, AR; Haddadi, NS; Hedayatyanfard, K; Kazemi, K; Shayan, M; Shokrian Zeini, M; Solaimanian, S, 2021) |
| "To investigate the effect of losartan on preventing bladder fibrosis and protecting renal function in rats with neurogenic paralysis bladder (NPB)." | 4.02 | Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. ( Bauer, SB; Chen, Y; He, YL; Ji, FP; Liu, EP; Ma, Y; Pu, QS; Wang, QW; Wang, Y; Wen, JG; Wen, YB; Xing, D; Yang, XH; Zhai, RQ, 2021) |
| "In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)." | 4.02 | Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021) |
| "To study the pro-apoptotic effect of Losartan on myocardial cells after acute myocardial infarction (AMI) in rats." | 3.96 | Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. ( Liu, R; Xin, LH; Yang, XW, 2020) |
| "Losartan prevented visceral allodynia and colonic hyperpermeability in rat IBS models." | 3.96 | Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. ( Miyagishi, S; Nozu, R; Nozu, T; Okumura, T; Takakusaki, K, 2020) |
| "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)." | 3.91 | Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019) |
| "Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan." | 3.91 | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. ( Balogh, DB; Barczi, A; Denes, A; Farkas, T; Fekete, A; Hodrea, J; Hosszu, A; Lenart, L; Lenart, N; Szabo, AJ; Szigeti, K, 2019) |
| "This study confirms that angiotensin II type 1 receptor antagonism (losartan) decreases aortic aneurysm growth in a mouse model of MFS." | 3.88 | The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome. ( Clijsters, M; Herijgers, P; Meuris, B; Schepens, J; Verbrugghe, P; Verhoeven, J; Vervoort, D, 2018) |
| " (Cucurbitaceae) is one of the most valued plant species to treat cardiovascular diseases, including hypertension." | 3.88 | Acetone fraction from Sechium edule (Jacq.) S.w. edible roots exhibits anti-endothelial dysfunction activity. ( Arrellín, G; Barrita-Cruz, GJ; Castro-Martínez, G; Fragoso, G; Hernández, B; Jiménez-Ferrer, JE; Lombardo-Earl, G; Medina-Campos, ON; Méndez-Martínez, M; Pedraza-Chaverri, J; Ramírez, CC; Rosas, G; Santana, MA; Trejo-Moreno, C; Zamilpa, A, 2018) |
| " Therefore, the aim of this study was to test whether avocado oil counteracts, to a similar degree as the Ang-II blocker losartan, the deleterious effects of hypertension on blood pressure, renal vascular performance, kidney mitochondrial function, and oxidative stress." | 3.88 | Comparative effects of avocado oil and losartan on blood pressure, renal vascular function, and mitochondrial oxidative stress in hypertensive rats. ( Cortés-Rojo, C; Godínez-Hernández, D; González-Hernández, JC; Hernández de la Paz, JL; Márquez-Ramírez, CA; Ortiz-Avila, O; Raya-Farias, A; Rodríguez-Orozco, AR; Saavedra-Molina, A; Salgado-Garciglia, R, 2018) |
| "We assessed the ability of poststroke losartan and captopril treatment to attenuate hematoma expansion and plasma extravasation after intracerebral hemorrhagic stroke in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 3.88 | Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. ( Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018) |
| "Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased." | 3.88 | Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion. ( Bie, P; Fialla, AD; Schaffalitzky de Muckadell, OB; Thiesson, HC, 2018) |
| " Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg-1·day-1) intraperitoneally for 2 weeks." | 3.85 | Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. ( Ali, SS; Gazzaz, ZJ; Ibraheem, MS; Murad, HA, 2017) |
| " Besides its antihypertensive effects, losartan can modulate inflammation in cardiovascular disease." | 3.85 | Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease. ( Aiba, Y; Hayashi, K; Kato, M; Koga, Y; Matsuda, S; Mochizuki, H; Nakamura, H; Niimura, F; Sekine, K; Suganuma, E; Takahashi, O; Ukawa, T, 2017) |
| "Stroke-prone spontaneously hypertensive (SHRSP) rats were administered losartan, amlodipine or saline for 6 or 16weeks at the onset of prehypertension." | 3.85 | Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model. ( He, DH; Lin, JX; Xie, Q; Xu, CS; Zhang, LM, 2017) |
| "Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart." | 3.85 | Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017) |
| "Chronic heart failure (CHF) increases sympathoexcitation through angiotensin II (ANG II) receptors (AT1R) in the paraventricular nucleus (PVN)." | 3.83 | Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus. ( Dong, Z; Huang, Q; Hultström, M; Lai, EY; Li, H; Qi, Y; Wang, H; Wang, R; Wei, X; Wilcox, CS; Wu, H; Zhou, R; Zhou, X, 2016) |
| "Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension." | 3.83 | Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension. ( Morgan, DA; Peotta, V; Pitz, KM; Rahmouni, K; Rice, OM; Roghair, RD; Segar, JL, 2016) |
| "To investigate the potential protective effects of losartan on varicocele-induced germ cell apoptosis, 24 adult male Sprague Dawley rats were divided into three groups: a sham operation was performed in SHAM group, and experimental left varicocele was created in VAR and VAR + LOS groups." | 3.83 | Effects of losartan on experimental varicocele-induced testicular germ cell apoptosis. ( Bolat, D; Gunlusoy, B; Kose, T; Oltulu, F; Turan, T; Turk, NS; Uysal, A; Yigitturk, G, 2016) |
| " β-AR overstimulation with associated cardiac hypertrophy and increased vasoconstrictor response to phenylephrine in aorta were modeled in rats by 7-day isoproterenol treatment." | 3.83 | Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. ( Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016) |
| "When compared with MDSC transplantation alone, MDSC/losartan treatment resulted in significantly decreased scar formation, an increase in the number of regenerating myofibers, and improved functional recovery after muscle contusions." | 3.83 | The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries. ( Fu, FH; Huard, J; Kawakami, Y; Kobayashi, M; Ota, S; Otsuka, T; Terada, S, 2016) |
| "Losartan suppressed the implant surface area of experimental endometriosis in rats and reduced the levels of plasma VEGF, TNF-α, PTX-3 and CRP." | 3.81 | Regression of experimental endometriotic implants in a rat model with the angiotensin II receptor blocker losartan. ( Ates, U; Cakmak, B; Cavusoglu, T; Erbaş, O; Meral, A; Nacar, MC, 2015) |
| "The anti-atherosclerosis effects of Ang-(1-7) and losartan in early lesion formation were equivalent." | 3.81 | Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice. ( Dong, M; Guan, J; Meng, X; Niu, R; Sun, Y; Yang, J; Yang, X; Zhang, C; Zhang, Y, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Angiotensin II (Ang II) and aldosterone contribute to hypertension, oxidative stress and cardiovascular damage, but the contributions of aldosterone during Ang II-dependent hypertension are not well defined because of the difficulty to assess each independently." | 3.81 | Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. ( Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP, 2015) |
| "To elucidate the reliability of MRI as a non-invasive tool for assessing in vivo muscle health and pathological amelioration in response to Losartan (Angiotensin II Type 1 receptor blocker) in DyW mice (mouse model for Laminin-deficient Congenital Muscular Dystrophy Type 1A)." | 3.81 | Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). ( Accorsi, A; Girgenrath, M; Kumar, A; Vohra, R; Walter, G, 2015) |
| "The neuroprotective effect of losartan in mouse glaucoma is associated with adaptive changes in the sclera expressed at the optic nerve head." | 3.81 | Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma. ( Berlinicke, CA; Jefferys, JJ; Kim, J; Kimball, EC; Mitchell, KL; Nguyen, C; Nguyen, TD; Oglesby, EN; Pease, ME; Pitha, IF; Quigley, HA; Steinhart, MR; Welsbie, DS, 2015) |
| "To investigate the mechanisms underlying the therapeutic effects of losartan on hyperuricemia-induced aortic atherosclerosis, in an experimental rabbit model." | 3.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| "We used myocytes from Wistar, SHR, losartan-treated SHR (Los-SHR), and Angiotensin II (Ang II)-induced cardiac hypertrophy." | 3.80 | Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system. ( Aiello, EA; Caldiz, CI; Ciancio, MC; De Giusti, VC; Orlowski, A, 2014) |
| " We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 3.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
| "Effects of intravenous LKP infusion and then superimposed losartan (AT1R antagonist) on MAP, total renal (RBF, Transonic probe) and renal medullary blood flows (laser-Doppler), and on renal excretion, were examined in anesthetized (1) Wistar rats with acute norepinephrine-induced hypertension, untreated or pretreated with AT2R antagonist (PD 123319) and (2) spontaneously hypertensive rats (SHR) maintained on standard or high-sodium (HS) diet." | 3.80 | Vascular effects of a tripeptide fragment of novokinine in hypertensive rats: Mechanism of the hypotensive action. ( Bądzyńska, B; Kompanowska-Jezierska, E; Lipkowski, AW; Sadowski, J, 2014) |
| "Losartan treatment improved PVS-associated pulmonary hypertension and intimal hyperplasia and might be a beneficial prophylactic therapy for patients at high risk of developing PVS after pulmonary vein surgery." | 3.80 | Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis. ( Caldarone, CA; Coles, JG; Fu, YY; Ide, H; Kato, H; Maynes, JT; Teichert, AM; Weisel, RD; Zhu, J, 2014) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 3.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "To assess the effect of losartan, angiotensin II receptor type 1 (AT1) receptor antagonist, on the pulmonary T helper (Th) cell polarization response in acute lung injury (ALI) mice." | 3.80 | [Losartan modulates T helper type 1 cells and T helper type 17 cells-mediated responses in a mouse model of lipopolysaccharide-induced acute lung injury]. ( Guo, F; He, H; Huang, Y; Liu, J; Liu, L; Qiu, H; Yang, Y; Yu, T; Zhang, P, 2014) |
| "Adjuvant arthritis was induced in rats with and without prophylactic losartan (AT1R antagonist) treatment." | 3.79 | Angiotensin II Type 1 receptor blockade protects endothelium-derived hyperpolarising factor-mediated relaxation in a rat model of monoarthritis. ( Dunning, L; Ferrell, WR; Lockhart, JC; Mackenzie, A, 2013) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 3.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| "Telmisartan and losartan, angiotensin II type 1 (AT1) receptor antagonists, are used to manage hypertension." | 3.79 | Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats. ( Kobara, M; Nakata, T; Ohigashi, M; Toba, H; Wang, J, 2013) |
| "To investigate the mechanisms of losartan- and exercise training-induced improvements on endothelial dysfunction in heart failure." | 3.79 | Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms. ( Ellingsen, Ø; Haram, PM; Høydal, MA; Kemi, OJ; Wisløff, U, 2013) |
| " In this study, we investigated the cardioprotective effects of combination therapy with low-dose simvastatin and low-dose losartan using a rat myocardial infarction model." | 3.78 | Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. ( Abe, S; Arikawa, T; Asanuma, H; Hikichi, Y; Inoue, T; Kikuchi, M; Kitakaze, M; Node, K; Sanada, S; Sohma, R; Taguchi, I; Toyoda, S, 2012) |
| " We here examined the effects of QL on the development of cardiac hypertrophy through comparing those of losartan in C57BL/6 mice underlying transverse aorta constriction for 4 weeks." | 3.78 | Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. ( Ge, J; Gong, H; Jia, Z; Li, L; Li, Y; Liang, Y; Lin, L; Wei, J; Wu, J; Wu, Y; Ye, Y; Zhou, J; Zhou, N; Zou, Y, 2012) |
| "To evaluate the in vivo effect of losartan - an angiotensin II receptor antagonist - on the course of chronic colitis-associated fibrosis and on TGF-b1 expression." | 3.78 | Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012) |
| " Treatment with losartan significantly attenuated TAC-induced cardiac hypertrophy, in parallel with decreased expression of RANKL, TNF-α, IL-1α, and IL-1β." | 3.78 | Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. ( Abel, ED; Ahn, J; Kim, HS; Kim, J; Lee, SH; Lee, WS; Min, JK; Ock, S; Oh, GT; Oh, JG; Park, H; Park, WJ; Rho, J; Son, JW; Yang, DK, 2012) |
| "67 Mb heterozygous deletion including the Eln gene, presented with a generalized arteriopathy, hypertension, and cardiac hypertrophy, associated with elevated angiotensin II (angII), oxidative stress parameters, and Ncf1 expression." | 3.78 | Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome. ( Bustelo, XR; Campuzano, V; Coustets, M; Francke, U; Menacho-Márquez, M; Nevado, J; Pérez-Jurado, LA; Sánchez-Rodríguez, C; Segura-Puimedon, M; Terrado, V, 2012) |
| "Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model." | 3.78 | The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012) |
| " The complex demonstrated efficiency in hypertension control, presenting antagonist action on the pressure effect of angiotensin II within 30 h, as compared to Los alone, 6h, indicating that inclusion of Los in HPβCD enhanced the extent and duration of its antagonistic action." | 3.77 | Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. ( Braga, AN; de Paula, WX; Denadai, AM; Santoro, MM; Santos, RA; Sinisterra, RD, 2011) |
| " The aim of this work was to assess the impact of hemin (heme oxygenase-1 inducer) on NADPH oxidase activation, cardiac oxidative stress, and development of fibrosis in a rat model of renovascular hypertensive cardiomyopathy in comparison to an anti-hypertensive reference treatment with losartan." | 3.77 | Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. ( Belmokhtar, K; Bonnet, P; Eder, V; Khamis, G; Machet, MC; Vourc'h, P; Worou, ME, 2011) |
| "Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown." | 3.77 | Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. ( Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F, 2011) |
| " The AT(1) receptor for angiotensin II (Ang II) is involved in the renal expression of the nuclear factor-kappa B (NF-ΚB) during this nephrosis." | 3.77 | Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. ( Hernández-Fonseca, JP; Mosquera, J; Muñoz, M; Pedreañez, A; Rincón, J; Viera, N, 2011) |
| "Statins are similar to losartan in attenuating aortic root dilation in a mouse model of Marfan syndrome." | 3.77 | Pravastatin reduces Marfan aortic dilation. ( Black, A; Byrne, J; Dietz, HC; Hill, AD; Huuskonen, V; Kay, E; Kearney, S; McAllister, H; McGuinness, J; McLoughlin, D; Redmond, JM; Terzo, E, 2011) |
| " We hypothesized that insulin-induced relaxation and the associated proline-rich tyrosine kinase 2 (Pyk2)/Src/Akt pathway would be abnormal in aortas from the Goto-Kakizaki (GK) type 2 diabetic rat, which exhibits hyperglycemia/insulin resistance, and that losartan treatment of such rats (25 mg·kg(-1)·day(-1) for 2 wk) would correct these abnormalities." | 3.77 | Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K, 2011) |
| "Losartan potassium (INN losartan), an antihypertensive drug, has been shown to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of transforming growth factor beta." | 3.76 | Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. ( Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2010) |
| " The aim of the current study was to evaluate the effects of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'(1H-tetrazol-5-yl)-biphenil-4-yl)methyl]imidazole) and telmisartan (49-[(1,49-dimethyl-29-propyl[2,69-bi-1H-benzimidazo]-19-yl)methyl]-[1,19-biphenyl]-2-carboxylic acid), the angiotensin AT1 receptor antagonists which are widely used in clinical practice, on the protective action of conventional antiepileptic drugs (carbamazepine, phenytoin, valproate and phenobarbital) against maximal electroshock-induced seizures in mice." | 3.76 | Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. ( Czuczwar, SJ; Jakubus, T; Janowska, A; Tochman-Gawda, A; Łukawski, K, 2010) |
| "6 hamsters (DL) with losartan, an AT1 receptor blocker, affects D1 receptor density in the striatum and nucleus tractus solitarius (NTS) and normalizes ventilation during exposure to air, hypoxia, following hypoxia, and hypercapnia, Ventilation was evaluated using plethysmography." | 3.76 | In dystrophic hamsters losartan affects control of ventilation and dopamine D1 receptor density. ( Schlenker, EH, 2010) |
| " This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels." | 3.76 | Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z, 2010) |
| "The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments." | 3.76 | Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| "To investigate the effect of ACE inhibitor, lisinopril and AT1 blocker, losartan, on the obstructive pancreatitis in rat." | 3.76 | The effect of anti-hypertensive drugs on the obstructive pancreatitis in rats. ( Ramalho, FS; Ramalho, LZ; Silva, Rde B, 2010) |
| "To evaluate the effect of losartan-an angiotensin II type 1 receptor (AT1R) antagonist- and telmisartan-an AT1R blocker with insulin-sensitizing properties-, on the hepatic expression of plasminogen activator inhibitor-1 (PAI-1) in a rat model of nonalcoholic fatty liver disease (NAFLD)." | 3.75 | Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. ( Burgueño, AL; Carabelli, J; Pirola, CJ; Rosselli, MS; Schuman, M; Sookoian, S, 2009) |
| "The purpose of this study was to evaluate the involvement of central angiotensin II (ANG II) and ANG II type 1 (AT(1)) receptors in systemic release of arginine vasopressin (AVP) and blood pressure regulation during endotoxemia." | 3.75 | Involvement of central angiotensin II type 1 receptors in LPS-induced systemic vasopressin release and blood pressure regulation in rats. ( Kasai, T; Shimizu, F; Takamata, A, 2009) |
| "The effect of centrally administered losartan, an AT(1) receptor antagonist, on gastric acid secretion and gastric cytoprotection was studied using different models of gastric ulcers, such as acetic acid-induced chronic gastric ulcers, pylorus ligation, ethanol-induced and stress-induced acute gastric ulcers and cysteamine hydrochloride-induced duodenal ulcer." | 3.75 | Effect of centrally administered losartan on gastric and duodenal ulcers in rats. ( Asad, M; Merai, AH; Prasad, VS, 2009) |
| "To investigate the effects of angiotensin-converting enzyme inhibitor (cilazapril) and angiotensin II type I receptor antagonist (losartan) on tubular and interstitial cell apoptosis and caspase-3 activity in rats with obstructive nephropathy after unilateral ureteral obstruction." | 3.74 | Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats. ( Cuzić, S; Knotek, M; Radović, N, 2008) |
| "To study the effect of angiotensin II (Ang II) and losartan, which is an angiotensin II type 1 receptor (AT1R) antagonist, on expression of AT2R in rat lung and the relationship between AT2R with acute lung injury (ALI)." | 3.74 | [Angiotensin II type 2 receptor expression and its modulation in angiotensin II induced acute lung injury in rat]. ( Chen, QH; Guo, T; Liu, L; Qiu, HB; Yang, Y; Zhao, MM; Zhu, Y, 2008) |
| "The purpose of this study was to evaluate the feasibility of noninvasive imaging of angiotensin II (AT) receptor upregulation in a mouse model of post-myocardial infarction (MI) heart failure (HF)." | 3.74 | Noninvasive imaging of angiotensin receptors after myocardial infarction. ( Bjurgert, E; Cuthbertson, A; Hofstra, L; Indrevoll, B; Kindberg, GM; Krasieva, TB; Lovhaug, D; Narula, J; Narula, N; Petersen, LB; Petrov, AD; Reutelingsperger, CP; Solbakken, M; Tromberg, BJ; Vannan, MA; Verjans, JW, 2008) |
| "Our previous studies demonstrated that peripheral overexpression of angiotensin II (ANG II) type 2 receptors (AT(2)R) prevents hypertension-induced cardiac hypertrophy and remodeling without altering high blood pressure." | 3.74 | Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. ( Gao, Y; Grobe, JL; Katovich, MJ; Li, H; Raizada, MK; Sumners, C, 2007) |
| "Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8." | 3.74 | Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007) |
| " Rats with congestive heart failure (CHF) have increased protein level of NKCC2, which can be normalized by angiotensin II receptor type-1 (AT(1)) blockade with losartan." | 3.74 | Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. ( Brønd, L; Christensen, S; Hadrup, N; Jonassen, TE; Nielsen, JB; Nielsen, S; Praetorius, J; Torp, M, 2007) |
| "The pulmonary vasoconstriction induced by acute hypoxia was significantly attenuated during losartan infusion, while Psa, SVR, CO, pH, PaCO(2), PaO(2) and base excess did not differ between groups." | 3.74 | The role of angiotensin II receptor-1 blockade in the hypoxic pulmonary vasoconstriction response in newborn piglets. ( Bancalari, E; Camelo, JS; Camelo, SH; Devia, C; Hehre, D; Suguihara, C, 2008) |
| " The purpose of this study was to investigate the anti-inflammatory effect of a selective AT1 receptor antagonist, losartan, on endotoxin-induced uveitis (EIU) and compare the effect on experimental autoimmune uveoretinitis (EAU)." | 3.74 | Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats. ( Iwabuchi, K; Iwata, D; Jin, XH; Kitaichi, N; Miyazaki, A; Morohashi, T; Ohgami, K; Ohno, S; Onoé, K, 2008) |
| " Angiotensin II (Ang II), one of the main vasoactive hormones of the renin-angiotensin system, has been associated with the development and progression of atherosclerosis." | 3.74 | Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. ( Badimon, L; Costales, P; Huesca-Gómez, C; Llorente-Cortés, V; Sendra, J, 2008) |
| " We examined the modulatory effect of the type 1 angiotensin II receptor blocker losartan on the ability of metabolic acidosis to stimulate ammonia production and secretion by mouse S2 proximal tubule segments." | 3.74 | Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis. ( Nagami, GT, 2008) |
| " Ischemia was induced by right femoral artery ligature in Wistar Kyoto rats (WKY) or spontaneously hypertensive rats (SHR) treated with or without angiotensin-converting enzyme inhibitor (Perindopril, 0." | 3.74 | Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. ( Cochain, C; Duriez, M; Lévy, BI; Loinard, C; Mees, B; Silvestre, JS; Vilar, J; You, D, 2008) |
| "The aim of our study was to investigate the changes in the early stages (at weeks 2 and 4) of experimental acute renal failure after short-time ischemia-reperfusion (I/R) compared with the impact of Losartan." | 3.73 | Morphological changes in experimental postischemic rat kidney. A pilot study. ( Arend, A; Aunapuu, M; Kühnel, W; Ots, M; Pechter, U, 2005) |
| "In pregnancy there is an attenuated response to vasoconstrictors and pressor agents, including Angiotensin II (Ang II)." | 3.73 | Renal vascular responses in an experimental model of preeclampsia. ( Bobadilla Lugo, RA; López Sanchez, P; Pérez-Alvarez, VM; Robledo, LA, 2005) |
| "Rats underwent unilateral ureteral obstruction and were given either drinking water or losartan for 21 days." | 3.73 | Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. ( Chen, J; El Chaar, M; Felsen, D; Kellner, D; Poppas, D; Richardson, I; Seshan, SV; Vaughan, ED, 2006) |
| "Our data do not support a role for the AT1 receptor in the progression of atherosclerosis in this model, since blockade with losartan did not alter plaque distribution." | 3.73 | Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE-/- mice. ( Bergström, G; Gan, LM; Johansson, ME; Skøtt, O; Wickman, A, 2006) |
| "Hypertension was induced in Sprague-Dawley rats by infusing angiotensin II (200 ng/kg per min) through osmotic pumps for 12 days." | 3.72 | NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. ( de Champlain, J; El Midaoui, A; Laplante, MA; Wu, R, 2003) |
| "Losartan attenuates BSO-induced hypertension, which appears to be mediated, in part, by angiotensin II and the prostanoid endothelium-derived factors." | 3.72 | Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. ( Abukhalaf, IK; Bayorh, MA; Eatman, D; Ganafa, AA; Silvestrov, N; Socci, RR, 2003) |
| "The aims of the present study were to determine the effects and mechanisms of angiotensin II (Ang II) on leukocyte-endothelium interactions and the role of Ang II in a novel model of ischemia/reperfusion (I/R) in the mouse colon." | 3.72 | Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. ( Jeppsson, B; Menger, MD; Riaz, AA; Sato, T; Schramm, R; Thorlacius, H; Wang, Y, 2004) |
| "We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT1a-R) 28 days after myocardial infarction." | 3.72 | Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. ( Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA, 2004) |
| "This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)." | 3.72 | [Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004) |
| " Since, losartan, an AT1 receptor antagonist, has been shown to attenuate the L-NAME-induced increase in blood pressure, we undertook the present studies to evaluate whether losartan-induced decreased blood pressure in this model of hypertension is associated with attenuation of enhanced expression of Gi proteins and adenylyl cyclase signalling." | 3.72 | Losartan-induced attenuation of blood pressure in L-NAME hypertensive rats is associated with reversal of the enhanced expression of Gi alpha proteins. ( Anand-Srivastava, MB; Hashim, S, 2004) |
| "To investigate the trend and potential pathogenic role of nuclear factor (NF)-kappaB P(65)/Rel-A mRNA and angiotensin-II (AngII) receptor type 1 (AT(1)) proteins expression, and the relativity between them in early stage of renal tubulointerstitial lesions in young rats with adriamycin nephrosis and the interfering effects of treatment with angiotensin converting enzyme inhibitor (ACEI) benazepril and ACEI combined with AngII type 1 receptor antagonist (AT(1)RA) Losartan." | 3.72 | [Relativity of nuclear factor-kappaB (P65/Rel-A) and angiotensin II type 1 receptor expression in early stage of lesions of adriamycin nephrosis in young rats and the effects of intervention]. ( Li, H; Li, WW; Li, XH; Li, Z; Ma, H; Meng, QH; Wang, XH, 2004) |
| "Losartan prevents apoptosis of pancreatic acinar cell by blocking AT1R during the development of pancreatic fibrosis." | 3.72 | Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. ( Dong, Y; Wang, XP; Wu, K; Wu, L; Zhang, R, 2004) |
| "Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II." | 3.71 | Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002) |
| "We randomized 24 adult cardiac troponin T (cTnT-Q(92)) mice, which exhibit myocyte disarray and interstitial fibrosis, to treatment with losartan or placebo and included 12 nontransgenic mice as controls." | 3.71 | Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. ( Bachireddy, P; Entman, M; Evans, A; Lim, DS; Lutucuta, S; Marian, AJ; Roberts, R; Youker, K, 2001) |
| " To evaluate this effect in vivo, apolipoprotein E(-/-) mice were randomly assigned to receive standard chow, a high-cholesterol diet, or a high-cholesterol diet with hypertension induced by angiotensin II infusion for 8 weeks." | 3.71 | Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. ( Aikawa, M; Hill, CC; Lee, RT; Libby, P; Sakamoto, H; Taylor, WR; Weiss, D, 2001) |
| "Cardiac hypertrophy is common in hypertension but its development is influenced by angiotensin II, sodium intake aldosterone, and the time of day blood pressure (BP) is elevated." | 3.71 | Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. ( Aubert, JF; Brunner, H; Morgan, T, 2001) |
| "A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion." | 3.71 | Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor. ( Browne, AE; Chatterjee, K; Lee, RJ; Parmley, WW; Sievers, RE; Sun, Y; Zhu, B, 2001) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 3.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "The three treatments regressed cardiac hypertrophy and normalized sodium/hydrogen ion exchange exchange activity in SHR, and losartan was the most effective treatment for reversing cardiac hypertrophy, despite producing effects on blood pressure and sodium/hydrogen exchange activity similar to that of other antihypertensive drugs." | 3.71 | Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats. ( Alvarez, BV; Cingolani, HE; De Hurtado, MC; Ennis, IL, 2002) |
| "The potential antithrombotic action of losartan, an AT1 receptor antagonist, administered to two-kidney, one-clip rats (2K1C) in an experimental model of venous thrombosis was evaluated." | 3.70 | Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. ( Buczko, W; Chabielska, E; Pawlak, R; Rółkowski, R; Wollny, T, 1999) |
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 3.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors." | 3.69 | Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995) |
| " In a single dose study in patients with heart failure, the AT1 antagonist losartan decreased mean arterial pressure and pulmonary arterial pressure and increased the cardiac index, with maximal effects at 25 mg/day." | 3.69 | Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. ( Fleck, E; Holzmeister, J; Neuss, M; Regitz-Zagrosek, V, 1995) |
| "We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats." | 3.69 | Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. ( Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC, 1994) |
| "We have previously shown that rats with congenital, unilateral hydronephrosis exhibit a reduction in GFR that returns to normal when either the renin angiotensin system or thromboxane A2 (TxA2) is blocked." | 3.69 | Alterations in glomerular dynamics in congenital, unilateral hydronephrosis. ( Hanss, BG; Lewy, JE; Vari, RC, 1994) |
| "Rats with a moderate to large myocardial infarction were treated with captopril (2 g/liter drinking water, n = 87) or losartan (2 g/liter drinking water, n = 96)." | 3.69 | Survival after myocardial infarction in rats: captopril versus losartan. ( Goldman, S; Johnson, CS; Milavetz, JJ; Morkin, E; Raya, TE, 1996) |
| "We compared the consequences of chronic angiotensin-converting enzyme (ACE) inhibition with quinapril and of specific AT1 blockade with losartan in a renin-dependent model of hypertension, the (mRen2)27 transgenic rats (TG)." | 3.69 | Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats. ( Bizollon, CA; Gharib, C; Lantelme, P; Lo, M; Mullins, JJ; Sassard, J, 1996) |
| " Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group." | 3.69 | Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996) |
| " Besides, its cholesterol-lowering effect, the ability of simvastatin to ameliorate endothelial dysfunction through increasing NO bioavailability and through suppression of oxidative stress and vascular inflammation may play an important role in these effects." | 2.79 | Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein. ( Abdel-Zaher, AO; Abudahab, LH; Elbakry, MH; Elkoussi, AE; Elsayed, EA, 2014) |
| "Transforming growth factor beta 1 is a key molecule in the development of postoperative fibrosis." | 2.58 | Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation. ( Bolia, I; Briggs, K; Huard, J; Lowe, WR; Philippon, MJ; Utsunomiya, H, 2018) |
| "Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs." | 2.43 | Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. ( Chiurchiu, C; Parvanova, A; Remuzzi, G; Ruggenenti, P, 2005) |
| "Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension." | 2.40 | Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. ( Morsing, P, 1999) |
| "Losartan is an auspicious candidate, as it has demonstrated an antifibrotic effect in other organs." | 1.91 | The effect of losartan on the development of post-traumatic joint stiffness in a rat model. ( Baranowski, A; Drees, P; Gercek, E; Harper, A; Mickan, T; Müller, L; Ritz, U; Rommens, PM; Slotina, E; Truffel, S; Wegner, E; Wunderlich, F, 2023) |
| " In addition, the nephrectomized db /db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II-receptor antagonist losartan." | 1.72 | Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease. ( Kitamoto, M; Konishi, N; Maekawa, M; Maekawa, T; Nakagawa, T; Ohta, T; Sasase, T; Takagi, K; Takeuchi, S; Toyoda, K; Yamada, T, 2022) |
| "Losartan treatment for 4 weeks is associated with lower AT1R protein level, Nitrotyrosine, and Tau protein in the frontal cortex of aged IL-10-/- mice." | 1.72 | Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice. ( Abadir, PM; Cosarderelioglu, C; Saleh, N; Vajapey, R; Walston, J, 2022) |
| "Hypertension is the major risk factor for SVDs, but how hypertension damages the brain microcirculation is unclear." | 1.62 | Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease. ( Dabertrand, F; Ferris, HR; Greenstein, AS; Harraz, OF; Hill-Eubanks, DC; Koide, M; Longden, TA; Nelson, MT; Wellman, GC, 2021) |
| "Paricalcitol treatment suppressed the induction of these RAS components, whereas vitamin D deficiency enhanced the activation of the lung RAS." | 1.62 | Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung. ( Chang, J; Du, J; Ge, X; Li, X; Li, YC; Liu, W; Nie, H; Sun, Y; Wei, X; Xun, Z, 2021) |
| "Podocyte loss and proteinuria are both key features of human diabetic nephropathy (DN)." | 1.56 | Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. ( Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA, 2020) |
| "Losartan-treated mice (10 mg/kg per day, drinking water, 7 months) received intracerebroventricular (1 month) administration of vehicle or AT2R antagonist PD123319 (1." | 1.56 | AT2R's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease. ( Fermigier, A; Hamel, E; Lacalle-Aurioles, M; Royea, J; Trigiani, LJ, 2020) |
| "Losartan treatment attenuated mechanical allodynia significantly." | 1.56 | Losartan attenuates neuroinflammation and neuropathic pain in paclitaxel-induced peripheral neuropathy. ( Diallo, M; Kalynovska, N; Palecek, J; Sotakova-Kasparova, D, 2020) |
| "Cerebral vasospasm was induced by the use of an established double-injection rat model." | 1.56 | The Role of Losartan as a Potential Neuroregenerative Pharmacological Agent after Aneurysmal Subarachnoid Haemorrhage. ( Andereggen, L; Kashefiolasl, S; Konczalla, J; Marbacher, S; Mrosek, J; Wanderer, S, 2020) |
| "In type 2 cardiorenal syndrome, chronic heart failure is thought to cause or promote chronic kidney disease; however, the underlying mechanisms remain poorly understood." | 1.51 | Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome. ( Hong, X; Hou, FF; Liao, Y; Liu, Y; Miao, J; Wang, C; Zhao, Y; Zhou, L, 2019) |
| "Losartan-treated human dermal fibroblasts displayed decreased contractile activity, migration, and gene expression of transforming growth factor-β1, collagen I, and monocyte chemoattractant protein-1 relative to controls (p < 0." | 1.51 | Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. ( Bezuhly, M; Boudreau, C; Gratzer, P; LeVatte, T; Marshall, J; Midgen, C; Murphy, A, 2019) |
| "Pleural fibrosis is associated with various inflammatory processes such as tuberculous pleurisy and bacterial empyema." | 1.48 | Inhibition of angiotensin II and calpain attenuates pleural fibrosis. ( Greer, PA; Huang, H; Ma, WL; Shi, HZ; Song, LJ; Su, Y; Xiang, F; Xin, JB; Xiong, L; Xu, JJ; Yang, J; Ye, H; Yu, F, 2018) |
| "Treatment with losartan reduced urinary protein excretion and blood lipids (triglyceride and cholesterol) dose-dependently in both studies." | 1.48 | Losartan improves renal function and pathology in obese ZSF-1 rats. ( Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018) |
| " Losartan carboxylic acid (LCA), the potent AT1 blocker metabolite of losartan, suffers from poor bioavailability and brain access." | 1.48 | Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats. ( Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB, 2018) |
| "Uric acid plays an important role in CVD pathogenesis by inducing inflammatory COX-2 and ROS pathways." | 1.46 | Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells. ( Çetin, A; Kırça, M; Oğuz, N; Yeşilkaya, A, 2017) |
| "Calcitriol has important effects on cellular differentiation and proliferation, as well as on the regulation of the renin gene." | 1.46 | Calcitriol reduces kidney development disorders in rats provoked by losartan administration during lactation. ( Coimbra, TM; Costa, RS; da Silva, CGA; de Almeida, LF; Francescato, HDC, 2017) |
| "Treatment with losartan significantly attenuated aortic AS, inhibited ER stress and reduced aortic inflammation." | 1.46 | Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation. ( Gan, H; Tang, W; Yang, J; Yu, X; Zhang, X, 2017) |
| "We treated a dilated cardiomyopathy-linked mouse model expressing a mutant tropomyosin (Tm-E54K) for 3 months with either TRV120067, a β-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II receptor blocker." | 1.46 | Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy. ( Cowan, CL; Li, J; Russell, B; Ryba, DM; Solaro, RJ; Wolska, BM, 2017) |
| "To examine the effects of losartan on scar formation after trabeculectomy and on fibrotic changes of human Tenon's fibroblasts (HTFs)." | 1.46 | Losartan Attenuates Scar Formation in Filtering Bleb After Trabeculectomy. ( Fu, S; Shi, H; Wang, H; Xiao, Y; Xu, K; Ye, W; Zhang, X, 2017) |
| "Spontaneous seizures were video- and EEG-monitored in spontaneously hypertensive rats (SHRs) for a 16-week period after SE." | 1.43 | Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy. ( Atanasova, D; Ivanova, N; Kortenska, L; Lazarov, N; Lozanov, V; Mitreva, R; Pechlivanova, DM; Stoynev, A; Tchekalarova, JD, 2016) |
| "Losartan was administered to male adult C57BL/6 J mice 2 weeks prior to the induction of colitis, and images of the whole colon were captured to record changes, scored according to a microscopic scoring system, and reverse transcription-quantitative polymerase chain reaction were performed in order to investigate colonic inflammation." | 1.43 | AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn's disease. ( Liu, TJ; Shi, YY; Wang, EB; Zhao, Q; Zhu, T, 2016) |
| "Losartan treatment had no impact on growth or kidney development." | 1.43 | Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. ( Béland-Bonenfant, S; Bertagnolli, M; Cloutier, A; Dios, A; Gascon, G; Lukaszewski, MA; Nuyt, AM; Paradis, P; Schiffrin, EL; Sutherland, M, 2016) |
| " We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)." | 1.43 | Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. ( Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016) |
| "Aldosterone effects were prevented by the AGTR1 antagonist losartan in WT mice." | 1.43 | Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors. ( Barhoumi, T; Briet, M; Coelho, SC; Coffman, TM; Mian, MOR; Ouerd, S; Paradis, P; Rautureau, Y; Schiffrin, EL, 2016) |
| " Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7)." | 1.43 | Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. ( Arnold, MR; Forte, BL; Hay, M; Largent-Milnes, TM; Slosky, LM; Staatz, WD; Vanderah, TW; Zhang, H, 2016) |
| "Hypertension is a powerful risk factor of atrial fibrillation (AF)." | 1.42 | Blockade of brain angiotensin II type 1 receptor inhibits the development of atrial fibrillation in hypertensive rats. ( Chishaki, A; Hirooka, Y; Inoue, S; Kishi, T; Mukai, Y; Nagayama, T; Sunagawa, K; Takase, S; Takemoto, M, 2015) |
| "Losartan treatment was associated with significantly increased serum tumor necrosis factor alpha (TNF-α) level, p65 nuclei accumulation, and decreased muscle IκB-β protein level, indicating NFκB activation." | 1.42 | Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A. ( Elbaz, M; Laban, S; Mitrani-Rosenbaum, S; Nevo, Y; Rabie, M; Yanay, N, 2015) |
| "Losartan treatment also provoked significant attenuation of endoplasmic reticulum stress parameters (GRP78, IRE1α, p-eIF2) which was consistent with reduced levels of both caspase 12 and caspase 3." | 1.42 | Losartan activates sirtuin 1 in rat reduced-size orthotopic liver transplantation. ( Bejaoui, M; Folch-Puy, E; Palmeira, CM; Panisello, A; Pantazi, E; Pinto Rolo, A; Roselló-Catafau, J; Zaouali, MA, 2015) |
| "The effect of YCHD on liver fibrosis and the detailed molecular mechanisms were assessed by liver function including total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IDBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)." | 1.42 | Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver. ( Hao, S; Wang, G; Wu, L; Wu, ZX; Xie, JW; Zhou, PQ; Zhou, SC; Zhu, R, 2015) |
| "Treatment with losartan used, the selective antagonist of angiotensin II type I receptor could improve the cardiac function of TAC rats." | 1.42 | [Preliminary Study of Necroptosis in Cardiac Hypertrophy Induced by Pressure Overload]. ( Fu, H; Liu, X; Lu, L; Qin, Y; Tang, X; Wu, W; Zhao, M, 2015) |
| "An advanced liver fibrosis model was developed using C3H/HeN mice subjected to 20 weeks of prolonged TAA/ethanol weight-adapted treatment." | 1.42 | Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model. ( Jeong, YY; Kim, JH; Lee, JH; Moon, MJ; Thomas, RG, 2015) |
| "Losartan attenuated lung injury by alleviation of the inflammation and cell apoptosis by inhibition of LOX-1 in LPS-induced lung injury." | 1.42 | Losartan attenuated lipopolysaccharide-induced lung injury by suppression of lectin-like oxidized low-density lipoprotein receptor-1. ( Deng, J; Deng, W; Deng, Y; Wang, DX; Zhang, T, 2015) |
| "Losartan attenuated key parameters of diabetic nephropathy and gene expression, and reversed some but not all the epigenetic changes in db/db mice." | 1.40 | Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. ( Alpers, CE; Bomsztyk, K; Lanting, L; Mar, D; Natarajan, R; Reddy, MA; Sumanth, P; Wang, M; Yuan, H, 2014) |
| "With an animal model of PTSD and the selective angiotensin receptor type 1 (AT1) antagonist losartan, we investigated the acute and long-term effects of AT1 receptor inhibition on fear memory and baseline anxiety." | 1.40 | Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. ( Banerjee, S; Choi, DC; Fuchs, S; Goodman, J; Marvar, PJ; Ressler, KJ, 2014) |
| "Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mapping is sensitive to pharmacological prevention of fibrosis." | 1.40 | T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. ( Fiedler, LR; Gsell, W; Habib, J; McSweeney, SJ; Prasad, SK; Price, AN; Schneider, MD; Stuckey, DJ; Thin, MZ, 2014) |
| "Rats treated with losartan present memory deficits and decreases in spine-density." | 1.40 | Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit. ( Gong, CX; Hu, J; Liu, X; Luo, H; Wang, JZ; Wang, XC; Wang, Z; Xia, Y; Yu, G; Zeng, K; Zhou, XW, 2014) |
| "A non-obese type 2 diabetes model, the spontaneously diabetic Torii (SDT) rat, is of increasing preclinical interest because of its pathophysiological similarities to human type 2 diabetic complications including diabetic nephropathy." | 1.40 | Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan. ( Fujitaka, K; Fukunari, A; Hirohashi, Y; Iguchi, T; Kakimoto, T; Kato, T; Kawai, M; Nishio, M; Okada, K; Relator, R; Utsumi, H, 2014) |
| "Treatment with losartan during the course of testosterone exposure significantly attenuated testosterone-induced hypertension." | 1.40 | Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats. ( Chinnathambi, V; Hankins, GD; More, AS; Sathishkumar, K; Yallampalli, C, 2014) |
| "Losartan treatment partially attenuated these responses." | 1.40 | Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014) |
| "Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0." | 1.40 | Losartan improves measures of activity, inflammation, and oxidative stress in older mice. ( Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014) |
| "Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle." | 1.40 | Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. ( Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014) |
| "Various attempts have been made to find treatments for Duchenne muscular dystrophy (DMD) patients." | 1.40 | Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice. ( Hwang, M; Jeong, KS; Kang, KK; Kim, AY; Kwon, SH; Lee, EJ; Lee, EM; Lee, MM; Min, CW; Park, JK; Tremblay, JP, 2014) |
| "Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy." | 1.40 | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014) |
| "The AKT-mTOR pathway is activated in diabetic nephropathy." | 1.39 | Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy. ( Daphnis, E; Ganotakis, E; Giannakakis, K; Katsarou, T; Mavroeidi, V; Papavasiliou, S; Perakis, K; Petrakis, I; Stratigis, S; Stylianou, K; Vardaki, E, 2013) |
| "Losartan treatment increased the baroreflex sensitivity of rSNA to pressor (67%) and depressor (140%) stimuli in the 2K-1C rats." | 1.39 | Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension. ( Bergamaschi, CT; Campos, RR; Nishi, EE; Oliveira-Sales, EB; Simon, KA, 2013) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 1.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Treatment with losartan decreased neutrophil recruitment, hypernociception and the production of TNF-α, IL-1β and chemokine (C-X-C motif) ligand 1 in mice subjected to AIA." | 1.39 | Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. ( Bader, M; Barroso, LC; Coelho, FM; Costa, VV; Oliveira, ML; Queiroz-Junior, CM; Santos, RA; Silva, AC; Silva, TA; Silveira, KD; Sousa, LF; Teixeira, MM; Vieira, AT, 2013) |
| "Arterial hypertension is an important risk factor for cerebrovascular diseases, such as transient ischemic attacks or stroke, and represents a major global health issue." | 1.39 | Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. ( Buck, A; Calcinaghi, N; Fritschy, JM; Jolivet, R; Keller, AL; Matter, CM; Singh, A; Weber, B; Winnik, S; Wyss, MT, 2013) |
| "AKF-PD was used to treat renal fibrosis in unilateral ureteral obstruction (UUO) obstructive nephropathy in rats." | 1.39 | Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. ( Cheng, GJ; Hu, GY; Huang, L; Mei, WJ; Peng, ZZ; Qin, J; Tao, LJ; Xie, YY; Yuan, QJ; Yuan, XN, 2013) |
| "Treatment with losartan significantly blocked TAC-induced vascular inflammation and macrophage accumulation." | 1.39 | Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. ( Brasier, AR; Cao, JM; Geng, L; Guo, S; Kuang, SQ; Kwartler, CS; Milewicz, DM; Peters, AM; Prakash, SK; Villamizar, C, 2013) |
| "Losartan (10 mg/kg) was administered by gavage daily, starting from 1 d before LPS stimulation." | 1.39 | Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury. ( Chen, Q; Huang, Y; Liu, L; Pan, C; Qiu, H; Yang, Y, 2013) |
| "Losartan treatment also abrogated fibro-inflammatory disease, assessed by markers at the protein and messenger level." | 1.39 | Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. ( Declèves, AE; Rychak, JJ; Sharma, K; Smith, DJ, 2013) |
| "ARB markedly inhibited liver fibrosis development along with suppression of the number of Ac-HSC and TGF-β." | 1.39 | Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. ( Aihara, Y; Douhara, A; Fukui, H; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yoshiji, H, 2013) |
| " We investigated the changes of ceramide lipid components in hypertrophied immature rabbit hearts after chronic administration of the AT1 -receptor blocker, losartan." | 1.39 | Modulation of C16:0-ceramide in hypertrophied immature hearts by losartan. ( Itoi, T; Oka, T; Terada, N, 2013) |
| "Treatment with losartan (15 mg/kg/day; n = 9) similarly mitigated signs of cardiac oxidative stress, but impairments in diastolic function persisted when compared with untreated rats (n = 7)." | 1.38 | Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats. ( Carter, CS; Groban, L; Kassik, KA; Lin, MS; Lindsey, S; Machado, FS; Wang, H, 2012) |
| "• Treatment with losartan mediated an insignificant reduction in mean bladder weight (68." | 1.38 | Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model. ( Comiter, C; Phull, HS, 2012) |
| "Chronic obstructive pulmonary disease (COPD) is a prevalent smoking-related disease for which no disease-altering therapies currently exist." | 1.38 | Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. ( Berger, A; Calvi, C; Cheadle, C; Dietz, HC; Ku, T; Lauer, T; Lopez-Mercado, A; McGrath-Morrow, S; Metzger, S; Misono, K; Mitzner, W; Neptune, E; Podowski, M; Poonyagariyagorn, H; Tuder, R; Wise, R, 2012) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 1.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Cotreatment with GW9662 partly blunted the normalization of vascular dysfunction and inflammation." | 1.38 | Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat. ( Kobara, M; Nakata, T; Noda, K; Toba, H; Tojo, C; Wang, J, 2012) |
| "Amiloride treatment also reduced high blood pressure caused by the high-salt diet in these mice." | 1.38 | Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. ( Chen, S; Cui, Y; Jiang, J; Peng, J; Shen, J; Wang, W; Wu, Q, 2012) |
| "Cotreatment with GW9662, a peroxisome proliferator-activated receptor-γ antagonist, interfered with these protective effects of telmisartan against cognitive function." | 1.38 | Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. ( Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Shudou, M; Tsukuda, K, 2012) |
| "Losartan treatment increased urine and tissue ACE activity and tissue levels of angiotensins, mainly angiotensin (1-7), and improved renal and histopathologic parameters." | 1.38 | Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats. ( Aragão, DS; Arita, DY; Arita, LS; Casarini, DE; Colucci, JA; Cunha, TS; Nogueira, MD; Perez, JD; Ronchi, FA; Teixeira, Vde P, 2012) |
| "Losartan treatment was associated with significant impressive improvement in muscle strength and amelioration of fibrosis." | 1.38 | Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. ( Aga-Mizrachi, S; Barak, V; Brunschwig, Z; Elbaz, M; Ettinger, K; Kassis, I; Nevo, Y; Yanay, N, 2012) |
| "Both captopril and losartan treatments reduced the inflammatory, vasoconstrictor, and profibrotic effects present at 48 hours (p<0." | 1.37 | Mitigating effects of captopril and losartan on lung histopathology in a rat model of fat embolism. ( Adler, F; Herndon, B; Lankachandra, K; McIff, TE; Molteni, A; Poisner, AM, 2011) |
| " Pharmacokinetic parameters of losartan and EXP-3174 in rats were determined after oral and intravenous administration of losartan (9 mg/kg) without and with HMG-CoA reductase inhibitors (1 mg/kg)." | 1.37 | Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ( Choi, DH; Choi, JS; Yang, SH, 2011) |
| "Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats." | 1.37 | Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. ( Cervenka, L; Chábová, VC; Hammock, BD; Honetschlägerová, Z; Husková, Z; Hwang, SH; Imig, JD; Kopkan, L; Kramer, HJ; Kujal, P; Sporková, A; Tesař, V; Vernerová, Z, 2011) |
| "These findings suggest that hyperinsulinemia increases lumbar SNA by activation of a glutamatergic NMDA-dependent projection to the RVLM." | 1.36 | Glutamatergic receptor activation in the rostral ventrolateral medulla mediates the sympathoexcitatory response to hyperinsulinemia. ( Bardgett, ME; McCarthy, JJ; Stocker, SD, 2010) |
| "To test this strategy in a model of type 2 diabetes, we treated 2-month-old diabetic Lprdb/db mice with losartan, paricalcitol, or a combination of losartan and paricalcitol for 3 months." | 1.36 | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. ( Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z, 2010) |
| "Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin." | 1.36 | Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Proteinuria was decreased in groups MR and AR compared with group P (on day 14 after PAN administration, respectively; group P vs AR, P < 0." | 1.36 | Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. ( Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K, 2010) |
| "We obtained dose-response curve for the administration of complete extract and extract fractions." | 1.36 | Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism. ( Badillo, FH; González-Cortazar, M; Herrera-Ruiz, M; Jiménez-Ferrer, E; Tortoriello, J, 2010) |
| " The protein levels for MnSOD were significantly elevated by exercise training in combination with losartan treatment." | 1.36 | Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats. ( Erikson, JM; Ji, LL; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2010) |
| "Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0." | 1.36 | Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010) |
| "Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation." | 1.36 | Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. ( Alcalai, R; Eminaga, S; Gorham, JM; Hoffman, SR; Kim, JB; Konno, T; Markwald, RR; Molkentin, JD; Nayor, M; Norris, RA; Schmitt, JP; Seidman, CE; Seidman, JG; Tager, AM; Teekakirikul, P; Toka, O; Wakimoto, H; Wang, L; Wolf, CM, 2010) |
| "Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease." | 1.36 | Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010) |
| "Losartan was administered (20 mg/kg/day) in drinking water by gavage for 5 weeks." | 1.35 | Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. ( Cebova, M; Koprdova, R; Kristek, F, 2009) |
| " There was no dose-response effect of losartan." | 1.35 | Regression of glomerular injury by losartan in experimental diabetic nephropathy. ( Fujihara, CK; Machado, FG; Malheiros, DM; Silva, LF; Teles, F; Ventura, BH; Zatz, R, 2009) |
| "Focal brain ischemia was induced by middle cerebral artery occlusion (MCAO)." | 1.35 | Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice. ( Chen, S; Chen, Y; Li, G; Olson, JE; Sigmund, CD; Wang, J; Zhang, W, 2009) |
| "Ischemic focal ventricular tachycardia (VT) occurs in animals and humans." | 1.35 | Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT(2) receptor. ( Chaudhary, AK; Ely, D; Gopinathannair, R; Martins, JB; Xing, D; Zheng, W, 2009) |
| "Nifedipine-treated animals displayed hemodynamics, LV dilatation, hypertrophy, and loss of function similar to those of the untreated group." | 1.35 | Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. ( Arsenault, M; Beaudoin, J; Champetier, S; Couet, J; Lachance, D; Plante, E; Roussel, E, 2009) |
| "Losartan has been proposed for the prevention of thoracic aortic aneurysm." | 1.35 | Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. ( Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2009) |
| "Losartan has protective effects against CDDP-induced nephrotoxicity as evidenced by restoration of normal serum levels of creatinine and BUN, and LDH leakage." | 1.35 | Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. ( Ain-Shoka, AA; El-Demerdash, E; Khalef, MM; Saleh, S, 2009) |
| "Pretreatment with Losartan attenuated ventilator-induced lung injury and prevented the increase in total protein, the number of apoptotic cells, W/D ratio, MPO, and neutrophil counts caused by high volume ventilation." | 1.35 | Losartan attenuates ventilator-induced lung injury. ( Feng, D; Li, K; Wang, L; Wu, Q; Yao, S, 2008) |
| "Losartan-treated (LOS group, n = 10) and untreated rats served as controls (n = 11)." | 1.35 | Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. ( Alexanderson, C; Andersson, IJ; Bergström, G; Holmäng, A; Johansson, ME; Skøtt, O, 2008) |
| "Losartan treatment and exercise training were initiated 1 week after infarction and continued for 8 weeks, either as a single intervention or combined." | 1.35 | Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. ( Erikson, JM; Ji, L; Lao, S; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2008) |
| "We investigated the effects of co-administration of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor." | 1.35 | Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Yoshida, K, 2008) |
| "Pharmacological treatment for stress urinary incontinence (SUI) is limited to the use of non-selective alpha-agonists, which are often ineffective." | 1.34 | The role of angiotensin II in stress urinary incontinence: A rat model. ( Comiter, CV; Escobar, C; Phull, H; Purves, T; Salkini, M, 2007) |
| "Diabetic nephropathy is the main cause of end-stage renal disease." | 1.34 | Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2007) |
| "Arterial hypertension is the most frequent chronic disease and it is an important cause of morbidity and mortality in the developed world." | 1.34 | Analysis of antihypertensive drugs in the heart of animal models: a proteomic approach. ( Egido, J; Gállego-Delgado, J; Lázaro, A; Osende, JI; Vivanco, F, 2007) |
| "Uremia was induced in apoE-/- mice by 5/6 nephrectomy (NX)." | 1.34 | Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. ( Binder, CJ; Bro, S; Nielsen, LB; Olgaard, K; Witztum, JL, 2007) |
| "Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver that may evolve into fibrosis or cirrhosis." | 1.34 | Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. ( Accatino, L; Aguayo, G; Arrese, M; Duarte, I; Ibañez, P; Miquel, JF; Pizarro, M; Solis, N, 2007) |
| "Losartan treatment also reduced AP-associated depletion of IkappaBbeta and elevation of phospho-NF-kappaB p65 protein expression as well as the enhanced nuclear kappaB binding activity and elevated levels of kappaB-related proteins." | 1.34 | Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis. ( Chan, YC; Leung, PS, 2007) |
| "Captopril was more effective than losartan in preserving of nitric oxide." | 1.34 | [Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits]. ( Antelava, NA; Gogolauri, MI; Gongadze, NV; Kezeli, TD; Pachkoriia, KZ, 2007) |
| " Chronic administration of Rut (10, 20, or 40 mg/kg/day, respectively) for 4 weeks caused a depressor effect and significantly regressed the lumen diameter and decreased the medium thickness of mesenteric arteries in hypertensive rats concomitantly with an increase in the plasma concentration of CGRP and the expression of CGRP mRNA in DRG." | 1.34 | Calcitonin gene-related Peptide-mediated depressor effect and inhibiting vascular hypertrophy of rutaecarpine in renovascular hypertensive rats. ( Chen, QQ; Deng, HW; Hu, GY; Li, D; Li, YJ; Luo, D; Qin, XP; Zeng, SY; Zhang, Z, 2007) |
| "Treatment with losartan did not affect serum lipid levels or systolic blood pressure but did reduce the aortic surface lesion area and mean intimal thickness." | 1.34 | Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. ( Li, GS; Li, JJ; Li, NX; Peng, J; Wang, J; Xu, HX, 2007) |
| "Malignant hypertension was present in 16 of the patients without anti-HLA antibodies, 4 of whom had seizures." | 1.33 | Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. ( Bräsen, JH; Budde, K; Dechend, R; Dragun, D; Eckert, D; Fritsche, L; Hoebeke, J; Kintscher, U; Luft, FC; Mazak, I; Müller, DN; Neumayer, HH; Nieminen-Kelhä, M; Plehm, R; Rudolph, B; Schönemann, C; Unger, T; Wallukat, G, 2005) |
| "Oral losartan treatment delayed the onset of diabetes, and reduced hyperglycemia and glucose intolerance in db/db mice, but did not affect the insulin sensitivity of peripheral tissues." | 1.33 | Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. ( Carlsson, PO; Chu, KY; Lau, T; Leung, PS, 2006) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 1.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Losartan was administered at 3 and 10 mg/kg/day and enalapril at 3 mg/kg/day for 14 weeks in the drinking water." | 1.32 | Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. ( Kemi, M; Matsumoto, H; Nishikibe, M; Ohta, H; Sasaki, M; Taguchi, K; Uehara, S, 2004) |
| "Losartan treatment lowered significantly LPO in kidney tissue after 2 and 4 weeks of treatment compared with untreated and atenolol-treated animals and induced the decrease of excretion of isoprostanes in urine at the end of the study." | 1.32 | Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. ( Aunapuu, M; Kullissaar, T; Ots, M; Pechter, U; Riispere, Z; Vihalemm, T; Zilmer, K; Zilmer, M, 2004) |
| "Since heart failure is also associated with attenuated responses to catecholamines, we examined the effects of imidapril, an ACE inhibitor, on the beta-adrenoceptor (beta-AR) signal transduction in the failing heart." | 1.32 | Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. ( Dhalla, NS; Ren, B; Saini, HK; Sethi, R; Shao, Q; Takeda, N, 2004) |
| "Rats treated with losartan had significantly higher levels of angiotensin II in their plasma." | 1.31 | Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. ( Browne, AE; Chatterjee, K; Chou, TM; Lee, RJ; Parmley, WW; Pulukurthy, S; Sievers, RE; Sudhir, K; Sun, Y; Zhu, B, 2000) |
| "Pre-treatment with losartan prevented the acute rise in the mid-frequency oscillations in SBP and partially reduced the low-frequency component observed at 2 and 4 days." | 1.31 | Acute and chronic alterations in blood pressure variability following experimental subarachnoid haemorrhage. ( Elghozi, J; Fassot, C; Friberg, P; Lambert, E; Lambert, G, 2001) |
| "We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters." | 1.31 | Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001) |
| "Losartan was subsequently shown to decrease central venous pressure and wedge pressure, while cardiac output, left ventricle stroke work and stroke volume all showed improvement." | 1.31 | The haemodynamic effects of losartan after right ventricle infarct in young pigs. ( Ala-Kokko, T; Alahuhta, S; Kiviluoma, K; Ruskoaho, H; Spalding, M, 2001) |
| "Captopril and quinapril were more effective than losartan in preserving vascular relaxation." | 1.31 | Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. ( Browne, AE; Chatterjee, K; Chou, TM; Deedwania, PC; Glantz, SA; Parmley, WW; Pulukurthy, S; Sudhir, K; Sun, YP; Zhu, BQ, 2001) |
| "Total duration of arrhythmia (seconds) after I/R injury was similar in TGR and SD rats (433 +/- 109 vs." | 1.31 | Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. ( Crijns, HJ; de Boer, RA; Pinto, YM; Suurmeijer, AJ; van Geel, PP; van Gilst, WH; van Veldhuisen, DJ, 2002) |
| "Treatment with losartan resulted in significant decreases in plasma ANF and N-terminal proANF, whereas BNP did not change." | 1.30 | Cardiac secretion of atrial and brain natriuretic peptides in acute ischaemic heart failure in pigs: effect of angiotensin II receptor antagonism. ( Djøseland, O; Hall, C; Karlberg, BE; Klinge, R, 1997) |
| " The pharmacodynamic activities of losartan and EXP3174 were determined during constant intravenous infusion as the degree of inhibition of angiotensin II-induced increase in the diastolic pressure." | 1.30 | Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ( Bai, SA; Christ, DD; Hellyer, P; Lankford, SM; Plummer, D, 1997) |
| " In isolated rabbit aorta, KRH-594 caused nonparallel shifts to the right of the dose-response curve to AII and decreased the maximal response with a pK(B) of 10." | 1.30 | Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. ( Amano, H; Hashimoto, K; Hirata, T; Inokuma, K; Mikoshiba, I; Okuhira, M; Tamura, K, 1997) |
| "Development of cardiac hypertrophy in ACF seemed independent of angiotensin II." | 1.30 | Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats. ( Friberg, P; Isgaard, J; Wåhlander, H; Wickman, A, 1999) |
| "Losartan treatment was used to determine the role of angiotensin II (AngII) AT1 receptors in the inhibition of nNOS expression in 5/6 Nx." | 1.30 | Downregulation of neuronal nitric oxide synthase in the rat remnant kidney. ( Burns, KD; Fryer, JN; Levine, DZ; Roczniak, A, 1999) |
| " Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability." | 1.29 | Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability. ( Dowle, MD; Hobson, JE; Jack, TI; Judd, DB; Middlemiss, D; Panchal, TA; Pass, M; Ross, BC; Scopes, DI; Tranquillini, E, 1994) |
| " In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril." | 1.29 | Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. ( Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994) |
| " Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age." | 1.29 | Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| "PD 123319 alone was without effect." | 1.29 | Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats. ( Porter, JP; Toney, GM, 1993) |
| "Intimal hyperplasia is a serious problem after percutaneous transluminal coronary angioplasty (PTCA)." | 1.29 | Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Miyazawa, K; Shibata, N; Ujiie, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 50 (9.40) | 18.2507 |
| 2000's | 183 (34.40) | 29.6817 |
| 2010's | 260 (48.87) | 24.3611 |
| 2020's | 39 (7.33) | 2.80 |
| Authors | Studies |
|---|---|
| Judd, DB | 1 |
| Dowle, MD | 1 |
| Middlemiss, D | 1 |
| Scopes, DI | 1 |
| Ross, BC | 1 |
| Jack, TI | 1 |
| Pass, M | 1 |
| Tranquillini, E | 1 |
| Hobson, JE | 1 |
| Panchal, TA | 1 |
| Sircar, I | 1 |
| Hodges, JC | 1 |
| Quin, J | 1 |
| Bunker, AM | 1 |
| Winters, RT | 1 |
| Edmunds, JJ | 1 |
| Kostlan, CR | 1 |
| Connolly, C | 1 |
| Kesten, SJ | 1 |
| Hamby, JM | 1 |
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Shokrian Zeini, M | 2 |
| Haddadi, NS | 1 |
| Shayan, M | 1 |
| Kazemi, K | 1 |
| Solaimanian, S | 1 |
| Abdollahifar, MA | 1 |
| Hedayatyanfard, K | 1 |
| Dehpour, AR | 1 |
| van Thiel, BS | 1 |
| van der Linden, J | 1 |
| Ridwan, Y | 1 |
| Garrelds, IM | 2 |
| Vermeij, M | 1 |
| Clahsen-van Groningen, MC | 2 |
| Qadri, F | 2 |
| Alenina, N | 1 |
| Bader, M | 4 |
| Roks, AJM | 1 |
| Danser, AHJ | 2 |
| Essers, J | 1 |
| van der Pluijm, I | 1 |
| Kovács, MG | 1 |
| Kovács, ZZA | 1 |
| Varga, Z | 1 |
| Szűcs, G | 1 |
| Freiwan, M | 1 |
| Farkas, K | 1 |
| Kővári, B | 1 |
| Cserni, G | 1 |
| Kriston, A | 1 |
| Kovács, F | 1 |
| Horváth, P | 1 |
| Földesi, I | 1 |
| Csont, T | 1 |
| Kahán, Z | 1 |
| Sárközy, M | 1 |
| Castoldi, G | 1 |
| Carletti, R | 1 |
| Ippolito, S | 1 |
| Stella, A | 1 |
| Zerbini, G | 1 |
| Pelucchi, S | 1 |
| Zatti, G | 1 |
| di Gioia, CRT | 1 |
| Wei, S | 1 |
| Sun, J | 1 |
| Li, Y | 3 |
| Xu, K | 2 |
| Wang, M | 3 |
| Zhang, Y | 10 |
| Maekawa, M | 1 |
| Maekawa, T | 1 |
| Sasase, T | 1 |
| Takagi, K | 1 |
| Takeuchi, S | 1 |
| Kitamoto, M | 1 |
| Nakagawa, T | 2 |
| Toyoda, K | 1 |
| Konishi, N | 1 |
| Ohta, T | 1 |
| Yamada, T | 1 |
| Saleh, N | 1 |
| Cosarderelioglu, C | 1 |
| Vajapey, R | 1 |
| Walston, J | 1 |
| Abadir, PM | 1 |
| Sawada, H | 1 |
| Ohno-Urabe, S | 1 |
| Ye, D | 1 |
| Franklin, MK | 1 |
| Moorleghen, JJ | 1 |
| Howatt, DA | 2 |
| Mullick, AE | 1 |
| Daugherty, A | 3 |
| Lu, HS | 1 |
| Wegner, E | 1 |
| Mickan, T | 2 |
| Truffel, S | 2 |
| Slotina, E | 2 |
| Müller, L | 1 |
| Wunderlich, F | 1 |
| Harper, A | 1 |
| Ritz, U | 2 |
| Rommens, PM | 2 |
| Gercek, E | 1 |
| Drees, P | 1 |
| Baranowski, A | 2 |
| White, Z | 1 |
| Milad, N | 2 |
| Tehrani, AY | 1 |
| Chen, WW | 1 |
| Donen, G | 1 |
| Sellers, SL | 2 |
| Bernatchez, P | 2 |
| Schlemmer, L | 1 |
| Förster, K | 1 |
| Klein, A | 1 |
| Mattyasovszky, SG | 1 |
| Hofmann, A | 1 |
| Kim, MD | 1 |
| Baumlin, N | 1 |
| Yoshida, M | 1 |
| Polineni, D | 1 |
| Salathe, SF | 1 |
| David, JK | 1 |
| Peloquin, CA | 1 |
| Wanner, A | 1 |
| Dennis, JS | 1 |
| Sailland, J | 1 |
| Whitney, P | 1 |
| Horrigan, FT | 1 |
| Sabater, JR | 1 |
| Abraham, WM | 1 |
| Salathe, M | 1 |
| Xing, L | 1 |
| Song, EL | 1 |
| Jia, XB | 1 |
| Ma, J | 2 |
| Li, B | 1 |
| Gao, X | 2 |
| Zhu, Y | 2 |
| Cui, H | 1 |
| Lv, J | 1 |
| Liang, H | 1 |
| Zheng, Y | 1 |
| Wang, S | 3 |
| Wang, H | 6 |
| Ye, F | 1 |
| Gao, J | 1 |
| Tian, Y | 1 |
| Xie, X | 2 |
| Zhao, J | 1 |
| Liu, CH | 1 |
| Sheng, Y | 1 |
| Cao, F | 1 |
| Binz-Lotter, J | 1 |
| Jüngst, C | 1 |
| Rinschen, MM | 1 |
| Koehler, S | 1 |
| Zentis, P | 1 |
| Schauss, A | 1 |
| Schermer, B | 1 |
| Benzing, T | 1 |
| Hackl, MJ | 1 |
| Xin, LH | 1 |
| Liu, R | 1 |
| Yang, XW | 1 |
| Nozu, T | 1 |
| Miyagishi, S | 1 |
| Nozu, R | 1 |
| Takakusaki, K | 1 |
| Okumura, T | 1 |
| Lima, TC | 1 |
| Barbosa, MA | 1 |
| Costa, DC | 1 |
| Becker, LK | 1 |
| Cardoso, LM | 1 |
| Alzamora, AC | 1 |
| Hudkins, KL | 1 |
| Wietecha, TA | 1 |
| Steegh, F | 1 |
| Alpers, CE | 2 |
| Messerli, FH | 1 |
| Siontis, GCM | 1 |
| Rexhaj, E | 1 |
| Korneva, A | 1 |
| Schaub, J | 1 |
| Jefferys, J | 1 |
| Kimball, E | 1 |
| Pease, ME | 2 |
| Nawathe, M | 1 |
| Johnson, TV | 1 |
| Pitha, I | 1 |
| Quigley, H | 1 |
| Royea, J | 1 |
| Lacalle-Aurioles, M | 1 |
| Trigiani, LJ | 1 |
| Fermigier, A | 1 |
| Hamel, E | 3 |
| Kalynovska, N | 2 |
| Diallo, M | 2 |
| Sotakova-Kasparova, D | 1 |
| Palecek, J | 2 |
| Wanderer, S | 2 |
| Andereggen, L | 1 |
| Mrosek, J | 2 |
| Kashefiolasl, S | 1 |
| Marbacher, S | 1 |
| Konczalla, J | 2 |
| Gonzalez, EA | 1 |
| Tobar Leitão, SA | 1 |
| Soares, DDS | 1 |
| Tavares, AMV | 1 |
| Giugliani, R | 1 |
| Baldo, G | 1 |
| Matte, U | 1 |
| Mohebbati, R | 1 |
| Kamkar-Del, Y | 1 |
| Shafei, MN | 1 |
| Hord, JM | 1 |
| Garcia, MM | 1 |
| Farris, KR | 1 |
| Guzzoni, V | 1 |
| Lee, Y | 1 |
| Lawler, MS | 1 |
| Lawler, JM | 1 |
| Fried, ND | 1 |
| Morris, TM | 1 |
| Whitehead, A | 1 |
| Lazartigues, E | 2 |
| Yue, X | 1 |
| Gardner, JD | 1 |
| He, YL | 1 |
| Wen, JG | 1 |
| Pu, QS | 1 |
| Wen, YB | 1 |
| Zhai, RQ | 1 |
| Chen, Y | 4 |
| Ma, Y | 2 |
| Liu, EP | 1 |
| Xing, D | 2 |
| Ji, FP | 1 |
| Yang, XH | 1 |
| Wang, QW | 1 |
| Wang, Y | 4 |
| Bauer, SB | 1 |
| Fernandes, MV | 1 |
| Rosso Melo, M | 1 |
| Mowry, FE | 1 |
| Lucera, GM | 1 |
| Lauar, MR | 1 |
| Frigieri, G | 1 |
| Biancardi, VC | 1 |
| Menani, JV | 2 |
| Colombari, DSA | 1 |
| Colombari, E | 2 |
| Bovée, DM | 1 |
| Ren, L | 1 |
| Uijl, E | 1 |
| van Veghel, R | 1 |
| Domenig, O | 1 |
| Poglitsch, M | 1 |
| Zlatev, I | 1 |
| Kim, JB | 2 |
| Huang, S | 1 |
| Melton, L | 1 |
| Lu, X | 2 |
| Hoorn, EJ | 1 |
| Foster, D | 1 |
| Franzén, S | 1 |
| Näslund, E | 1 |
| Frithiof, R | 1 |
| Hashimoto, T | 1 |
| Shibata, K | 1 |
| Honda, K | 2 |
| Nobe, K | 1 |
| Akazawa, Y | 1 |
| Fujioka, T | 1 |
| Ide, H | 2 |
| Yazaki, K | 1 |
| Honjo, O | 1 |
| Sun, M | 1 |
| Friedberg, MK | 1 |
| Akbar Nekooeian, A | 1 |
| Rasti Pour, A | 1 |
| Dehghani, F | 1 |
| Mashghoolozekr, E | 1 |
| Esmaeilpour, T | 1 |
| Gao, H | 1 |
| Du, WY | 1 |
| Lin, J | 2 |
| Han, SL | 1 |
| Zhang, YJ | 1 |
| Sun, XF | 1 |
| Peruchetti, DB | 2 |
| Barahuna-Filho, PFR | 1 |
| Silva-Aguiar, RP | 2 |
| Abreu, TP | 2 |
| Takiya, CM | 2 |
| Cheng, J | 2 |
| Pinheiro, AAS | 2 |
| Cebotaru, L | 1 |
| Guggino, WB | 1 |
| Caruso-Neves, C | 2 |
| Leite, APO | 1 |
| Li, XC | 1 |
| Hassan, R | 1 |
| Zheng, X | 1 |
| Alexander, B | 1 |
| Casarini, DE | 4 |
| Zhuo, JL | 1 |
| Koide, M | 1 |
| Harraz, OF | 1 |
| Dabertrand, F | 1 |
| Longden, TA | 1 |
| Ferris, HR | 1 |
| Wellman, GC | 1 |
| Hill-Eubanks, DC | 1 |
| Greenstein, AS | 1 |
| Nelson, MT | 1 |
| Chang, J | 1 |
| Nie, H | 1 |
| Ge, X | 1 |
| Du, J | 1 |
| Liu, W | 1 |
| Li, X | 2 |
| Sun, Y | 6 |
| Wei, X | 2 |
| Xun, Z | 1 |
| Li, YC | 4 |
| Ragab, TIM | 1 |
| Ali, NA | 1 |
| El Gendy, ANG | 1 |
| Mohamed, SH | 1 |
| Shalby, AB | 1 |
| Farrag, AH | 1 |
| Shalaby, ASG | 1 |
| Boshra, V | 1 |
| Abbas, AM | 1 |
| Bar-Klein, G | 2 |
| Lublinsky, S | 1 |
| Kamintsky, L | 2 |
| Noyman, I | 1 |
| Veksler, R | 1 |
| Dalipaj, H | 1 |
| Senatorov, VV | 1 |
| Swissa, E | 1 |
| Rosenbach, D | 1 |
| Elazary, N | 1 |
| Milikovsky, DZ | 1 |
| Milk, N | 1 |
| Kassirer, M | 1 |
| Rosman, Y | 1 |
| Serlin, Y | 1 |
| Eisenkraft, A | 1 |
| Chassidim, Y | 1 |
| Parmet, Y | 1 |
| Kaufer, D | 2 |
| Friedman, A | 2 |
| Fanelli, C | 3 |
| Arias, SCA | 1 |
| Machado, FG | 5 |
| Okuma, JK | 1 |
| Malheiros, DMAC | 1 |
| Azevedo, H | 1 |
| Moreira-Filho, CA | 1 |
| Camara, NOS | 1 |
| Fujihara, CK | 7 |
| Zatz, R | 7 |
| Culman, J | 1 |
| Jacob, T | 1 |
| Schuster, SO | 1 |
| Brolund-Spaether, K | 1 |
| Brolund, L | 1 |
| Cascorbi, I | 1 |
| Zhao, Y | 3 |
| Gohlke, P | 1 |
| Vatter, H | 1 |
| Seifert, V | 1 |
| Oğuz, N | 1 |
| Kırça, M | 1 |
| Çetin, A | 1 |
| Yeşilkaya, A | 1 |
| Smeda, JS | 2 |
| Daneshtalab, N | 1 |
| Bartko, PE | 1 |
| Dal-Bianco, JP | 1 |
| Guerrero, JL | 1 |
| Beaudoin, J | 2 |
| Szymanski, C | 1 |
| Kim, DH | 1 |
| Seybolt, MM | 1 |
| Handschumacher, MD | 1 |
| Sullivan, S | 1 |
| Garcia, ML | 1 |
| Titus, JS | 1 |
| Wylie-Sears, J | 1 |
| Irvin, WS | 1 |
| Messas, E | 1 |
| Hagège, AA | 1 |
| Carpentier, A | 1 |
| Aikawa, E | 1 |
| Bischoff, J | 1 |
| Levine, RA | 1 |
| de Almeida, LF | 1 |
| Francescato, HDC | 1 |
| da Silva, CGA | 1 |
| Costa, RS | 1 |
| Coimbra, TM | 1 |
| Zheng, M | 1 |
| Pan, F | 1 |
| Liu, Y | 3 |
| Li, Z | 3 |
| Zhou, X | 2 |
| Meng, X | 2 |
| Liu, L | 4 |
| Ge, S | 1 |
| Murad, HA | 1 |
| Gazzaz, ZJ | 1 |
| Ali, SS | 1 |
| Ibraheem, MS | 1 |
| Song, LJ | 1 |
| Xiang, F | 1 |
| Ye, H | 1 |
| Huang, H | 1 |
| Yang, J | 5 |
| Yu, F | 1 |
| Xiong, L | 1 |
| Xu, JJ | 1 |
| Greer, PA | 1 |
| Shi, HZ | 1 |
| Xin, JB | 1 |
| Su, Y | 2 |
| Ma, WL | 1 |
| Nelson, JW | 1 |
| Ferdaus, MZ | 1 |
| McCormick, JA | 1 |
| Minnier, J | 1 |
| Kaul, S | 1 |
| Ellison, DH | 1 |
| Barnes, AP | 1 |
| Atanasova, D | 2 |
| Tchekalarova, J | 2 |
| Ivanova, N | 2 |
| Nenchovska, Z | 1 |
| Pavlova, E | 1 |
| Atanassova, N | 1 |
| Lazarov, N | 2 |
| Montes-Rivera, JO | 1 |
| Tamay-Cach, F | 1 |
| Quintana-Pérez, JC | 1 |
| Guevara-Salazar, JA | 1 |
| Trujillo-Ferrara, JG | 1 |
| Del Valle-Mondragón, L | 1 |
| Arellano-Mendoza, MG | 1 |
| Verbrugghe, P | 1 |
| Verhoeven, J | 1 |
| Clijsters, M | 1 |
| Vervoort, D | 1 |
| Schepens, J | 1 |
| Meuris, B | 1 |
| Herijgers, P | 1 |
| Su, Z | 1 |
| Widomski, D | 1 |
| Nikkel, A | 1 |
| Leys, L | 1 |
| Namovic, M | 1 |
| Donnelly-Roberts, D | 1 |
| Gopalakrishnan, M | 1 |
| McGaraughty, S | 1 |
| Chan, R | 1 |
| Mielnik, M | 1 |
| Jermilova, U | 1 |
| Huang, PL | 1 |
| de Crom, R | 1 |
| Hirota, JA | 1 |
| Hogg, JC | 1 |
| Sandor, GG | 1 |
| Van Breemen, C | 3 |
| Esfandiarei, M | 1 |
| Seidman, MA | 1 |
| Trejo-Moreno, C | 1 |
| Castro-Martínez, G | 1 |
| Méndez-Martínez, M | 1 |
| Jiménez-Ferrer, JE | 1 |
| Pedraza-Chaverri, J | 1 |
| Arrellín, G | 1 |
| Zamilpa, A | 1 |
| Medina-Campos, ON | 1 |
| Lombardo-Earl, G | 1 |
| Barrita-Cruz, GJ | 1 |
| Hernández, B | 1 |
| Ramírez, CC | 1 |
| Santana, MA | 1 |
| Fragoso, G | 1 |
| Rosas, G | 1 |
| Lino Cardenas, CL | 1 |
| Kessinger, CW | 1 |
| MacDonald, C | 1 |
| Jassar, AS | 1 |
| Isselbacher, EM | 1 |
| Jaffer, FA | 1 |
| Lindsay, ME | 2 |
| Jönsson, S | 1 |
| Melville, JM | 1 |
| Becirovic-Agic, M | 1 |
| Hultström, M | 3 |
| Márquez-Ramírez, CA | 1 |
| Hernández de la Paz, JL | 1 |
| Ortiz-Avila, O | 1 |
| Raya-Farias, A | 1 |
| González-Hernández, JC | 1 |
| Rodríguez-Orozco, AR | 1 |
| Salgado-Garciglia, R | 1 |
| Saavedra-Molina, A | 1 |
| Godínez-Hernández, D | 1 |
| Cortés-Rojo, C | 1 |
| Abukar, Y | 1 |
| Ramchandra, R | 2 |
| Hood, SG | 2 |
| McKinley, MJ | 1 |
| Booth, LC | 1 |
| Yao, ST | 1 |
| May, CN | 2 |
| Huard, J | 3 |
| Bolia, I | 1 |
| Briggs, K | 1 |
| Utsunomiya, H | 1 |
| Lowe, WR | 1 |
| Philippon, MJ | 1 |
| Watson, D | 1 |
| Stuckless, J | 1 |
| Negandhi, A | 1 |
| Silva, LS | 1 |
| Dal-Cheri, BKA | 1 |
| Souza, MC | 1 |
| Henriques, MG | 1 |
| Fialla, AD | 1 |
| Schaffalitzky de Muckadell, OB | 1 |
| Bie, P | 1 |
| Thiesson, HC | 1 |
| Subudhi, BB | 1 |
| Sahu, PK | 1 |
| Singh, VK | 1 |
| Prusty, S | 1 |
| Ougaard, ME | 1 |
| Jensen, HE | 1 |
| Thuen, ID | 1 |
| Petersen, EG | 1 |
| Kvist, PH | 1 |
| Lezama-Martinez, D | 1 |
| Flores-Monroy, J | 1 |
| Fonseca-Coronado, S | 1 |
| Hernandez-Campos, ME | 1 |
| Valencia-Hernandez, I | 1 |
| Martinez-Aguilar, L | 1 |
| Leenen, FHH | 1 |
| Ahmad, M | 1 |
| Marc, Y | 1 |
| Llorens-Cortes, C | 1 |
| Thomas, M | 1 |
| Fronk, Z | 1 |
| Gross, A | 1 |
| Willmore, D | 1 |
| Arango, A | 1 |
| Higham, C | 1 |
| Nguyen, V | 1 |
| Lim, H | 1 |
| Kale, V | 1 |
| McMillan, G | 1 |
| Seegmiller, RE | 1 |
| Walker, AE | 1 |
| Kronquist, EK | 1 |
| Chinen, KT | 1 |
| Reihl, KD | 1 |
| Li, DY | 1 |
| Lesniewski, LA | 1 |
| Donato, AJ | 1 |
| Cao, J | 1 |
| Melamed, A | 1 |
| Worley, M | 1 |
| Gockley, A | 1 |
| Jones, D | 1 |
| Nia, HT | 1 |
| Stylianopoulos, T | 1 |
| Kumar, AS | 1 |
| Mpekris, F | 1 |
| Datta, M | 1 |
| Wu, L | 3 |
| Yeku, O | 1 |
| Del Carmen, MG | 1 |
| Spriggs, DR | 1 |
| Jain, RK | 1 |
| Xu, L | 3 |
| Wang, C | 2 |
| Hong, X | 1 |
| Miao, J | 1 |
| Liao, Y | 1 |
| Hou, FF | 1 |
| Zhou, L | 1 |
| Azis, NA | 1 |
| Agarwal, R | 1 |
| Ismail, NM | 1 |
| Ismail, NH | 1 |
| Kamal, MSA | 1 |
| Radjeni, Z | 1 |
| Singh, HJ | 1 |
| Kim, E | 1 |
| Hwang, SH | 2 |
| Kim, HK | 2 |
| Abdi, S | 1 |
| Lenart, L | 1 |
| Balogh, DB | 1 |
| Lenart, N | 1 |
| Barczi, A | 1 |
| Hosszu, A | 1 |
| Farkas, T | 1 |
| Hodrea, J | 1 |
| Szabo, AJ | 1 |
| Szigeti, K | 1 |
| Denes, A | 1 |
| Fekete, A | 1 |
| Hofmann Bowman, MA | 1 |
| Eagle, KA | 1 |
| Milewicz, DM | 3 |
| Hong, S | 1 |
| JianCheng, H | 1 |
| JiaWen, W | 1 |
| ShuQin, Z | 1 |
| GuiLian, Z | 1 |
| HaiQin, W | 1 |
| Ru, Z | 1 |
| Zhen, G | 1 |
| HongWei, R | 1 |
| Dougherty, U | 1 |
| Mustafi, R | 1 |
| Haider, HI | 1 |
| Khalil, A | 1 |
| Souris, JS | 1 |
| Joseph, L | 1 |
| Hart, J | 1 |
| Konda, VJ | 1 |
| Zhang, W | 2 |
| Pekow, J | 1 |
| Bissonnette, M | 1 |
| Shu, S | 1 |
| Wang, L | 3 |
| Wu, Y | 2 |
| Yuan, Z | 1 |
| Zhou, J | 3 |
| Reyes-Pardo, H | 1 |
| Bautista, R | 1 |
| Vargas-Robles, H | 1 |
| Rios, A | 1 |
| Sánchez, D | 1 |
| Escalante, B | 1 |
| Poletto Bonetto, JH | 1 |
| Fernandes, RO | 1 |
| Dartora, DR | 1 |
| Flahault, A | 1 |
| Sonea, A | 1 |
| He, Y | 1 |
| Cloutier, A | 2 |
| Belló-Klein, A | 1 |
| Nuyt, AM | 2 |
| Murphy, A | 1 |
| LeVatte, T | 1 |
| Boudreau, C | 1 |
| Midgen, C | 1 |
| Gratzer, P | 1 |
| Marshall, J | 1 |
| Bezuhly, M | 1 |
| Mavroeidi, V | 1 |
| Petrakis, I | 1 |
| Stylianou, K | 1 |
| Katsarou, T | 1 |
| Giannakakis, K | 1 |
| Perakis, K | 1 |
| Vardaki, E | 1 |
| Stratigis, S | 1 |
| Ganotakis, E | 1 |
| Papavasiliou, S | 1 |
| Daphnis, E | 1 |
| Nishi, EE | 1 |
| Bergamaschi, CT | 1 |
| Oliveira-Sales, EB | 2 |
| Simon, KA | 1 |
| Campos, RR | 1 |
| Abdel-Zaher, AO | 1 |
| Elkoussi, AE | 1 |
| Abudahab, LH | 1 |
| Elbakry, MH | 1 |
| Elsayed, EA | 1 |
| Jian, DY | 1 |
| Chao, YW | 1 |
| Ting, CH | 1 |
| Huang, SW | 1 |
| Chang, CF | 1 |
| Juan, CC | 1 |
| Chen, JY | 1 |
| Kusunoki, H | 2 |
| Taniyama, Y | 2 |
| Rakugi, H | 2 |
| Morishita, R | 2 |
| Mackenzie, A | 1 |
| Dunning, L | 1 |
| Ferrell, WR | 2 |
| Lockhart, JC | 2 |
| Liu, S | 3 |
| Xie, Z | 1 |
| Cassis, LA | 3 |
| Pearson, KJ | 1 |
| Gong, MC | 1 |
| Guo, Z | 1 |
| Pacheco, Dda F | 1 |
| Pacheco, CM | 1 |
| Lima, Mde P | 1 |
| Souza, Ade L | 1 |
| Pesquero, JL | 1 |
| Castro Perez, A | 1 |
| Duarte, ID | 1 |
| Kim, HS | 3 |
| No, CW | 1 |
| Goo, SH | 1 |
| Cha, TJ | 1 |
| Silveira, KD | 2 |
| Coelho, FM | 1 |
| Vieira, AT | 2 |
| Barroso, LC | 2 |
| Queiroz-Junior, CM | 1 |
| Costa, VV | 1 |
| Sousa, LF | 1 |
| Oliveira, ML | 1 |
| Silva, TA | 1 |
| Santos, RA | 3 |
| Silva, AC | 1 |
| Teixeira, MM | 2 |
| Calcinaghi, N | 1 |
| Wyss, MT | 1 |
| Jolivet, R | 1 |
| Singh, A | 1 |
| Keller, AL | 1 |
| Winnik, S | 1 |
| Fritschy, JM | 1 |
| Buck, A | 1 |
| Matter, CM | 1 |
| Weber, B | 1 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Nagata, T | 1 |
| Fukuzawa, T | 1 |
| Takeda, M | 1 |
| Fukazawa, M | 1 |
| Mori, T | 1 |
| Nihei, T | 1 |
| Suzuki, Y | 1 |
| Kawabe, Y | 1 |
| Cisalpino, D | 1 |
| Lima, CX | 1 |
| Arantes, RM | 1 |
| Dos Santos, RA | 1 |
| Simões-E-Silva, AC | 1 |
| Matouk, AI | 1 |
| Taye, A | 1 |
| Heeba, GH | 1 |
| El-Moselhy, MA | 1 |
| Chen, H | 2 |
| Zhou, CH | 1 |
| Watts, MN | 1 |
| Eshaq, RS | 1 |
| Carter, PR | 1 |
| Harris, NR | 1 |
| Qin, J | 1 |
| Xie, YY | 1 |
| Huang, L | 1 |
| Yuan, QJ | 1 |
| Mei, WJ | 1 |
| Yuan, XN | 1 |
| Hu, GY | 2 |
| Cheng, GJ | 1 |
| Tao, LJ | 1 |
| Peng, ZZ | 1 |
| Kuang, SQ | 1 |
| Geng, L | 1 |
| Prakash, SK | 2 |
| Cao, JM | 1 |
| Guo, S | 1 |
| Villamizar, C | 1 |
| Kwartler, CS | 1 |
| Peters, AM | 1 |
| Brasier, AR | 1 |
| Chen, Q | 1 |
| Yang, Y | 4 |
| Huang, Y | 2 |
| Pan, C | 1 |
| Qiu, H | 2 |
| Xu, C | 2 |
| Ding, W | 1 |
| Zhang, M | 1 |
| Gu, Y | 1 |
| Jia, Z | 2 |
| Downton, M | 1 |
| Liu, G | 2 |
| Du, Y | 2 |
| Yang, T | 1 |
| Knight, WD | 1 |
| Saxena, A | 1 |
| Shell, B | 1 |
| Nedungadi, TP | 1 |
| Mifflin, SW | 1 |
| Cunningham, JT | 2 |
| Declèves, AE | 1 |
| Rychak, JJ | 1 |
| Smith, DJ | 1 |
| Sharma, K | 1 |
| Borgdorff, MA | 1 |
| Bartelds, B | 1 |
| Dickinson, MG | 1 |
| Steendijk, P | 1 |
| Berger, RM | 1 |
| Reddy, MA | 1 |
| Sumanth, P | 1 |
| Lanting, L | 1 |
| Yuan, H | 1 |
| Mar, D | 1 |
| Bomsztyk, K | 1 |
| Natarajan, R | 1 |
| Marvar, PJ | 1 |
| Goodman, J | 1 |
| Fuchs, S | 1 |
| Choi, DC | 1 |
| Banerjee, S | 1 |
| Ressler, KJ | 1 |
| van der Graaf, AM | 1 |
| Wiegman, MJ | 1 |
| Plösch, T | 1 |
| Zeeman, GG | 1 |
| van Buiten, A | 1 |
| Henning, RH | 2 |
| Buikema, H | 2 |
| Faas, MM | 1 |
| Orlowski, A | 1 |
| Ciancio, MC | 1 |
| Caldiz, CI | 1 |
| De Giusti, VC | 1 |
| Aiello, EA | 1 |
| Toba, H | 2 |
| Wang, J | 5 |
| Ohigashi, M | 1 |
| Kobara, M | 2 |
| Nakata, T | 2 |
| Stuckey, DJ | 1 |
| McSweeney, SJ | 1 |
| Thin, MZ | 1 |
| Habib, J | 1 |
| Price, AN | 1 |
| Fiedler, LR | 1 |
| Gsell, W | 2 |
| Prasad, SK | 1 |
| Schneider, MD | 1 |
| Liu, X | 2 |
| Wang, Z | 1 |
| Xia, Y | 2 |
| Yu, G | 2 |
| Zeng, K | 1 |
| Luo, H | 1 |
| Hu, J | 1 |
| Gong, CX | 1 |
| Wang, JZ | 1 |
| Zhou, XW | 1 |
| Wang, XC | 1 |
| Janssen, PM | 1 |
| Murray, JD | 1 |
| Schill, KE | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Rafael-Fortney, JA | 1 |
| Cacheaux, LP | 1 |
| Prager, O | 1 |
| Weissberg, I | 1 |
| Schoknecht, K | 1 |
| Cheng, P | 1 |
| Kim, SY | 1 |
| Wood, L | 1 |
| Heinemann, U | 1 |
| Criss, CN | 1 |
| Gao, Y | 2 |
| De Silva, G | 1 |
| Anderson, JM | 1 |
| Novitsky, YW | 1 |
| Soltanian, H | 1 |
| Rosen, MJ | 1 |
| Kakimoto, T | 1 |
| Okada, K | 1 |
| Hirohashi, Y | 1 |
| Relator, R | 1 |
| Kawai, M | 1 |
| Iguchi, T | 1 |
| Fujitaka, K | 1 |
| Nishio, M | 1 |
| Kato, T | 1 |
| Fukunari, A | 1 |
| Utsumi, H | 1 |
| Ongali, B | 2 |
| Nicolakakis, N | 2 |
| Tong, XK | 2 |
| Aboulkassim, T | 2 |
| Papadopoulos, P | 1 |
| Rosa-Neto, P | 1 |
| Lecrux, C | 1 |
| Imboden, H | 2 |
| Komers, R | 1 |
| Xu, B | 1 |
| Fu, Y | 1 |
| McClelland, A | 1 |
| Kantharidis, P | 1 |
| Mittal, A | 1 |
| Cohen, HT | 1 |
| Cohen, DM | 1 |
| Chinnathambi, V | 1 |
| More, AS | 1 |
| Hankins, GD | 1 |
| Yallampalli, C | 1 |
| Sathishkumar, K | 1 |
| He, P | 1 |
| Li, D | 4 |
| Zhang, B | 1 |
| Liu, Q | 2 |
| Wang, T | 1 |
| Yu, H | 1 |
| Liu, B | 3 |
| Jia, R | 1 |
| Walcott, BP | 1 |
| Lin, CH | 1 |
| Yang, H | 3 |
| Xue, QL | 1 |
| Chuang, YF | 1 |
| Roy, CN | 1 |
| Abadir, P | 1 |
| Walston, JD | 1 |
| Andersen, S | 1 |
| Schultz, JG | 1 |
| Andersen, A | 1 |
| Ringgaard, S | 1 |
| Nielsen, JM | 1 |
| Holmboe, S | 1 |
| Vildbrad, MD | 1 |
| de Man, FS | 1 |
| Bogaard, HJ | 1 |
| Vonk-Noordegraaf, A | 1 |
| Nielsen-Kudsk, JE | 1 |
| Lee, EJ | 2 |
| Kim, AY | 2 |
| Lee, EM | 2 |
| Lee, MM | 1 |
| Min, CW | 1 |
| Kang, KK | 2 |
| Park, JK | 2 |
| Hwang, M | 1 |
| Kwon, SH | 1 |
| Tremblay, JP | 1 |
| Jeong, KS | 2 |
| Bądzyńska, B | 1 |
| Lipkowski, AW | 1 |
| Sadowski, J | 1 |
| Kompanowska-Jezierska, E | 1 |
| Zhu, J | 1 |
| Fu, YY | 1 |
| Teichert, AM | 1 |
| Kato, H | 1 |
| Weisel, RD | 1 |
| Maynes, JT | 1 |
| Coles, JG | 1 |
| Caldarone, CA | 1 |
| Li, M | 1 |
| Zheng, C | 1 |
| Kawada, T | 1 |
| Inagaki, M | 1 |
| Uemura, K | 1 |
| Sugimachi, M | 1 |
| Garg, K | 1 |
| Corona, BT | 1 |
| Walters, TJ | 1 |
| López, RM | 1 |
| Castillo, MC | 1 |
| López, JS | 1 |
| Guevara, G | 1 |
| López, P | 1 |
| Castillo, EF | 1 |
| Cakmak, B | 1 |
| Cavusoglu, T | 1 |
| Ates, U | 1 |
| Meral, A | 1 |
| Nacar, MC | 1 |
| Erbaş, O | 1 |
| Sahin, I | 1 |
| Ozkaynak, B | 1 |
| Sar, M | 1 |
| Biter, HI | 1 |
| Mert, B | 1 |
| Okuyan, E | 1 |
| Kayalar, N | 1 |
| Can, MM | 1 |
| Güngör, B | 1 |
| Erentug, V | 1 |
| Dinckal, MH | 1 |
| Nagayama, T | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Mukai, Y | 1 |
| Inoue, S | 1 |
| Takase, S | 1 |
| Takemoto, M | 1 |
| Chishaki, A | 1 |
| Sunagawa, K | 1 |
| Yan, W | 1 |
| Li, J | 2 |
| Chai, R | 1 |
| Guo, W | 1 |
| Han, Y | 2 |
| Bai, X | 1 |
| Liu, J | 3 |
| Zhang, P | 1 |
| He, H | 1 |
| Yu, T | 1 |
| Guo, F | 2 |
| Araújo, WF | 1 |
| Naves, MA | 1 |
| Ravanini, JN | 1 |
| Schor, N | 1 |
| Teixeira, VP | 1 |
| Cook, JR | 2 |
| Clayton, NP | 1 |
| Carta, L | 3 |
| Galatioto, J | 2 |
| Chiu, E | 1 |
| Smaldone, S | 2 |
| Nelson, CA | 1 |
| Cheng, SH | 1 |
| Wentworth, BM | 1 |
| Ramirez, F | 5 |
| Afroze, SH | 1 |
| Munshi, MK | 1 |
| Martínez, AK | 1 |
| Uddin, M | 1 |
| Gergely, M | 1 |
| Szynkarski, C | 1 |
| Guerrier, M | 1 |
| Nizamutdinov, D | 1 |
| Dostal, D | 1 |
| Glaser, S | 1 |
| Elbaz, M | 2 |
| Yanay, N | 2 |
| Laban, S | 1 |
| Rabie, M | 1 |
| Mitrani-Rosenbaum, S | 1 |
| Nevo, Y | 2 |
| Zhang, D | 2 |
| Zheng, H | 4 |
| Tu, H | 1 |
| Muelleman, RL | 1 |
| Li, YL | 1 |
| Dong, M | 1 |
| Yang, X | 2 |
| Niu, R | 1 |
| Guan, J | 1 |
| Zhang, C | 1 |
| Mo, L | 1 |
| Xiao, X | 1 |
| Song, S | 1 |
| Miao, H | 1 |
| Guo, D | 1 |
| Bu, C | 1 |
| Hou, L | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 2 |
| Yancey, PG | 1 |
| Zuo, Y | 4 |
| Linton, MF | 3 |
| Fazio, S | 3 |
| Narita, I | 1 |
| Kon, V | 4 |
| Pantazi, E | 1 |
| Bejaoui, M | 1 |
| Zaouali, MA | 1 |
| Folch-Puy, E | 1 |
| Pinto Rolo, A | 1 |
| Panisello, A | 1 |
| Palmeira, CM | 1 |
| Roselló-Catafau, J | 1 |
| Nyström, A | 1 |
| Thriene, K | 1 |
| Mittapalli, V | 1 |
| Kern, JS | 1 |
| Kiritsi, D | 1 |
| Dengjel, J | 1 |
| Bruckner-Tuderman, L | 1 |
| Mehrotra, P | 1 |
| Patel, JB | 1 |
| Ivancic, CM | 1 |
| Collett, JA | 1 |
| Basile, DP | 1 |
| Zhou, PQ | 1 |
| Xie, JW | 1 |
| Zhu, R | 1 |
| Zhou, SC | 1 |
| Wang, G | 1 |
| Wu, ZX | 1 |
| Hao, S | 1 |
| Minas, JN | 1 |
| Thorwald, MA | 1 |
| Conte, D | 1 |
| Vázquez-Medina, JP | 1 |
| Nishiyama, A | 3 |
| Ortiz, RM | 1 |
| Chen, R | 1 |
| Mian, M | 1 |
| Fu, M | 1 |
| Zhao, JY | 1 |
| Yang, L | 1 |
| Vohra, R | 1 |
| Accorsi, A | 1 |
| Kumar, A | 1 |
| Walter, G | 1 |
| Girgenrath, M | 1 |
| Li, P | 2 |
| Zhang, F | 2 |
| Sun, HJ | 1 |
| Tchekalarova, JD | 1 |
| Pechlivanova, DM | 1 |
| Kortenska, L | 1 |
| Mitreva, R | 1 |
| Lozanov, V | 1 |
| Stoynev, A | 1 |
| Zhao, M | 1 |
| Qin, Y | 1 |
| Lu, L | 1 |
| Tang, X | 1 |
| Wu, W | 1 |
| Fu, H | 1 |
| Quigley, HA | 1 |
| Pitha, IF | 1 |
| Welsbie, DS | 1 |
| Nguyen, C | 1 |
| Steinhart, MR | 1 |
| Nguyen, TD | 1 |
| Oglesby, EN | 1 |
| Berlinicke, CA | 1 |
| Mitchell, KL | 1 |
| Kim, J | 3 |
| Jefferys, JJ | 1 |
| Kimball, EC | 1 |
| Walsh, KR | 1 |
| Kuwabara, JT | 1 |
| Shim, JW | 1 |
| Wainford, RD | 1 |
| Li, N | 1 |
| Ding, Y | 2 |
| Miao, P | 1 |
| Liu, TJ | 1 |
| Shi, YY | 1 |
| Wang, EB | 1 |
| Zhu, T | 1 |
| Zhao, Q | 1 |
| Wang, R | 2 |
| Huang, Q | 1 |
| Zhou, R | 1 |
| Dong, Z | 1 |
| Qi, Y | 1 |
| Li, H | 4 |
| Wu, H | 1 |
| Wilcox, CS | 1 |
| Lai, EY | 1 |
| Thomas, RG | 1 |
| Moon, MJ | 1 |
| Kim, JH | 2 |
| Lee, JH | 1 |
| Jeong, YY | 1 |
| Maranon, RO | 2 |
| Reckelhoff, JF | 1 |
| Bertagnolli, M | 1 |
| Dios, A | 1 |
| Béland-Bonenfant, S | 1 |
| Gascon, G | 1 |
| Sutherland, M | 1 |
| Lukaszewski, MA | 1 |
| Paradis, P | 3 |
| Schiffrin, EL | 4 |
| Hwang, OK | 1 |
| Deng, W | 1 |
| Deng, Y | 1 |
| Deng, J | 1 |
| Wang, DX | 1 |
| Zhang, T | 1 |
| Janic, M | 2 |
| Lunder, M | 2 |
| Cerne, D | 1 |
| Marc, J | 1 |
| Jerin, A | 2 |
| Skitek, M | 2 |
| Drevensek, G | 2 |
| Sabovic, M | 2 |
| Briet, M | 1 |
| Barhoumi, T | 1 |
| Mian, MOR | 1 |
| Coelho, SC | 1 |
| Ouerd, S | 1 |
| Rautureau, Y | 2 |
| Coffman, TM | 1 |
| Peotta, V | 1 |
| Rahmouni, K | 1 |
| Segar, JL | 1 |
| Morgan, DA | 1 |
| Pitz, KM | 1 |
| Rice, OM | 1 |
| Roghair, RD | 1 |
| Lee, JJ | 1 |
| Rao, S | 1 |
| Costa, KD | 1 |
| de Jong, MA | 1 |
| Mirkovic, K | 1 |
| Mencke, R | 1 |
| Hoenderop, JG | 1 |
| Bindels, RJ | 1 |
| Vervloet, MG | 1 |
| Hillebrands, JL | 1 |
| van den Born, J | 1 |
| Navis, G | 1 |
| de Borst, MH | 1 |
| Kopaliani, I | 1 |
| Martin, M | 1 |
| Zatschler, B | 1 |
| Müller, B | 1 |
| Deussen, A | 1 |
| Fang, J | 1 |
| Wang, W | 4 |
| Sun, S | 1 |
| Li, Q | 1 |
| Qiu, M | 1 |
| Lu, D | 1 |
| Wang, K | 1 |
| Zhang, Q | 1 |
| Fang, P | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| Kho, MC | 1 |
| Lee, YJ | 1 |
| Park, JH | 1 |
| Kim, HY | 2 |
| Yoon, JJ | 1 |
| Ahn, YM | 1 |
| Tan, R | 1 |
| Park, MC | 1 |
| Cha, JD | 1 |
| Choi, KM | 1 |
| Kang, DG | 1 |
| Lee, HS | 1 |
| Bolat, D | 1 |
| Oltulu, F | 1 |
| Uysal, A | 1 |
| Kose, T | 1 |
| Gunlusoy, B | 1 |
| Yigitturk, G | 1 |
| Turk, NS | 1 |
| Turan, T | 1 |
| Anan, HH | 1 |
| Zidan, RA | 1 |
| Shaheen, MA | 1 |
| Abd-El Fattah, EA | 1 |
| Victorio, JA | 1 |
| Clerici, SP | 1 |
| Palacios, R | 1 |
| Alonso, MJ | 1 |
| Vassallo, DV | 1 |
| Jaffe, IZ | 1 |
| Rossoni, LV | 1 |
| Davel, AP | 1 |
| Kobayashi, M | 1 |
| Ota, S | 1 |
| Terada, S | 1 |
| Kawakami, Y | 1 |
| Otsuka, T | 1 |
| Fu, FH | 1 |
| Forte, BL | 1 |
| Slosky, LM | 1 |
| Zhang, H | 1 |
| Arnold, MR | 1 |
| Staatz, WD | 1 |
| Hay, M | 1 |
| Largent-Milnes, TM | 1 |
| Vanderah, TW | 1 |
| Okawada, M | 1 |
| Wilson, MW | 1 |
| Larsen, SD | 1 |
| Lipka, E | 1 |
| Hillfinger, J | 1 |
| Teitelbaum, DH | 1 |
| Osborn, MJ | 1 |
| Webber, BR | 1 |
| McElmurry, RT | 1 |
| Rudser, KD | 1 |
| DeFeo, AP | 1 |
| Muradian, M | 1 |
| Petryk, A | 1 |
| Hallgrimsson, B | 1 |
| Blazar, BR | 1 |
| Tolar, J | 1 |
| Braunlin, EA | 1 |
| Yu, XJ | 1 |
| Chen, WS | 1 |
| Gao, HL | 1 |
| Liu, KL | 1 |
| Shi, XL | 1 |
| Fan, XY | 1 |
| Jia, LL | 1 |
| Cui, W | 1 |
| Zhu, GQ | 1 |
| Liu, JJ | 2 |
| Kang, YM | 2 |
| Suganuma, E | 2 |
| Niimura, F | 1 |
| Matsuda, S | 1 |
| Ukawa, T | 1 |
| Nakamura, H | 1 |
| Sekine, K | 1 |
| Kato, M | 1 |
| Aiba, Y | 1 |
| Koga, Y | 1 |
| Hayashi, K | 1 |
| Takahashi, O | 1 |
| Mochizuki, H | 1 |
| Maida, KD | 1 |
| Gastaldi, AC | 1 |
| de Paula Facioli, T | 1 |
| de Araújo, JE | 1 |
| de Souza, HC | 1 |
| Zhang, X | 4 |
| Yu, X | 1 |
| Tang, W | 1 |
| Gan, H | 1 |
| Ryba, DM | 1 |
| Cowan, CL | 1 |
| Russell, B | 1 |
| Wolska, BM | 1 |
| Solaro, RJ | 1 |
| Kim, H | 1 |
| Baek, CH | 1 |
| Lee, RB | 1 |
| Chang, JW | 1 |
| Yang, WS | 1 |
| Lee, SK | 1 |
| He, DH | 1 |
| Lin, JX | 1 |
| Zhang, LM | 1 |
| Xu, CS | 1 |
| Xie, Q | 1 |
| Oosterhuis, NR | 1 |
| Bongartz, LG | 1 |
| Verhaar, MC | 1 |
| Cheng, C | 1 |
| Xu, YJ | 1 |
| van Koppen, A | 1 |
| Cramer, MJ | 1 |
| Goldschmeding, R | 1 |
| Gaillard, CA | 1 |
| Doevendans, PA | 1 |
| Braam, B | 1 |
| Joles, JA | 2 |
| Gao, XM | 1 |
| Tsai, A | 1 |
| Al-Sharea, A | 1 |
| Moore, S | 1 |
| Han, LP | 1 |
| Kiriazis, H | 1 |
| Dart, AM | 1 |
| Murphy, AJ | 1 |
| Du, XJ | 1 |
| Shi, H | 2 |
| Fu, S | 1 |
| Xiao, Y | 1 |
| Ye, W | 1 |
| Wu, J | 2 |
| Wang, Q | 1 |
| Guo, J | 1 |
| Hu, Z | 1 |
| Yin, Z | 1 |
| Xu, J | 1 |
| Wu, X | 1 |
| Crespo, MJ | 4 |
| Cruz, N | 1 |
| Altieri, PI | 2 |
| Escobales, N | 3 |
| Teschemacher, AG | 1 |
| Raizada, MK | 2 |
| Paton, JF | 3 |
| Kasparov, S | 3 |
| Aquilina, K | 1 |
| Hobbs, C | 1 |
| Tucker, A | 1 |
| Whitelaw, A | 1 |
| Thoresen, M | 1 |
| Yu, M | 1 |
| Wang, X | 2 |
| Guo, X | 2 |
| Xia, L | 1 |
| Chen, J | 2 |
| Koprdova, R | 1 |
| Cebova, M | 1 |
| Kristek, F | 1 |
| Wei, SG | 1 |
| Yu, Y | 1 |
| Zhang, ZH | 2 |
| Weiss, RM | 2 |
| Felder, RB | 2 |
| Timmermans, PB | 5 |
| Wong, PC | 4 |
| Chiu, AT | 2 |
| Smith, RD | 2 |
| Siegl, PK | 1 |
| Kivlighn, SD | 1 |
| Broten, TP | 1 |
| Regitz-Zagrosek, V | 1 |
| Neuss, M | 1 |
| Holzmeister, J | 1 |
| Fleck, E | 1 |
| Deng, A | 1 |
| Tang, T | 1 |
| Singh, P | 1 |
| Satriano, J | 1 |
| Thomson, SC | 1 |
| Blantz, RC | 1 |
| Radović, N | 1 |
| Cuzić, S | 1 |
| Knotek, M | 1 |
| Qiu, HB | 1 |
| Zhao, MM | 1 |
| Chen, QH | 1 |
| Guo, T | 1 |
| Teles, F | 1 |
| Ventura, BH | 2 |
| Malheiros, DM | 6 |
| Silva, LF | 1 |
| Mihailovic-Stanojevic, N | 2 |
| Jovovic, D | 2 |
| Miloradovic, Z | 2 |
| Grujic-Milanovic, J | 1 |
| Jerkic, M | 1 |
| Markovic-Lipkovski, J | 1 |
| Qin, XP | 2 |
| Zeng, SY | 2 |
| Tian, HH | 1 |
| Deng, SX | 1 |
| Ren, JF | 1 |
| Zheng, YB | 1 |
| Li, YJ | 2 |
| Liao, DF | 1 |
| Chen, SY | 1 |
| Perico, N | 3 |
| Cattaneo, D | 1 |
| Remuzzi, G | 4 |
| Xia, H | 1 |
| Feng, Y | 1 |
| Obr, TD | 1 |
| Hickman, PJ | 1 |
| Yang, R | 1 |
| Yang, B | 1 |
| Wen, Y | 1 |
| Fang, F | 1 |
| Cui, S | 1 |
| Lin, G | 1 |
| Sun, Z | 1 |
| Dai, Y | 1 |
| Müller, D | 1 |
| Müller, DN | 3 |
| Senador, D | 2 |
| Kanakamedala, K | 1 |
| Irigoyen, MC | 2 |
| Morris, M | 2 |
| Elased, KM | 2 |
| Rosselli, MS | 1 |
| Burgueño, AL | 1 |
| Carabelli, J | 1 |
| Schuman, M | 1 |
| Pirola, CJ | 1 |
| Sookoian, S | 1 |
| Li, CY | 1 |
| Deng, YL | 1 |
| Sun, BH | 1 |
| Chan, EC | 1 |
| Jones, GT | 1 |
| Dusting, GJ | 1 |
| Datla, SR | 1 |
| Jiang, F | 1 |
| Moreira, TS | 1 |
| Takakura, AC | 1 |
| Verjans, JW | 1 |
| Lovhaug, D | 2 |
| Narula, N | 2 |
| Petrov, AD | 1 |
| Indrevoll, B | 1 |
| Bjurgert, E | 1 |
| Krasieva, TB | 1 |
| Petersen, LB | 1 |
| Kindberg, GM | 1 |
| Solbakken, M | 1 |
| Cuthbertson, A | 1 |
| Vannan, MA | 2 |
| Reutelingsperger, CP | 1 |
| Tromberg, BJ | 1 |
| Hofstra, L | 2 |
| Narula, J | 2 |
| van den Borne, SW | 1 |
| Isobe, S | 1 |
| Zandbergen, HR | 1 |
| Petrov, A | 1 |
| Wong, ND | 1 |
| Fujimoto, S | 2 |
| Fujimoto, A | 1 |
| Smits, JF | 2 |
| Daemen, MJ | 1 |
| Blankesteijn, WM | 1 |
| Reutelingsperger, C | 1 |
| Zannad, F | 1 |
| Pitt, B | 1 |
| Shimizu, F | 1 |
| Kasai, T | 1 |
| Takamata, A | 1 |
| Klinge, R | 1 |
| Djøseland, O | 1 |
| Karlberg, BE | 1 |
| Hall, C | 1 |
| Helle, F | 2 |
| Iversen, BM | 2 |
| Choi, SM | 1 |
| Seo, MJ | 1 |
| Ahn, BO | 1 |
| Yoo, M | 1 |
| Jessup, JA | 1 |
| Westwood, BM | 1 |
| Chappell, MC | 1 |
| Groban, L | 2 |
| Pereira, TM | 1 |
| Balarini, CM | 1 |
| Silva, IV | 1 |
| Cabral, AM | 1 |
| Vasquez, EC | 1 |
| Meyrelles, SS | 1 |
| Merai, AH | 1 |
| Asad, M | 1 |
| Prasad, VS | 1 |
| Zoja, C | 1 |
| Corna, D | 1 |
| Rottoli, D | 1 |
| Gaspari, F | 1 |
| Haskell, L | 1 |
| Choi, JH | 1 |
| Shin, S | 1 |
| Park, D | 1 |
| Jeon, JH | 1 |
| Choi, BH | 1 |
| Jang, MJ | 1 |
| Joo, SS | 1 |
| Oh, KW | 1 |
| Hong, JT | 1 |
| Suh, KH | 1 |
| Kim, YB | 1 |
| Yancey, P | 1 |
| Castro, I | 1 |
| Khan, WN | 1 |
| Khan, W | 1 |
| Motojima, M | 1 |
| Ichikawa, I | 3 |
| Fogo, AB | 4 |
| Polizio, AH | 1 |
| Gorzalczany, SB | 1 |
| Tomaro, ML | 1 |
| Li, YF | 2 |
| Patel, KP | 2 |
| Pelegrini-da-Silva, A | 1 |
| Rosa, E | 1 |
| Guethe, LM | 1 |
| Juliano, MA | 1 |
| Prado, WA | 1 |
| Martins, AR | 1 |
| Chen, S | 2 |
| Li, G | 1 |
| Sigmund, CD | 2 |
| Olson, JE | 1 |
| Gopinathannair, R | 1 |
| Chaudhary, AK | 1 |
| Ely, D | 1 |
| Zheng, W | 1 |
| Martins, JB | 1 |
| Abdel Aziz, MT | 1 |
| El Asmer, MF | 1 |
| Mostafa, T | 1 |
| Atta, H | 1 |
| Mahfouz, S | 1 |
| Fouad, H | 1 |
| Rashed, L | 1 |
| Sabry, D | 1 |
| Hassouna, A | 1 |
| Abdel Aziz, AT | 1 |
| Senbel, A | 1 |
| Demery, A | 1 |
| Plante, E | 1 |
| Lachance, D | 1 |
| Champetier, S | 1 |
| Roussel, E | 1 |
| Arsenault, M | 1 |
| Couet, J | 1 |
| Yang, HH | 2 |
| Kim, JM | 2 |
| Chum, E | 2 |
| Chung, AW | 2 |
| Watanabe, MA | 1 |
| Kucenas, S | 1 |
| Bowman, TA | 1 |
| Ruhlman, M | 1 |
| Knuepfer, MM | 1 |
| Irani, RA | 1 |
| Blackwell, SC | 1 |
| Zhou, CC | 1 |
| Ramin, SM | 1 |
| Kellems, RE | 1 |
| Erokhina, IL | 1 |
| Okovityĭ, SV | 1 |
| Kulikov, AN | 1 |
| Kazachenko, AA | 1 |
| Emel'ianova, OI | 1 |
| Saleh, S | 1 |
| Ain-Shoka, AA | 1 |
| El-Demerdash, E | 2 |
| Khalef, MM | 1 |
| Key, M | 1 |
| Brosnihan, KB | 2 |
| Chai, W | 1 |
| Barrett, EJ | 1 |
| Carey, RM | 1 |
| Cao, W | 1 |
| Liu, Z | 1 |
| Hitomi, H | 1 |
| Bocanegra, V | 2 |
| Manucha, W | 2 |
| Peña, MR | 1 |
| Cacciamani, V | 2 |
| Vallés, PG | 2 |
| Naito, T | 1 |
| Ma, LJ | 2 |
| Tang, Y | 1 |
| Han, JY | 1 |
| Cheng, WH | 1 |
| Lu, PJ | 1 |
| Ho, WY | 1 |
| Tung, CS | 1 |
| Cheng, PW | 1 |
| Hsiao, M | 1 |
| Tseng, CJ | 1 |
| Ishizaka, N | 3 |
| Hongo, M | 1 |
| Matsuzaki, G | 1 |
| Furuta, K | 1 |
| Saito, K | 2 |
| Sakurai, R | 1 |
| Sakamoto, A | 1 |
| Koike, K | 1 |
| Nagai, R | 3 |
| Bardgett, ME | 1 |
| McCarthy, JJ | 1 |
| Stocker, SD | 1 |
| Deb, DK | 2 |
| Sun, T | 1 |
| Wong, KE | 1 |
| Zhang, Z | 2 |
| Ning, G | 1 |
| Kong, J | 2 |
| Chang, A | 2 |
| Tang, F | 1 |
| Lane, S | 1 |
| Souslova, EA | 1 |
| Chudakov, DM | 1 |
| Sakuta, T | 1 |
| Morita, Y | 1 |
| Satoh, M | 1 |
| Fox, DA | 1 |
| Kashihara, N | 1 |
| Chatziantoniou, C | 1 |
| Rosón, MI | 1 |
| Della Penna, SL | 1 |
| Cao, G | 2 |
| Gorzalczany, S | 1 |
| Pandolfo, M | 1 |
| Toblli, JE | 2 |
| Fernández, BE | 1 |
| Dilauro, M | 1 |
| Zimpelmann, J | 1 |
| Robertson, SJ | 1 |
| Genest, D | 1 |
| Burns, KD | 2 |
| Huang, F | 1 |
| Lezama, MA | 1 |
| Ontiveros, JA | 1 |
| Bravo, G | 1 |
| Villafaña, S | 1 |
| del-Rio-Navarro, BE | 1 |
| Hong, E | 1 |
| Luo, Y | 1 |
| Escano, CS | 1 |
| Yang, Z | 1 |
| Asico, L | 1 |
| Jones, JE | 1 |
| Armando, I | 1 |
| Lu, Q | 1 |
| Sibley, DR | 1 |
| Eisner, GM | 1 |
| Jose, PA | 1 |
| Ulmasov, B | 1 |
| Xu, Z | 1 |
| Talkad, V | 1 |
| Oshima, K | 1 |
| Neuschwander-Tetri, BA | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Łukawski, K | 1 |
| Janowska, A | 1 |
| Jakubus, T | 1 |
| Tochman-Gawda, A | 1 |
| Czuczwar, SJ | 1 |
| Fukuda, A | 1 |
| Iwatsubo, S | 1 |
| Kawachi, H | 1 |
| Kitamura, K | 1 |
| Jiménez-Ferrer, E | 1 |
| Badillo, FH | 1 |
| González-Cortazar, M | 1 |
| Tortoriello, J | 1 |
| Herrera-Ruiz, M | 1 |
| Pereira, MG | 1 |
| Becari, C | 1 |
| Oliveira, JA | 1 |
| Salgado, MC | 1 |
| Garcia-Cairasco, N | 1 |
| Costa-Neto, CM | 1 |
| Vieira, JM | 1 |
| Sena, CR | 1 |
| Schlenker, EH | 1 |
| Detaint, D | 1 |
| Aegerter, P | 1 |
| Tubach, F | 1 |
| Hoffman, I | 1 |
| Plauchu, H | 1 |
| Dulac, Y | 1 |
| Faivre, LO | 1 |
| Delrue, MA | 1 |
| Collignon, P | 1 |
| Odent, S | 1 |
| Tchitchinadze, M | 1 |
| Bouffard, C | 1 |
| Arnoult, F | 1 |
| Gautier, M | 1 |
| Boileau, C | 1 |
| Jondeau, G | 1 |
| Durand, MJ | 1 |
| Raffai, G | 1 |
| Weinberg, BD | 1 |
| Lombard, JH | 1 |
| Xu, X | 3 |
| Zhao, W | 2 |
| Wan, W | 2 |
| Ji, LL | 1 |
| Powers, AS | 2 |
| Erikson, JM | 2 |
| Zhang, JQ | 2 |
| Vaňourková, Z | 3 |
| Kramer, HJ | 4 |
| Husková, Z | 4 |
| Cervenka, L | 4 |
| Vaněčková, I | 3 |
| Rakusan, D | 1 |
| Kujal, P | 3 |
| Vernerová, Z | 3 |
| Mrázová, I | 1 |
| Thumová, M | 1 |
| McIff, TE | 1 |
| Poisner, AM | 1 |
| Herndon, B | 1 |
| Lankachandra, K | 1 |
| Molteni, A | 1 |
| Adler, F | 1 |
| Günther, S | 1 |
| Baba, HA | 1 |
| Hauptmann, S | 1 |
| Holzhausen, HJ | 1 |
| Grossmann, C | 1 |
| Punkt, K | 1 |
| Kusche, T | 1 |
| Jones, LR | 1 |
| Gergs, U | 1 |
| Neumann, J | 1 |
| Ferreira, DN | 1 |
| Katayama, IA | 1 |
| Oliveira, IB | 1 |
| Rosa, KT | 1 |
| Furukawa, LN | 1 |
| Coelho, MS | 1 |
| Heimann, JC | 1 |
| Teekakirikul, P | 1 |
| Eminaga, S | 1 |
| Toka, O | 1 |
| Alcalai, R | 1 |
| Wakimoto, H | 1 |
| Nayor, M | 1 |
| Konno, T | 1 |
| Gorham, JM | 1 |
| Wolf, CM | 1 |
| Schmitt, JP | 1 |
| Molkentin, JD | 1 |
| Norris, RA | 1 |
| Tager, AM | 1 |
| Hoffman, SR | 1 |
| Markwald, RR | 1 |
| Seidman, CE | 1 |
| Seidman, JG | 1 |
| Nistala, H | 1 |
| Lee-Arteaga, S | 1 |
| Siciliano, G | 1 |
| Rifkin, AN | 1 |
| Dietz, HC | 7 |
| Rifkin, DB | 2 |
| Silva, Rde B | 1 |
| Ramalho, FS | 1 |
| Ramalho, LZ | 1 |
| da Silva, AQ | 1 |
| Fontes, MA | 2 |
| Kanagy, NL | 1 |
| Ng, ET | 1 |
| Sim, MK | 1 |
| Loke, WK | 1 |
| Xie, L | 1 |
| Lin, P | 1 |
| Xie, H | 1 |
| de Paula, WX | 1 |
| Denadai, AM | 1 |
| Santoro, MM | 1 |
| Braga, AN | 1 |
| Sinisterra, RD | 1 |
| Thatcher, SE | 2 |
| Lu, H | 2 |
| Gurley, SB | 1 |
| Worou, ME | 1 |
| Belmokhtar, K | 1 |
| Bonnet, P | 1 |
| Vourc'h, P | 1 |
| Machet, MC | 1 |
| Khamis, G | 1 |
| Eder, V | 1 |
| Holm, TM | 3 |
| Habashi, JP | 3 |
| Doyle, JJ | 2 |
| Bedja, D | 3 |
| van Erp, C | 1 |
| Kim, D | 1 |
| Schoenhoff, F | 2 |
| Cohn, RD | 3 |
| Loeys, BL | 2 |
| Thomas, CJ | 1 |
| Patnaik, S | 1 |
| Marugan, JJ | 1 |
| Judge, DP | 3 |
| Aziz, H | 1 |
| Modiri, AN | 1 |
| Dong, XG | 1 |
| Fernandes, BH | 1 |
| Okabe, C | 1 |
| Muñoz, M | 1 |
| Rincón, J | 1 |
| Pedreañez, A | 1 |
| Viera, N | 1 |
| Hernández-Fonseca, JP | 1 |
| Mosquera, J | 1 |
| Yang, SH | 1 |
| Choi, JS | 1 |
| Choi, DH | 1 |
| Honetschlägerová, Z | 1 |
| Sporková, A | 1 |
| Kopkan, L | 1 |
| Hammock, BD | 1 |
| Imig, JD | 1 |
| Chábová, VC | 1 |
| Tesař, V | 2 |
| Lindsey, S | 1 |
| Lin, MS | 1 |
| Kassik, KA | 1 |
| Machado, FS | 1 |
| Carter, CS | 1 |
| El-Lakkany, NM | 1 |
| El-Maadawy, W | 1 |
| Ain-Shoka, A | 1 |
| Badawy, A | 1 |
| Hammam, O | 1 |
| Ebeid, F | 1 |
| Sharma, NM | 1 |
| Mehta, PP | 1 |
| Ishida, K | 1 |
| Matsumoto, T | 3 |
| Taguchi, K | 4 |
| Kamata, K | 3 |
| Kobayashi, T | 3 |
| Venegas-Pont, M | 1 |
| Mathis, KW | 1 |
| Iliescu, R | 1 |
| Ray, WH | 1 |
| Glover, PH | 1 |
| Ryan, MJ | 1 |
| McLoughlin, D | 1 |
| McGuinness, J | 1 |
| Byrne, J | 1 |
| Terzo, E | 1 |
| Huuskonen, V | 1 |
| McAllister, H | 1 |
| Black, A | 1 |
| Kearney, S | 1 |
| Kay, E | 1 |
| Hill, AD | 1 |
| Redmond, JM | 1 |
| Sohma, R | 1 |
| Inoue, T | 1 |
| Abe, S | 1 |
| Taguchi, I | 1 |
| Kikuchi, M | 1 |
| Toyoda, S | 1 |
| Arikawa, T | 1 |
| Hikichi, Y | 1 |
| Sanada, S | 1 |
| Asanuma, H | 1 |
| Kitakaze, M | 1 |
| Node, K | 1 |
| Nemoto, S | 1 |
| Comiter, C | 1 |
| Phull, HS | 1 |
| Wösten-van Asperen, RM | 2 |
| Lutter, R | 2 |
| Specht, PA | 1 |
| Moll, GN | 1 |
| van Woensel, JB | 2 |
| van der Loos, CM | 2 |
| van Goor, H | 1 |
| Kamilic, J | 1 |
| Florquin, S | 2 |
| Bos, AP | 2 |
| Zou, Y | 1 |
| Lin, L | 1 |
| Ye, Y | 1 |
| Wei, J | 1 |
| Zhou, N | 1 |
| Liang, Y | 1 |
| Gong, H | 1 |
| Li, L | 1 |
| Ge, J | 1 |
| Merk, DR | 1 |
| Chin, JT | 1 |
| Dake, BA | 1 |
| Maegdefessel, L | 1 |
| Miller, MO | 1 |
| Kimura, N | 1 |
| Tsao, PS | 1 |
| Iosef, C | 1 |
| Berry, GJ | 1 |
| Mohr, FW | 1 |
| Spin, JM | 1 |
| Alvira, CM | 1 |
| Robbins, RC | 1 |
| Fischbein, MP | 1 |
| Podowski, M | 2 |
| Calvi, C | 2 |
| Metzger, S | 1 |
| Misono, K | 1 |
| Poonyagariyagorn, H | 1 |
| Lopez-Mercado, A | 1 |
| Ku, T | 1 |
| Lauer, T | 1 |
| McGrath-Morrow, S | 1 |
| Berger, A | 1 |
| Cheadle, C | 1 |
| Tuder, R | 1 |
| Mitzner, W | 1 |
| Wise, R | 1 |
| Neptune, E | 1 |
| Rehman, A | 1 |
| Leibowitz, A | 1 |
| Yamamoto, N | 1 |
| Scott, L | 1 |
| Crambert, S | 1 |
| Zelenin, S | 1 |
| Eklöf, AC | 1 |
| Di Ciano, L | 1 |
| Ibarra, F | 1 |
| Aperia, A | 1 |
| Azuma, J | 1 |
| Iekushi, K | 1 |
| Sanada, F | 1 |
| Otsu, R | 1 |
| Iwabayashi, M | 1 |
| Okayama, K | 1 |
| Wengrower, D | 1 |
| Zanninelli, G | 1 |
| Latella, G | 1 |
| Necozione, S | 1 |
| Metanes, I | 1 |
| Israeli, E | 1 |
| Lysy, J | 1 |
| Pines, M | 1 |
| Papo, O | 1 |
| Goldin, E | 1 |
| Deji, N | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Chin-Kanasaki, M | 1 |
| Tanaka, Y | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Ock, S | 1 |
| Ahn, J | 1 |
| Lee, SH | 2 |
| Park, H | 1 |
| Son, JW | 1 |
| Oh, JG | 1 |
| Yang, DK | 1 |
| Lee, WS | 1 |
| Rho, J | 1 |
| Oh, GT | 1 |
| Abel, ED | 1 |
| Park, WJ | 1 |
| Min, JK | 1 |
| Watson, AM | 1 |
| Allen, AM | 1 |
| Tojo, C | 1 |
| Noda, K | 1 |
| Campuzano, V | 1 |
| Segura-Puimedon, M | 1 |
| Terrado, V | 1 |
| Sánchez-Rodríguez, C | 1 |
| Coustets, M | 1 |
| Menacho-Márquez, M | 1 |
| Nevado, J | 1 |
| Bustelo, XR | 1 |
| Francke, U | 1 |
| Pérez-Jurado, LA | 1 |
| Shen, J | 1 |
| Cui, Y | 1 |
| Jiang, J | 1 |
| Peng, J | 2 |
| Wu, Q | 2 |
| Shimizu, A | 1 |
| Miyazaki, Y | 1 |
| Hosoya, T | 1 |
| Matsusaka, T | 1 |
| Min, LJ | 1 |
| Mogi, M | 1 |
| Shudou, M | 1 |
| Jing, F | 1 |
| Tsukuda, K | 1 |
| Ohshima, K | 1 |
| Iwanami, J | 1 |
| Horiuchi, M | 1 |
| Gharaibeh, B | 1 |
| Chun-Lansinger, Y | 1 |
| Hagen, T | 1 |
| Ingham, SJ | 1 |
| Wright, V | 1 |
| Fu, F | 1 |
| Gupte, M | 1 |
| Boustany-Kari, CM | 1 |
| Shoemaker, R | 1 |
| Yiannikouris, F | 1 |
| Karounos, M | 1 |
| Arita, DY | 1 |
| Cunha, TS | 1 |
| Perez, JD | 1 |
| Colucci, JA | 1 |
| Ronchi, FA | 1 |
| Nogueira, MD | 1 |
| Arita, LS | 1 |
| Aragão, DS | 1 |
| Teixeira, Vde P | 1 |
| Certíková Chábová, V | 1 |
| Skaroupková, P | 1 |
| Aga-Mizrachi, S | 1 |
| Brunschwig, Z | 1 |
| Kassis, I | 1 |
| Ettinger, K | 1 |
| Barak, V | 1 |
| Yousif, MH | 1 |
| Dhaunsi, GS | 1 |
| Makki, BM | 1 |
| Qabazard, BA | 1 |
| Akhtar, S | 1 |
| Benter, IF | 1 |
| Ziberna, L | 1 |
| Rinaldi Tosi, M | 1 |
| Gil Lorenzo, A | 1 |
| Fornés, M | 1 |
| Hong, NJ | 1 |
| Garvin, JL | 1 |
| Meems, LM | 1 |
| Cannon, MV | 1 |
| Mahmud, H | 1 |
| Voors, AA | 1 |
| van Gilst, WH | 3 |
| Silljé, HH | 1 |
| Ruifrok, WP | 1 |
| de Boer, RA | 2 |
| Kim, KS | 1 |
| Abraham, D | 1 |
| Williams, B | 1 |
| Violin, JD | 1 |
| Mao, L | 1 |
| Rockman, HA | 1 |
| MacDonald, EM | 1 |
| Xu, H | 1 |
| McBride, F | 1 |
| Hewinson, J | 1 |
| Toward, M | 1 |
| Hendy, EB | 1 |
| Graham, D | 1 |
| Dominiczak, AF | 1 |
| Giannotta, M | 1 |
| Waki, H | 1 |
| Ascione, R | 1 |
| Ashrafi, F | 1 |
| Nematbakhsh, M | 1 |
| Safari, T | 1 |
| Talebi, A | 1 |
| Nasri, H | 1 |
| Khazaei, M | 1 |
| Baradaran-Mahdavi, MM | 1 |
| Jafapisheh, A | 1 |
| Olia, B | 1 |
| Pirhaji, O | 1 |
| Hashemi-Nia, SJ | 1 |
| Eshraghi, F | 1 |
| Pezeshki, Z | 1 |
| Mortazavi, M | 1 |
| Koba, S | 1 |
| Watanabe, R | 1 |
| Kano, N | 1 |
| Watanabe, T | 3 |
| Zhang, TL | 1 |
| Fu, JL | 1 |
| Geng, Z | 1 |
| Yang, JJ | 1 |
| Sun, XJ | 1 |
| Rius, C | 1 |
| Piqueras, L | 1 |
| González-Navarro, H | 1 |
| Albertos, F | 1 |
| Company, C | 1 |
| López-Ginés, C | 1 |
| Ludwig, A | 1 |
| Blanes, JI | 1 |
| Morcillo, EJ | 1 |
| Sanz, MJ | 1 |
| Kemi, OJ | 1 |
| Haram, PM | 1 |
| Høydal, MA | 1 |
| Wisløff, U | 2 |
| Ellingsen, Ø | 1 |
| Walch, JD | 1 |
| Carreño, FR | 1 |
| Shirai, Y | 1 |
| Yoshiji, H | 1 |
| Noguchi, R | 1 |
| Kaji, K | 1 |
| Aihara, Y | 1 |
| Douhara, A | 1 |
| Moriya, K | 1 |
| Namisaki, T | 1 |
| Kawaratani, H | 1 |
| Fukui, H | 1 |
| Itoi, T | 1 |
| Oka, T | 1 |
| Terada, N | 1 |
| Shihab, FS | 1 |
| Bennett, WM | 1 |
| Isaac, J | 1 |
| Yi, H | 1 |
| Andoh, TF | 1 |
| Bergström, G | 4 |
| Johansson, I | 1 |
| Wickman, A | 3 |
| Gan, L | 1 |
| Thorup, C | 1 |
| Mitani, H | 1 |
| Yamazaki, I | 1 |
| Sata, M | 1 |
| Usui, S | 1 |
| Mori, I | 2 |
| Ohno, M | 2 |
| Kucharewicz, I | 1 |
| Pawlak, R | 2 |
| Matys, T | 1 |
| Pawlak, D | 1 |
| Buczko, W | 3 |
| Morgan, T | 2 |
| Griffiths, C | 1 |
| Delbridge, L | 1 |
| Pechlivanova, D | 1 |
| Kambourova, T | 1 |
| Matsoukas, J | 1 |
| Georgiev, V | 1 |
| Asiedu-Gyekye, IJ | 1 |
| Antwi, DA | 1 |
| Zhu, BQ | 2 |
| Sievers, RE | 3 |
| Browne, AE | 4 |
| Lee, RJ | 3 |
| Chatterjee, K | 4 |
| Grossman, W | 2 |
| Karliner, JS | 1 |
| Parmley, WW | 4 |
| Laplante, MA | 1 |
| Wu, R | 1 |
| El Midaoui, A | 1 |
| de Champlain, J | 1 |
| Bayorh, MA | 1 |
| Ganafa, AA | 1 |
| Socci, RR | 1 |
| Eatman, D | 1 |
| Silvestrov, N | 1 |
| Abukhalaf, IK | 1 |
| Appenroth, D | 1 |
| Beutinger, R | 1 |
| Lupp, A | 1 |
| Fleck, C | 1 |
| Gschwend, S | 1 |
| Pinto, YM | 3 |
| de Zeeuw, D | 1 |
| Morato, M | 1 |
| Sousa, T | 1 |
| Guimarães, S | 1 |
| Moura, D | 1 |
| Albino-Teixeira, A | 1 |
| Aunapuu, M | 3 |
| Pechter, U | 3 |
| Arend, A | 2 |
| Suuroja, T | 1 |
| Ots, M | 3 |
| Rizzoni, D | 1 |
| Rodella, L | 1 |
| Porteri, E | 1 |
| Rezzani, R | 1 |
| Sleiman, I | 1 |
| Paiardi, S | 1 |
| Guelfi, D | 1 |
| De Ciuceis, C | 1 |
| Boari, GE | 1 |
| Bianchi, R | 1 |
| Agabiti-Rosei, E | 1 |
| Shimizu, H | 1 |
| Miyoshi, M | 1 |
| Matsumoto, K | 1 |
| Goto, O | 1 |
| Imoto, T | 1 |
| Rosário, LB | 1 |
| Rocha, I | 1 |
| Silva-Carvalho, L | 1 |
| Ueno, T | 1 |
| Tremblay, J | 1 |
| Kunes, J | 1 |
| Zicha, J | 1 |
| Dobesová, Z | 1 |
| Pausova, Z | 1 |
| Deng, AY | 1 |
| Jacob, HJ | 1 |
| Hamet, P | 1 |
| Kowala, MC | 1 |
| Murugesan, N | 1 |
| Tellew, J | 1 |
| Carlson, K | 1 |
| Monshizadegan, H | 1 |
| Ryan, C | 1 |
| Gu, Z | 1 |
| Kane, B | 1 |
| Fadnis, L | 1 |
| Baska, RA | 1 |
| Beyer, S | 1 |
| Arthur, S | 1 |
| Dickinson, K | 1 |
| Perrone, M | 1 |
| Ferrer, P | 1 |
| Giancarli, M | 1 |
| Baumann, J | 1 |
| Bird, E | 1 |
| Panchal, B | 1 |
| Trippodo, N | 1 |
| Barrish, J | 1 |
| Macor, JE | 1 |
| Kumar, D | 1 |
| Menon, V | 1 |
| Ford, WR | 1 |
| Clanachan, AS | 1 |
| Jugdutt, BI | 1 |
| Riaz, AA | 1 |
| Schramm, R | 1 |
| Sato, T | 2 |
| Menger, MD | 1 |
| Jeppsson, B | 1 |
| Thorlacius, H | 1 |
| Ishiyama, Y | 1 |
| Gallagher, PE | 1 |
| Averill, DB | 1 |
| Tallant, EA | 1 |
| Ferrario, CM | 1 |
| González, GE | 1 |
| Mangas, F | 1 |
| Palleiro, J | 1 |
| Rodríguez, M | 1 |
| Depetris Chauvin, A | 1 |
| Gelpi, RJ | 1 |
| Morales, C | 1 |
| Singh, D | 2 |
| Chopra, K | 1 |
| Hashim, S | 1 |
| Anand-Srivastava, MB | 1 |
| Ma, H | 1 |
| Meng, QH | 1 |
| Li, XH | 1 |
| Wang, XH | 1 |
| Li, WW | 1 |
| el-Batran, SA | 2 |
| el-Shenawy, SM | 1 |
| Nofal, SM | 1 |
| Abdel-Salam, OM | 1 |
| Arbid, MS | 1 |
| Sasaki, M | 1 |
| Uehara, S | 1 |
| Ohta, H | 1 |
| Kemi, M | 1 |
| Nishikibe, M | 1 |
| Matsumoto, H | 1 |
| Riispere, Z | 1 |
| Vihalemm, T | 1 |
| Kullissaar, T | 1 |
| Zilmer, K | 1 |
| Zilmer, M | 1 |
| Iglarz, M | 1 |
| Touyz, RM | 1 |
| Viel, EC | 1 |
| Amiri, F | 1 |
| Wang, XP | 1 |
| Zhang, R | 1 |
| Wu, K | 1 |
| Dong, Y | 1 |
| Sethi, R | 1 |
| Shao, Q | 1 |
| Ren, B | 1 |
| Saini, HK | 1 |
| Takeda, N | 1 |
| Dhalla, NS | 2 |
| Sun, BK | 2 |
| Li, C | 2 |
| Lim, SW | 2 |
| Choi, BS | 1 |
| Kim, IS | 1 |
| Kim, YS | 2 |
| Bang, BK | 1 |
| Yang, CW | 2 |
| Dragun, D | 1 |
| Bräsen, JH | 1 |
| Fritsche, L | 1 |
| Nieminen-Kelhä, M | 1 |
| Dechend, R | 2 |
| Kintscher, U | 1 |
| Rudolph, B | 1 |
| Hoebeke, J | 1 |
| Eckert, D | 1 |
| Mazak, I | 1 |
| Plehm, R | 1 |
| Schönemann, C | 1 |
| Unger, T | 2 |
| Budde, K | 1 |
| Neumayer, HH | 1 |
| Luft, FC | 2 |
| Wallukat, G | 1 |
| Kühnel, W | 1 |
| Velho, M | 1 |
| Epifanio, HB | 1 |
| Zornoff, LA | 1 |
| Matsubara, BB | 1 |
| de Paiva, SA | 1 |
| Inoue, RM | 1 |
| Matsubara, LS | 1 |
| Song, JC | 1 |
| Kang, SW | 1 |
| Kang, DH | 1 |
| Cha, JH | 1 |
| Wolf, SC | 1 |
| Sauter, G | 1 |
| Risler, T | 1 |
| Brehm, BR | 1 |
| Parvanova, A | 1 |
| Chiurchiu, C | 1 |
| Ruggenenti, P | 1 |
| Akil, I | 1 |
| Inan, S | 1 |
| Gurcu, B | 1 |
| Nazikoglu, A | 1 |
| Ozbilgin, K | 1 |
| Muftuoglu, S | 1 |
| Aldigier, JC | 1 |
| Kanjanbuch, T | 1 |
| Brown, NJ | 1 |
| Tuttle, JB | 1 |
| Ayabe, N | 1 |
| Babaev, VR | 1 |
| Kamińska, M | 1 |
| Mogielnicki, A | 1 |
| Stankiewicz, A | 1 |
| Kramkowski, K | 1 |
| Domaniewski, T | 1 |
| Chabielska, E | 2 |
| Bobadilla Lugo, RA | 1 |
| Pérez-Alvarez, VM | 1 |
| Robledo, LA | 1 |
| López Sanchez, P | 1 |
| Chu, KY | 1 |
| Lau, T | 1 |
| Carlsson, PO | 1 |
| Leung, PS | 2 |
| Travis, J | 1 |
| Cooper, TK | 1 |
| Myers, L | 1 |
| Klein, EC | 1 |
| Neptune, ER | 1 |
| Halushka, MK | 1 |
| Gabrielson, K | 1 |
| Huso, DL | 1 |
| Kellner, D | 1 |
| Richardson, I | 1 |
| Seshan, SV | 1 |
| El Chaar, M | 1 |
| Vaughan, ED | 1 |
| Poppas, D | 1 |
| Felsen, D | 1 |
| Laudanno, OM | 1 |
| Cesolari, JA | 1 |
| Otani, L | 1 |
| Yasumatsu, T | 1 |
| Murakami, M | 1 |
| Hayashi, A | 1 |
| Kimoto, K | 1 |
| Murakami, T | 1 |
| Johansson, ME | 2 |
| Skøtt, O | 2 |
| Gan, LM | 1 |
| Yoshizumi, M | 1 |
| Ishizawa, K | 1 |
| Izawa, Y | 1 |
| Tamaki, T | 1 |
| Phull, H | 1 |
| Salkini, M | 1 |
| Escobar, C | 1 |
| Purves, T | 1 |
| Comiter, CV | 1 |
| Grobe, JL | 1 |
| Katovich, MJ | 1 |
| Sumners, C | 1 |
| Zoccal, DB | 1 |
| Bonagamba, LG | 1 |
| Oliveira, FR | 1 |
| Antunes-Rodrigues, J | 1 |
| Machado, BH | 1 |
| Sugaru, E | 1 |
| Ono-Kishino, M | 1 |
| Nagamine, J | 1 |
| Tokunaga, T | 1 |
| Kitoh, M | 1 |
| Hume, WE | 1 |
| Nagata, R | 1 |
| Taiji, M | 1 |
| McGrath, JC | 1 |
| Baumann, M | 1 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Struijker Boudier, HA | 1 |
| Lebel, M | 1 |
| Rodrigue, ME | 1 |
| Agharazii, M | 1 |
| Larivière, R | 1 |
| Lázaro, A | 1 |
| Gállego-Delgado, J | 1 |
| Osende, JI | 1 |
| Egido, J | 1 |
| Vivanco, F | 1 |
| Price, A | 1 |
| McLean, S | 1 |
| Sturrock, RD | 1 |
| Bro, S | 1 |
| Binder, CJ | 1 |
| Witztum, JL | 1 |
| Olgaard, K | 1 |
| Nielsen, LB | 1 |
| Fischer, R | 1 |
| Gapelyuk, A | 1 |
| Shagdarsuren, E | 1 |
| Gruner, K | 1 |
| Gruner, A | 1 |
| Gratze, P | 1 |
| Wellner, M | 1 |
| Fiebeler, A | 1 |
| Dietz, R | 1 |
| Schirdewan, A | 1 |
| Yamamoto, T | 1 |
| Shirayama, T | 1 |
| Sakatani, T | 1 |
| Takahashi, T | 1 |
| Tanaka, H | 1 |
| Takamatsu, T | 1 |
| Spitzer, KW | 1 |
| Matsubara, H | 1 |
| Ibañez, P | 1 |
| Solis, N | 1 |
| Pizarro, M | 1 |
| Aguayo, G | 1 |
| Duarte, I | 1 |
| Miquel, JF | 1 |
| Accatino, L | 1 |
| Arrese, M | 1 |
| Tokuyama, H | 1 |
| Kelly, DJ | 1 |
| Gow, RM | 1 |
| Gilbert, RE | 1 |
| Chan, YC | 1 |
| Torp, M | 1 |
| Brønd, L | 1 |
| Hadrup, N | 1 |
| Nielsen, JB | 1 |
| Praetorius, J | 1 |
| Nielsen, S | 1 |
| Christensen, S | 1 |
| Jonassen, TE | 1 |
| Messadi-Laribi, E | 1 |
| Griol-Charhbili, V | 1 |
| Pizard, A | 1 |
| Vincent, MP | 1 |
| Heudes, D | 1 |
| Meneton, P | 1 |
| Alhenc-Gelas, F | 1 |
| Richer, C | 1 |
| Etcheverry, SB | 1 |
| Ferrer, EG | 1 |
| Naso, L | 1 |
| Barrio, DA | 1 |
| Lezama, L | 1 |
| Rojo, T | 1 |
| Williams, PA | 1 |
| Yao, S | 1 |
| Feng, D | 1 |
| Li, K | 1 |
| Lombraña, A | 1 |
| Rivero, M | 1 |
| Lin, YX | 1 |
| Gao, GD | 1 |
| Salam, OM | 1 |
| Abdallah, HM | 1 |
| Shaffie, NM | 1 |
| Mori, K | 1 |
| Yoshida, K | 2 |
| Tani, J | 1 |
| Nakagawa, Y | 1 |
| Hoshikawa, S | 1 |
| Ozaki, H | 1 |
| Ito, S | 1 |
| Dai, Q | 1 |
| Xu, M | 2 |
| Yao, M | 1 |
| Sun, B | 1 |
| Wang, B | 1 |
| Scott, RC | 1 |
| Pattillo, CB | 1 |
| Prabhakarpandian, B | 1 |
| Sundaram, S | 1 |
| Kiani, MF | 1 |
| Haitsma, JJ | 1 |
| Merkus, MP | 1 |
| Lachmann, B | 1 |
| Ferreira, JC | 1 |
| Bacurau, AV | 1 |
| Evangelista, FS | 1 |
| Coelho, MA | 1 |
| Oliveira, EM | 2 |
| Krieger, JE | 2 |
| Brum, PC | 1 |
| Antelava, NA | 1 |
| Gongadze, NV | 1 |
| Gogolauri, MI | 1 |
| Kezeli, TD | 1 |
| Pachkoriia, KZ | 1 |
| Camelo, JS | 1 |
| Hehre, D | 1 |
| Devia, C | 1 |
| Camelo, SH | 1 |
| Bancalari, E | 1 |
| Suguihara, C | 1 |
| Miyazaki, A | 1 |
| Kitaichi, N | 1 |
| Ohgami, K | 1 |
| Iwata, D | 1 |
| Jin, XH | 1 |
| Iwabuchi, K | 1 |
| Morohashi, T | 1 |
| Ohno, S | 1 |
| Onoé, K | 1 |
| Chen, QQ | 1 |
| Luo, D | 1 |
| Deng, HW | 1 |
| Tufescu, A | 1 |
| Kanazawa, M | 1 |
| Ishida, A | 1 |
| Sasaki, Y | 1 |
| Ootaka, T | 1 |
| Kohzuki, M | 1 |
| Bedette, D | 1 |
| Mattar, AL | 1 |
| Xu, HX | 1 |
| Li, JJ | 1 |
| Li, GS | 1 |
| Li, NX | 1 |
| Tiurenkov, IN | 1 |
| Nazvanova, AN | 1 |
| Tchepurina, NG | 1 |
| Kheyfets, IA | 1 |
| Dugina, JL | 1 |
| Martyushev-Poklad, AV | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Andersson, IJ | 1 |
| Alexanderson, C | 1 |
| Holmäng, A | 1 |
| Matt, P | 1 |
| Habashi, J | 1 |
| Carrel, T | 1 |
| Cameron, DE | 1 |
| Van Eyk, JE | 1 |
| Ji, L | 1 |
| Lao, S | 1 |
| Sendra, J | 1 |
| Llorente-Cortés, V | 1 |
| Costales, P | 1 |
| Huesca-Gómez, C | 1 |
| Badimon, L | 1 |
| Nagami, GT | 1 |
| Rosenfeld, CR | 1 |
| Zagariya, AM | 1 |
| Liu, XT | 1 |
| Willis, BC | 1 |
| Fluharty, S | 1 |
| Vidyasagar, D | 1 |
| Matsuhisa, S | 1 |
| Otani, H | 1 |
| Okazaki, T | 2 |
| Yamashita, K | 1 |
| Akita, Y | 1 |
| Sato, D | 1 |
| Moriguchi, A | 1 |
| Imamura, H | 1 |
| Iwasaka, T | 1 |
| Poppi, EP | 1 |
| Elimban, V | 1 |
| Milanović, JG | 1 |
| Milanović, S | 1 |
| You, D | 1 |
| Cochain, C | 1 |
| Loinard, C | 1 |
| Vilar, J | 1 |
| Mees, B | 1 |
| Duriez, M | 1 |
| Lévy, BI | 2 |
| Silvestre, JS | 1 |
| Sabino, B | 1 |
| Lessa, MA | 1 |
| Nascimento, AR | 1 |
| Rodrigues, CA | 1 |
| Henriques, Md | 1 |
| Garzoni, LR | 1 |
| Tibiriçá, E | 1 |
| Mecawi, AS | 1 |
| Lepletier, A | 1 |
| Araujo, IG | 1 |
| Fonseca, FV | 1 |
| Reis, LC | 1 |
| Zhang, YM | 1 |
| Wei, EQ | 1 |
| Hu, X | 1 |
| Shi, Y | 1 |
| Zhang, JF | 1 |
| Elks, C | 1 |
| Zheng, JP | 1 |
| Yang, ZM | 1 |
| Francis, J | 2 |
| Barauna, VG | 1 |
| Magalhaes, FC | 1 |
| Kang, YJ | 1 |
| Song, IH | 1 |
| Choi, HC | 1 |
| Imanishi, T | 1 |
| Kuroi, A | 1 |
| Ikejima, H | 1 |
| Kobayashi, K | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Akasaka, T | 1 |
| Morita, O | 1 |
| Kushida, H | 1 |
| Kunihara, M | 1 |
| Stauss, HM | 1 |
| Zhu, YC | 1 |
| Redlich, T | 1 |
| Adamiak, D | 1 |
| Mott, A | 1 |
| Kregel, KC | 1 |
| Niederberger, M | 1 |
| Aubert, JF | 2 |
| Nussberger, J | 1 |
| Brunner, HR | 1 |
| Waeber, B | 1 |
| Lacour, C | 1 |
| Canals, F | 1 |
| Galindo, G | 1 |
| Cazaubon, C | 1 |
| Segondy, D | 1 |
| Nisato, D | 1 |
| Sweet, CS | 1 |
| Rucinska, EJ | 1 |
| Kanda, T | 1 |
| Araki, M | 1 |
| Nakano, M | 1 |
| Imai, S | 1 |
| Suzuki, T | 1 |
| Murata, K | 1 |
| Kobayashi, I | 1 |
| Nagura, J | 1 |
| Yasuda, S | 1 |
| Fujishima, K | 1 |
| Yamamoto, M | 1 |
| Hui, C | 1 |
| Kawano, K | 1 |
| Katano, K | 1 |
| Ogino, H | 1 |
| Hachisu, M | 1 |
| Konno, F | 1 |
| Hanss, BG | 1 |
| Lewy, JE | 1 |
| Vari, RC | 1 |
| Duncia, JV | 1 |
| Santella, JB | 1 |
| Wexler, RR | 1 |
| Inada, Y | 1 |
| Wada, T | 1 |
| Shibouta, Y | 1 |
| Ojima, M | 1 |
| Sanada, T | 1 |
| Ohtsuki, K | 1 |
| Itoh, K | 1 |
| Kubo, K | 1 |
| Kohara, Y | 1 |
| Naka, T | 1 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Richard, V | 1 |
| Ghaleh, B | 1 |
| Berdeaux, A | 1 |
| Giudicelli, JF | 1 |
| Toney, GM | 1 |
| Porter, JP | 1 |
| Ponchon, P | 1 |
| Elghozi, JL | 1 |
| Milavetz, JJ | 1 |
| Raya, TE | 2 |
| Johnson, CS | 1 |
| Morkin, E | 2 |
| Goldman, S | 2 |
| Greene, EL | 1 |
| Kren, S | 1 |
| Hostetter, TH | 2 |
| Deegan, PM | 1 |
| Nolan, C | 1 |
| Ryan, MP | 1 |
| Basinger, MA | 1 |
| Jones, MM | 1 |
| Hande, KR | 1 |
| Fukuyama, J | 1 |
| Ichikawa, K | 1 |
| Miyazawa, K | 1 |
| Hamano, S | 1 |
| Shibata, N | 1 |
| Ujiie, A | 1 |
| Lantelme, P | 1 |
| Lo, M | 1 |
| Mullins, JJ | 1 |
| Gharib, C | 1 |
| Bizollon, CA | 1 |
| Sassard, J | 1 |
| Rosenthal, T | 1 |
| Erlich, Y | 1 |
| Rosenmann, E | 1 |
| Cohen, A | 1 |
| Yotsumoto, T | 1 |
| Naitoh, T | 1 |
| Shikada, K | 1 |
| Tanaka, S | 1 |
| Albrecht, D | 1 |
| Henklein, P | 1 |
| Ganten, D | 1 |
| Junaid, A | 1 |
| Rosenberg, ME | 1 |
| Lankford, SM | 1 |
| Plummer, D | 1 |
| Hellyer, P | 1 |
| Christ, DD | 1 |
| Bai, SA | 1 |
| Tamura, K | 1 |
| Okuhira, M | 1 |
| Amano, H | 1 |
| Inokuma, K | 1 |
| Hirata, T | 1 |
| Mikoshiba, I | 1 |
| Hashimoto, K | 1 |
| Maeso, R | 1 |
| Rodrigo, E | 1 |
| Muñoz-Garcia, R | 1 |
| Navarro-Cid, J | 1 |
| Ruilope, LM | 1 |
| Lahera, V | 1 |
| Cachofeiro, V | 1 |
| Nishikawa, K | 1 |
| Kikuchi, K | 1 |
| Suga, A | 1 |
| Shibasaki, M | 1 |
| Fujimori, A | 1 |
| Inagaki, O | 1 |
| Yanagisawa, I | 1 |
| Massart, PE | 1 |
| Hodeige, DG | 1 |
| Van Mechelen, H | 1 |
| Charlier, AA | 1 |
| Ketelslegers, JM | 1 |
| Heyndrickx, GR | 1 |
| Donckier, JE | 1 |
| Pipinos, II | 1 |
| Nypaver, TJ | 1 |
| Moshin, SK | 1 |
| Careterro, OA | 1 |
| Beierwaltes, WH | 1 |
| Amuchastegui, SC | 1 |
| Azzollini, N | 1 |
| Mister, M | 1 |
| Pezzotta, A | 1 |
| Morsing, P | 1 |
| Wåhlander, H | 1 |
| Isgaard, J | 1 |
| Friberg, P | 2 |
| Venkata, C | 1 |
| Ram, S | 1 |
| Fierro, G | 1 |
| Roczniak, A | 1 |
| Fryer, JN | 1 |
| Levine, DZ | 1 |
| Wollny, T | 1 |
| Rółkowski, R | 1 |
| Gard, PR | 1 |
| Mandy, A | 1 |
| Sutcliffe, MA | 1 |
| Lynch, JJ | 1 |
| Stump, GL | 1 |
| Wallace, AA | 1 |
| Painter, CA | 1 |
| Thomas, JM | 1 |
| Kusma, SE | 1 |
| Gould, RJ | 1 |
| Zhu, B | 2 |
| Pulukurthy, S | 2 |
| Sudhir, K | 2 |
| Chou, TM | 2 |
| Aizawa, T | 1 |
| Taguchi, Ji | 1 |
| Tang, SS | 1 |
| Ingelfinger, JR | 1 |
| Davisson, RL | 1 |
| Stec, DE | 1 |
| Catterall, JF | 1 |
| Sorooshian, M | 1 |
| Olson, JL | 1 |
| Meyer, TW | 1 |
| Pinto-Sietsma, SJ | 1 |
| Philipp, T | 1 |
| Engler, S | 1 |
| Kossamehl, P | 1 |
| Hocher, B | 1 |
| Marquardt, H | 1 |
| Sethmann, S | 1 |
| Lauster, R | 1 |
| Merker, HJ | 1 |
| Paul, M | 1 |
| Stevenson, KM | 1 |
| Edgley, AJ | 1 |
| Worthy, K | 1 |
| Kett, MM | 1 |
| Anderson, WP | 1 |
| Lim, DS | 1 |
| Lutucuta, S | 1 |
| Bachireddy, P | 1 |
| Youker, K | 1 |
| Evans, A | 1 |
| Entman, M | 1 |
| Roberts, R | 1 |
| Marian, AJ | 1 |
| Cheng, CP | 1 |
| Ukai, T | 1 |
| Onishi, K | 1 |
| Ohte, N | 1 |
| Suzuki, M | 1 |
| Zhang, ZS | 1 |
| Cheng, HJ | 1 |
| Tachibana, H | 1 |
| Igawa, A | 1 |
| Little, WC | 1 |
| Raghavendra, V | 1 |
| Kulkarni, SK | 1 |
| Fassot, C | 1 |
| Lambert, E | 1 |
| Lambert, G | 1 |
| Elghozi, J | 1 |
| Silva-Antonialli, MM | 1 |
| Fortes, ZB | 1 |
| Carvalho, MH | 1 |
| Scivoletto, R | 1 |
| Nigro, D | 1 |
| Mankad, S | 1 |
| d'Amato, TA | 1 |
| Reichek, N | 1 |
| McGregor, WE | 1 |
| Rogers, WJ | 1 |
| Kramer, CM | 1 |
| Matsuno, H | 1 |
| Kozawa, O | 1 |
| Niwa, M | 1 |
| Abe, A | 1 |
| Takiguchi, Y | 1 |
| Uematsu, T | 1 |
| Sakamoto, H | 1 |
| Aikawa, M | 1 |
| Hill, CC | 1 |
| Weiss, D | 1 |
| Taylor, WR | 1 |
| Libby, P | 1 |
| Lee, RT | 1 |
| Spalding, M | 1 |
| Ala-Kokko, T | 1 |
| Kiviluoma, K | 1 |
| Ruskoaho, H | 1 |
| Alahuhta, S | 1 |
| De Bruno, MP | 1 |
| Reynoso, HA | 1 |
| Coviello, A | 1 |
| Sun, YP | 1 |
| Glantz, SA | 1 |
| Deedwania, PC | 1 |
| Rouleau, JL | 1 |
| Kapuku, G | 1 |
| Pelletier, S | 1 |
| Gosselin, H | 1 |
| Adam, A | 1 |
| Gagnon, C | 1 |
| Lambert, C | 1 |
| Meloche, S | 1 |
| Dobrian, AD | 1 |
| Schriver, SD | 1 |
| Prewitt, RL | 1 |
| Mazouz, H | 2 |
| Oprisiu, R | 1 |
| Monge, M | 1 |
| Andrejak, M | 1 |
| Fournier, A | 2 |
| Brunner, H | 1 |
| Liang, X | 1 |
| Su, M | 1 |
| Zhao, S | 1 |
| Kiatchoosakun, S | 1 |
| Lawrence, E | 1 |
| Nakada, S | 1 |
| Restivo, J | 1 |
| Walsh, RA | 1 |
| Hoit, BD | 1 |
| Dalmay, F | 1 |
| Allard, J | 1 |
| Pesteil, F | 1 |
| Achard, JM | 1 |
| Loennechen, JP | 1 |
| Falck, G | 1 |
| Ellingsen, O | 1 |
| van Geel, PP | 1 |
| Suurmeijer, AJ | 1 |
| Crijns, HJ | 1 |
| van Veldhuisen, DJ | 1 |
| Garcia, R | 1 |
| Bonhomme, MC | 1 |
| Diebold, S | 1 |
| Alvarez, BV | 1 |
| Ennis, IL | 1 |
| De Hurtado, MC | 1 |
| Cingolani, HE | 1 |
| Véniant, M | 1 |
| Clozel, JP | 1 |
| Hess, P | 1 |
| Fischli, W | 1 |
| Bovee, KC | 1 |
| Thoolen, MJ | 1 |
| Fonken, SJ | 1 |
| Lee, RW | 1 |
| Daugherty, S | 1 |
| Camargo, MJ | 1 |
| von Lutterotti, N | 1 |
| Pecker, MS | 1 |
| James, GD | 1 |
| Laragh, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA[NCT04899206] | 120 participants (Anticipated) | Observational [Patient Registry] | 2021-04-12 | Active, not recruiting | |||
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars[NCT05259137] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder[NCT02709018] | 149 participants (Actual) | Interventional | 2016-07-16 | Completed | |||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| Computational Drug Repurposing for All Epidermolysis Bullosa Simplex (EBS) Cases[NCT03269474] | 60 participants (Anticipated) | Observational | 2017-11-28 | Recruiting | |||
| Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity: a Retrospective Study[NCT04481464] | 500 participants (Anticipated) | Observational | 2020-11-01 | Not yet recruiting | |||
| A Multicenter Randomized Controlled Trial of Exercise in Aortic Dissection Survivors[NCT05610462] | 126 participants (Anticipated) | Interventional | 2023-01-01 | Active, not recruiting | |||
| Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study[NCT03255551] | 50 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome[NCT04575844] | Phase 4 | 80 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | ||
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)[NCT03883412] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes[NCT04203927] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2020-02-01 | Recruiting | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome[NCT00763893] | Phase 3 | 303 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.) | ||
| Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)[NCT02679261] | Phase 3 | 220 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).[NCT04632732] | 140 participants (Actual) | Observational [Patient Registry] | 2020-10-26 | Completed | |||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity[NCT02896309] | 45 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study[NCT06098300] | 30 participants (Anticipated) | Observational | 2023-09-01 | Recruiting | |||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome. (NCT02709018)
Timeframe: 10 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| CC Homozygotes on Losartan | 16.7 |
| T Carriers on Losartan | 15.8 |
"Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week.~The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome." (NCT02709018)
Timeframe: 10 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Losartan | -15.96 |
| Placebo | -16.89 |
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
13 reviews available for losartan and Disease Models, Animal
| Article | Year |
|---|---|
Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.
Topics: Animals; Antifibrinolytic Agents; Cartilage; Disease Models, Animal; Fibrosis; Humans; Losartan; Mus | 2018 |
Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Thor | 2019 |
Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Dise | 2017 |
The preclinical basis of the therapeutic evaluation of losartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease M | 1995 |
Biological approaches to improve skeletal muscle healing after injury and disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Humans; Losartan; Muscle, | 2012 |
TGFβ signaling: its role in fibrosis formation and myopathies.
Topics: Animals; Caveolin 3; Disease Models, Animal; Fibrosis; Humans; Losartan; MicroRNAs; Muscle, Skeletal | 2012 |
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2005 |
[Intracellular signal transduction of vascular injury in insulin resistance].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2006 |
Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Thoracic; Cohort Studies; Disease | 2008 |
Losartan in heart failure: preclinical experiences and initial clinical outcomes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1994 |
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1998 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1998 |
2 trials available for losartan and Disease Models, Animal
| Article | Year |
|---|---|
Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Antihypertensive Agents; Aorta; Blood Pressure; C-Re | 2014 |
Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Disease Models, Animal; Double-Bl | 2010 |
517 other studies available for losartan and Disease Models, Animal
| Article | Year |
|---|---|
Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
Topics: Administration, Oral; Amino Acid Sequence; Angiotensin Receptor Antagonists; Animals; Antihypertensi | 1994 |
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Disease Models, Animal; GABA Antagonists; gamma-Am | 1993 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Topics: Administration, Cutaneous; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agent | 2021 |
In Vivo Renin Activity Imaging in the Kidney of Progeroid
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA | 2021 |
Investigation of the Antihypertrophic and Antifibrotic Effects of Losartan in a Rat Model of Radiation-Induced Heart Disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chymases; Disease Models, Animal; Heart Failure; H | 2021 |
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
Topics: Angiotensin I; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Hypertension | 2021 |
Losartan Attenuates Atherosclerosis in Uremic Mice by Regulating Treg/Th17 Balance via Mediating PTEN/PI3K/Akt Pathway.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Interleukin-10; Interleukin-17; Interleukin-6; Los | 2022 |
Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; | 2022 |
Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Disease Models, Animal; Frailty; Inflammati | 2022 |
Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report.
Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupt | 2022 |
The effect of losartan on the development of post-traumatic joint stiffness in a rat model.
Topics: Animals; Contracture; Disease Models, Animal; Joint Diseases; Joint Dislocations; Losartan; Rats; Ra | 2023 |
Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cholesterol; Creatine Kinase; Dise | 2019 |
Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Joint Capsule; Knee Injuries; Knee Joint; L | 2019 |
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bronchi; Cells, Cultured; Cystic Fibrosis; Disease | 2020 |
Nephroprotective effect of losartan in IgA model rat.
Topics: Actins; Animals; Chemokine CCL2; Disease Models, Animal; Gene Expression Regulation; Glomerulonephri | 2019 |
AT1 and AT2 receptors modulate renal tubular cell necroptosis in angiotensin II-infused renal injury mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2019 |
Losartan inhibits hyposmotic-induced increase of IKs current and shortening of action potential duration in guinea pig atrial myocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Femal | 2020 |
Injured Podocytes Are Sensitized to Angiotensin II-Induced Calcium Signaling.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Signaling; Cells, Cultured; Disease Model | 2020 |
Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Disease Models, Animal; | 2020 |
Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome.
Topics: Animals; Colon; Corticotropin-Releasing Hormone; Disease Models, Animal; Hyperalgesia; Irritable Bow | 2020 |
Fitness is improved by adjustments in muscle intracellular signaling in rats with renovascular hypertension 2K1C undergoing voluntary physical exercise.
Topics: Animals; Baroreflex; Blood Pressure; Bradycardia; Disease Models, Animal; Heart Rate; Hypertension, | 2020 |
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Ne | 2020 |
COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.
Topics: Angiotensin Receptor Antagonists; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Diseas | 2020 |
A method to quantify regional axonal transport blockade at the optic nerve head after short term intraocular pressure elevation in mice.
Topics: Amyloid beta-Protein Precursor; Animals; Antihypertensive Agents; Axonal Transport; Axons; Disease M | 2020 |
AT2R's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease.
Topics: Alzheimer Disease; Angiotensin II Type 2 Receptor Blockers; Animals; Anti-Inflammatory Agents; Cogni | 2020 |
Losartan attenuates neuroinflammation and neuropathic pain in paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Disease Models, Animal; Enzyme-Linked Immuno | 2020 |
The Role of Losartan as a Potential Neuroregenerative Pharmacological Agent after Aneurysmal Subarachnoid Haemorrhage.
Topics: Animals; Basilar Artery; Disease Models, Animal; Endothelin-1; Losartan; Male; NG-Nitroarginine Meth | 2020 |
Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodeling.
Topics: Animals; Disease Models, Animal; Echocardiography; Female; Heart Diseases; Iduronidase; Losartan; Ma | 2021 |
The Possible Regulatory Mechanisms of Aqueous, Ethyl Acetate and NHexane Fractions of the Ribes khorassanicum Extract on Acute Hypertension in Rats.
Topics: Acetates; Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiovas | 2021 |
Nox2 signaling and muscle fiber remodeling are attenuated by losartan administration during skeletal muscle unloading.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Hindlimb Suspension; Losartan; Male; Muscl | 2021 |
Angiotensin II type 1 receptor mediates pulmonary hypertension and right ventricular remodeling induced by inhaled nicotine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Disease Models, Animal; E-Cigar | 2021 |
Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Losartan; Male; | 2021 |
Intracranial Pressure During the Development of Renovascular Hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood-Brain Barrier; Disease Models, Animal; Hyper | 2021 |
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Arterial Pressure; Captopril; Dis | 2021 |
Prevention of hemorrhage-induced renal vasoconstriction and hypoxia by angiotensin II type 1 receptor antagonism in pigs.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Hemodynamics; Hemorrhage; | 2021 |
Acetic acid treatment causes renal inflammation and chronic kidney disease in mice.
Topics: Acetic Acid; Animals; Creatine; Disease Models, Animal; Gene Expression; Interleukin-1beta; Kidney; | 2021 |
Impaired right and left ventricular function and relaxation induced by pulmonary regurgitation are not reversed by tardive antifibrosis treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Fibrosis | 2021 |
Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Dise | 2021 |
Losartan Protects Podocytes against High Glucose-induced Injury by Inhibiting B7-1 Expression.
Topics: Angiotensin II; Animals; Apoptosis; B7-1 Antigen; Class I Phosphatidylinositol 3-Kinases; Diabetic N | 2021 |
Megalin-mediated albumin endocytosis in renal proximal tubules is involved in the antiproteinuric effect of angiotensin II type 1 receptor blocker in a subclinical acute kidney injury animal model.
Topics: Acute Kidney Injury; Albumins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cel | 2021 |
Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial | 2021 |
Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cerebral Smal | 2021 |
Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Bleomycin; Diseas | 2021 |
Renoprotective and therapeutic effects of newly water, ethanol, and butanol ginseng fractions in hypertensive and chronic kidney disease with L-NAME.
Topics: Animals; Butanols; Disease Models, Animal; Ethanol; Female; Gas Chromatography-Mass Spectrometry; Ge | 2021 |
Effects of peripherally and centrally applied ghrelin on the oxidative stress induced by renin angiotensin system in a rat model of renovascular hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Pressure; Disease Models, Animal; Ghrelin; Heart | 2017 |
Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis.
Topics: Anesthesia, Inhalation; Anesthetics, Inhalation; Angiotensin II Type 1 Receptor Blockers; Animals; B | 2017 |
Innate And Adaptive Immunity are Progressively Activated in Parallel with Renal Injury in the 5/6 Renal Ablation Model.
Topics: Acute Kidney Injury; Adaptive Immunity; Animals; Catheter Ablation; Creatinine; Disease Models, Anim | 2017 |
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2017 |
Crosstalk between the angiotensin and endothelin system in the cerebrovasculature after experimental induced subarachnoid hemorrhage.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Basilar Artery; Disease Models, Anim | 2018 |
Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Cyclooxygenase 2; Disease Models, Animal; Humans; Hypertension; Inflammatio | 2017 |
Cerebrovascular recovery after stroke with individual and combined losartan and captopril treatment of SHRsp.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2017 |
Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography, Three-Di | 2017 |
Calcitriol reduces kidney development disorders in rats provoked by losartan administration during lactation.
Topics: Animals; Biomarkers; Biopsy; Blood Pressure; Body Weight; Breast Feeding; Calcitriol; Chemokine CCL2 | 2017 |
Echocardiographic Strain Analysis for the Early Detection of Myocardial Structural Abnormality and Initiation of Drug Therapy in a Mouse Model of Dilated Cardiomyopathy.
Topics: Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Disease Models, Animal; Echocardiography; | 2017 |
Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.
Topics: Alanine Transaminase; Ammonia; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bip | 2017 |
Inhibition of angiotensin II and calpain attenuates pleural fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bleomycin; Calpain; Carbon; Cell L | 2018 |
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea | 2018 |
Losartan suppresses the kainate-induced changes of angiotensin AT
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Pressure; Como | 2018 |
Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease.
Topics: Acetophenones; Adjuvants, Pharmaceutic; Animals; Antihypertensive Agents; Antioxidants; Blood Pressu | 2018 |
The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Dilatation, Pathologic; Di | 2018 |
Losartan improves renal function and pathology in obese ZSF-1 rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cholesterol; Diabetes Mellitus, Experi | 2018 |
Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Dissection; Blood | 2018 |
Acetone fraction from Sechium edule (Jacq.) S.w. edible roots exhibits anti-endothelial dysfunction activity.
Topics: Acetone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cinnamates; | 2018 |
Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm.
Topics: Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Disease Models, Animal; DNA Methylation; Enhanc | 2018 |
Losartan does not decrease renal oxygenation and norepinephrine effects in rats after resuscitated hemorrhage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Disease Models, Animal; Hemodyn | 2018 |
Comparative effects of avocado oil and losartan on blood pressure, renal vascular function, and mitochondrial oxidative stress in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, | 2018 |
Increased cardiac sympathetic nerve activity in ovine heart failure is reduced by lesion of the area postrema, but not lamina terminalis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Postrema; Arterial Pressure; Baroreflex; Dise | 2018 |
Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2018 |
The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2018 |
Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholestasis; Disease Models, Animal; Kidney; Liver | 2018 |
Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Ascorbic Acid; Behavior, Ani | 2018 |
Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Di | 2018 |
Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2018 |
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Brain; Dise | 2019 |
Losartan attenuates progression of osteoarthritis in the synovial temporomandibular and knee joints of a chondrodysplasia mouse model through inhibition of TGF-β1 signaling pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cartilage, Articular; Cells, Cu | 2019 |
Cerebral and skeletal muscle feed artery vasoconstrictor responses in a mouse model with greater large elastic artery stiffness.
Topics: Angiotensin II; Animals; Cerebral Arteries; Disease Models, Animal; Endothelin-1; Endothelium, Vascu | 2019 |
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Topics: Animals; Antineoplastic Agents; Ascites; Collagen; Disease Models, Animal; Drug Synergism; Extracell | 2019 |
Losartan treatment attenuates the development of neuropathic thermal hyperalgesia induced by peripheral nerve injury in rats.
Topics: Animals; Disease Models, Animal; Ganglia, Spinal; Hyperalgesia; Losartan; Male; Neuralgia; Pain Meas | 2019 |
Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome.
Topics: Animals; beta Catenin; Cardio-Renal Syndrome; Cell Line; Cytokines; Disease Models, Animal; Echocard | 2019 |
Blood pressure lowering effect of Ficus deltoidea var kunstleri in spontaneously hypertensive rats: possible involvement of renin-angiotensin-aldosterone system, endothelial function and anti-oxidant system.
Topics: Angiotensin II; Animals; Antioxidants; Blood Pressure; Captopril; Disease Models, Animal; Drugs, Chi | 2019 |
Losartan, an Angiotensin II Type 1 Receptor Antagonist, Alleviates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain by Inhibiting Inflammatory Cytokines in the Dorsal Root Ganglia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cytokines; Disease Models, Animal; Ganglia, Spinal | 2019 |
Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Behavior, Animal; | 2019 |
Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain; Disease Models, Animal; Epilepsy; Losartan; Male; N | 2019 |
Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer.
Topics: Adenomatous Polyposis Coli Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cel | 2019 |
The role of monocyte chemotactic protein-induced protein 1 (MCPIP1) in angiotensin II-induced macrophage apoptosis and vulnerable plaque formation.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apo | 2019 |
Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Co | 2019 |
Impact of early life AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Biomarkers; Cardiomyopathies; Di | 2019 |
Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Movement; Cells, Cultured; Cicatrix, Hypertro | 2019 |
Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Models, Animal; Kidney Glomerulu | 2013 |
Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Baroreflex; Disease Models, Ani | 2013 |
Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats.
Topics: Adipokines; Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ce | 2013 |
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe | 2013 |
Angiotensin II Type 1 receptor blockade protects endothelium-derived hyperpolarising factor-mediated relaxation in a rat model of monoarthritis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Arthritis, Experimental; Aspirin; Charyb | 2013 |
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2013 |
Antinociceptive response in transgenic mice expressing rat tonin.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; D | 2013 |
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, A | 2013 |
Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Stero | 2013 |
Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Mod | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blo | 2013 |
Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Doxorubicin | 2013 |
Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers | 2013 |
A modified rat model of exercise-induced renal injury and the protective effects of losartan and yishen huanji decoction.
Topics: Acute Kidney Injury; Angiotensin II; Animals; Blood Urea Nitrogen; Disease Models, Animal; Drugs, Ch | 2013 |
Decreased retinal blood flow in experimental colitis; improvement by eye drop administration of losartan.
Topics: Administration, Topical; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Flow | 2013 |
Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis.
Topics: Angiotensin II; Animals; Antioxidants; Cell Line; Class Ia Phosphatidylinositol 3-Kinase; Collagen T | 2013 |
Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Aortic Aneurysm, T | 2013 |
Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury.
Topics: Acute Lung Injury; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; | 2013 |
Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease.
Topics: Angiopoietins; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Dise | 2013 |
Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diab | 2013 |
Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Autonomic Nervous System; Brain | 2013 |
Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Diet, High-Fat; Disease Models, Animal | 2013 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Mal | 2013 |
Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cells, Cultured; Chemokine CCL2; C | 2014 |
Angiotensin type 1 receptor inhibition enhances the extinction of fear memory.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Extinction, Psychological; | 2014 |
Endothelium-dependent relaxation and angiotensin II sensitivity in experimental preeclampsia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Cyclooxygenase 1; Cyclooxyg | 2013 |
Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system.
Topics: Ammonium Compounds; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2014 |
Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Benzoates; Blood | 2013 |
T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contrast Media; Disease Models, Animal; Dose-Respo | 2014 |
Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Avoidance Learning; Blood Pressure; Dendritic Spin | 2014 |
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; | 2014 |
Losartan prevents acquired epilepsy via TGF-β signaling suppression.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Benzamides; Blood-Brain Barrier; Cells, Cult | 2014 |
The effects of Losartan on abdominal wall fascial healing.
Topics: Abdominal Muscles; Abdominal Wall; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, | 2015 |
Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Glucose; Body Weight; Desmin; Di | 2014 |
Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Angiotensin II Type 1 Receptor Blockers; Animals; | 2014 |
Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.
Topics: Amino Acid Transport System y+; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Type 1 | 2014 |
Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats.
Topics: Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Female; Hypertension, Pregnancy-Ind | 2014 |
Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy.
Topics: Actins; Animals; Apoptosis; bcl-2-Associated X Protein; Collagen Type I; Dimethyl Sulfoxide; Disease | 2014 |
Interaction between interleukin-1 beta and angiotensin II receptor 1 in hypothalamic paraventricular nucleus contributes to progression of heart failure.
Topics: Animals; Corticotropin-Releasing Hormone; Disease Models, Animal; Disease Progression; gamma-Aminobu | 2014 |
BMP signaling modulation attenuates cerebral arteriovenous malformation formation in a vertebrate model.
Topics: Activin Receptors, Type I; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents | 2014 |
Losartan improves measures of activity, inflammation, and oxidative stress in older mice.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Catalase; Disease | 2014 |
Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bisoprolol | 2014 |
Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice.
Topics: Animals; Disease Models, Animal; Dystrophin; Exons; Losartan; Male; Mice; Mice, Inbred mdx; Muscle, | 2014 |
Vascular effects of a tripeptide fragment of novokinine in hypertensive rats: Mechanism of the hypotensive action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease M | 2014 |
Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antigens, CD; Cadherins; Constri | 2014 |
Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholinesterase Inhibitors; Chronic Disease; Diseas | 2014 |
Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Dose-Response Relationship | 2014 |
Activation of upregulated angiotensin II type 2 receptors decreases carotid pulse pressure in rats with suprarenal abdominal aortic coarctation.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Aortic Coarctation; Blood Pressure; Blotting, West | 2015 |
Regression of experimental endometriotic implants in a rat model with the angiotensin II receptor blocker losartan.
Topics: Angiotensin Receptor Antagonists; Animals; C-Reactive Protein; Cytokines; Disease Models, Animal; En | 2015 |
Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model.
Topics: Animals; Contrast Media; Disease Models, Animal; Drug Therapy, Combination; Ergocalciferols; Kidney | 2014 |
Blockade of brain angiotensin II type 1 receptor inhibits the development of atrial fibrillation in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; A | 2015 |
Combining use of captopril and losartan attenuates the progress of Streptococcus pneumoniae-induced tympanosclerosis through the suppression of TGF-β1 expression.
Topics: Animals; Blotting, Western; Calcinosis; Calcium; Captopril; Disease Models, Animal; Disease Progress | 2014 |
[Losartan modulates T helper type 1 cells and T helper type 17 cells-mediated responses in a mouse model of lipopolysaccharide-induced acute lung injury].
Topics: Acute Lung Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Enzyme- | 2014 |
Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carc | 2015 |
Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Neutralizing; Aorta, Thoracic; Aortic | 2015 |
Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts, Extrahepatic; Cell Lin | 2015 |
Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A.
Topics: Animals; Apoptosis; Caspase 3; Disease Models, Animal; Ferritins; Humans; Inhibitor of Apoptosis Pro | 2015 |
Effect of angiotensin II on voltage-gated sodium currents in aortic baroreceptor neurons and arterial baroreflex sensitivity in heart failure rats.
Topics: Angiotensin II; Animals; Aorta; Arteries; Baroreflex; Chronic Disease; Disease Models, Animal; Heart | 2015 |
Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Diseases; | 2015 |
Protective effect of Huang Gan formula in 5/6 nephrectomized rats by depressing the Wnt/β-catenin signaling pathway.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Kidney Fun | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Losartan activates sirtuin 1 in rat reduced-size orthotopic liver transplantation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cytoprotection; Disease Models, Animal; | 2015 |
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.
Topics: Animals; Disease Models, Animal; Epidermolysis Bullosa Dystrophica; Immunologic Factors; Inflammatio | 2015 |
Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultur | 2015 |
Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Liver; Liver Cir | 2015 |
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomark | 2015 |
Attenuation of the progression of articular cartilage degeneration by inhibition of TGF-β1 signaling in a mouse model of osteoarthritis.
Topics: Animals; Cartilage, Articular; Chondrogenesis; Disease Models, Animal; Disease Progression; Female; | 2015 |
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Laminin; Losarta | 2015 |
Angiotensin-(1-7) enhances the effects of angiotensin II on the cardiac sympathetic afferent reflex and sympathetic activity in rostral ventrolateral medulla in renovascular hypertensive rats.
Topics: Analysis of Variance; Angiotensin I; Angiotensin II; Animals; Blood Pressure; Disease Models, Animal | 2015 |
Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Hippocampus; Hypertension; Losartan; Male; Neuron | 2016 |
[Preliminary Study of Necroptosis in Cardiac Hypertrophy Induced by Pressure Overload].
Topics: Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Echocardiography; Heart; Losartan; Myocyte | 2015 |
Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma.
Topics: Animals; Disease Models, Animal; Glaucoma; Humans; Intraocular Pressure; Losartan; Mice; Neuroprotec | 2015 |
Norepinephrine-evoked salt-sensitive hypertension requires impaired renal sodium chloride cotransporter activity in Sprague-Dawley rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease M | 2016 |
Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model.
Topics: Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blotting, Western; Disease Models, Animal; | 2015 |
AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn's disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; | 2016 |
Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus.
Topics: 3' Untranslated Regions; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding S | 2016 |
Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model.
Topics: Animals; Biological Transport; Cell Line; Cell Survival; Collagen; Disease Models, Animal; Drug Carr | 2015 |
Mechanisms responsible for postmenopausal hypertension in a rat model: Roles of the renal sympathetic nervous system and the renin-angiotensin system.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Female; Hypertension; Kidn | 2016 |
Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cardiomegaly; Disease Models, An | 2016 |
Therapeutic Effect of Losartan, an Angiotensin II Type 1 Receptor Antagonist, on CCl₄-Induced Skeletal Muscle Injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Carbon Tetrachloride; Disease Models, | 2016 |
Losartan attenuated lipopolysaccharide-induced lung injury by suppression of lectin-like oxidized low-density lipoprotein receptor-1.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Apoptosis; Bronchoalveol | 2015 |
Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Analysis of V | 2016 |
The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Atorvastatin; Cardiovas | 2016 |
Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors.
Topics: Aldosterone; Analysis of Variance; Animals; Disease Models, Animal; Endothelium, Vascular; Hypertens | 2016 |
Neonatal growth restriction-related leptin deficiency enhances leptin-triggered sympathetic activation and central angiotensin II receptor-dependent stress-evoked hypertension.
Topics: Angiotensins; Animals; Blood Pressure; Disease Models, Animal; Growth Disorders; Hypertension; Lepti | 2016 |
Losartan Attenuates Degradation of Aorta and Lung Tissue Micromechanics in a Mouse Model of Severe Marfan Syndrome.
Topics: Animals; Aorta; Disease Models, Animal; Fibrillin-1; Humans; Losartan; Lung; Marfan Syndrome; Mice; | 2016 |
Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblast Gr | 2017 |
Whey peptide Isoleucine-Tryptophan inhibits expression and activity of matrix metalloproteinase-2 in rat aorta.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptides; Disease Models, Anima | 2016 |
Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Discr | 2016 |
Renal denervation significantly attenuates cardiorenal fibrosis in rats with sustained pressure overload.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiomyo | 2016 |
Fermented Red Ginseng Potentiates Improvement of Metabolic Dysfunction in Metabolic Syndrome Rat Models.
Topics: Adipocytes; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Blood Pressur | 2016 |
Effects of losartan on experimental varicocele-induced testicular germ cell apoptosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Disease Models, Animal; Germ Cells; Hum | 2016 |
Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; Disease Progression | 2016 |
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol; | 2016 |
The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries.
Topics: Animals; Cicatrix; Contusions; Disease Models, Animal; Losartan; Mice; Muscle, Skeletal; Myogenic Re | 2016 |
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.
Topics: Analgesics; Analysis of Variance; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensi | 2016 |
Blockade of the renin-angiotensin system prevents acute and immunologically relevant colitis in murine models.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2016 |
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
Topics: Angiotensin Receptor Antagonists; Animals; Craniofacial Abnormalities; Disease Models, Animal; Femal | 2017 |
Exercise training attenuates renovascular hypertension partly via RAS- ROS- glutamate pathway in the hypothalamic paraventricular nucleus.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Dizocilpine Maleate; Excit | 2016 |
Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.
Topics: Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cell Wall; Chemokine CCL2; Disease Models | 2017 |
Physical training associated with Enalapril but not to Losartan, results in better cardiovascular autonomic effects.
Topics: Animals; Antihypertensive Agents; Atropine; Autonomic Nervous System; Baroreflex; Blood Pressure; Co | 2017 |
Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Ce | 2017 |
Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Arrestins; Calcium; Cardiomyopathy, Dilated; Disease | 2017 |
Anti-Fibrotic Effect of Losartan, an Angiotensin II Receptor Blocker, Is Mediated through Inhibition of ER Stress via Up-Regulation of SIRT1, Followed by Induction of HO-1 and Thioredoxin.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Disease Models, Ani | 2017 |
Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Gene Expression Regula | 2017 |
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess | 2017 |
Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2017 |
Losartan Attenuates Scar Formation in Filtering Bleb After Trabeculectomy.
Topics: Actins; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cell Movement; Ce | 2017 |
Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Th | 2008 |
Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Area-specific differences in transmitter release in central catecholaminergic neurons of spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Brain Stem; Catecholamines; Disease Models, Animal; Dopamine beta-Hydroxyla | 2008 |
Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-St | 2008 |
Comparative analysis of renal protein expression in spontaneously hypertensive rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Blotting, Western; Disease Models, Ani | 2008 |
Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiomeg | 2009 |
Mitogen-activated protein kinases mediate upregulation of hypothalamic angiotensin II type 1 receptors in heart failure rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Disease Models, Animal; Heart F | 2008 |
Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 1995 |
Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Down-Regul | 1995 |
Regulation of oxygen utilization by angiotensin II in chronic kidney disease.
Topics: Angiotensin II; Animals; Captopril; Disease Models, Animal; Kidney Diseases; Losartan; Nitric Oxide | 2009 |
Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
[Angiotensin II type 2 receptor expression and its modulation in angiotensin II induced acute lung injury in rat].
Topics: Acute Lung Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, | 2008 |
Regression of glomerular injury by losartan in experimental diabetic nephropathy.
Topics: Animals; Antihypertensive Agents; Cell Proliferation; Diabetic Nephropathies; Disease Models, Animal | 2009 |
Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bl | 2009 |
Involvement of prolylcarboxypeptidase in the effect of rutaecarpine on the regression of mesenteric artery hypertrophy in renovascular hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pre | 2009 |
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression.
Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr | 2009 |
Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Conver | 2009 |
Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Diabetes Mellitus, Experimental | 2009 |
Battle against the renin-angiotensin system: help from an unexpected party.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Disease Models, Animal; Di | 2009 |
Cardiovascular and autonomic phenotype of db/db diabetic mice.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; B | 2009 |
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Disease M | 2009 |
Effects of apocynin and losartan treatment on renal oxidative stress in a rat model of calcium oxalate nephrolithiasis.
Topics: Acetophenones; Analysis of Variance; Angiotensin II; Animals; Antioxidants; Biopsy, Needle; Blotting | 2009 |
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseas | 2009 |
Antihypertensive effects of central ablations in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Baroreflex; Blood Pressur | 2009 |
Noninvasive imaging of angiotensin receptors after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Biomarkers; Disease | 2008 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri | 2009 |
Involvement of central angiotensin II type 1 receptors in LPS-induced systemic vasopressin release and blood pressure regulation in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Conver | 2009 |
Cardiac secretion of atrial and brain natriuretic peptides in acute ischaemic heart failure in pigs: effect of angiotensin II receptor antagonism.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; A | 1997 |
AT(1) receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats.
Topics: Amidohydrolases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arginase; Arterio | 2009 |
Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; A | 2009 |
Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, | 2009 |
Endogenous angiotensin II modulates nNOS expression in renovascular hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclic N-Oxides; Disease Models, A | 2009 |
Effect of centrally administered losartan on gastric and duodenal ulcers in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Ulcer Agents; Brain; Disease Models, Animal; | 2009 |
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidiur | 2009 |
Comparative antihypertensive activities of losartan and HM70186 in rats with hepatic dysfunction.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Carbon Tetra | 2009 |
Renal dysfunction potentiates foam cell formation by repressing ABCA1.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Ca | 2009 |
Lowering arterial pressure delays the oxidative stress generation in a renal experimental model of hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Disease Models, Animal; Heme Oxyg | 2009 |
Enhanced angiotensin-mediated excitation of renal sympathetic nerve activity within the paraventricular nucleus of anesthetized rats with heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, An | 2009 |
Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter.
Topics: Analgesics; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Disease Mode | 2009 |
Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Pressure; B | 2009 |
Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT(2) receptor.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Re | 2009 |
Effects of losartan, HO-1 inducers or HO-1 inhibitors on erectile signaling in diabetic rats.
Topics: Animals; Antihypertensive Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Disease Models, | 2009 |
Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic V | 2009 |
Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Aneurysm, Tho | 2009 |
Angiotensin II and CRF receptors in the central nucleus of the amygdala mediate hemodynamic response variability to cocaine in conscious rats.
Topics: Amygdala; Angiotensin II Type 1 Receptor Blockers; Animals; Cocaine; Cocaine-Related Disorders; Cons | 2010 |
The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Autoantibodies; CHO Cells; Crice | 2009 |
[Effect of renin-angiotensin system inhibitors on the density of myocardial, pericardial and pulmonary rat mast cells under experimental heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Cou | 2009 |
Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Cispla | 2009 |
Cardiovascular interactions between losartan and fructose in mice.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Cardiovas | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Blood Glucose | 2010 |
Role of caveolin and heat shock protein 70 interaction in the antioxidative effects of an angiotensin II type 1 receptor blocker in spontaneously hypertensive rats proximal tubules.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Caveolin 1; Disease Models, Animal; | 2010 |
Caveolin-1 and Hsp70 interaction in microdissected proximal tubules from spontaneously hypertensive rats as an effect of Losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Caveolin 1; Cell Fractionation; Cell | 2010 |
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2010 |
Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxida | 2010 |
Effects of the AT(1) receptor blocker losartan and the calcium channel blocker benidipine on the accumulation of lipids in the kidney of a rat model of metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Channel Blo | 2010 |
Glutamatergic receptor activation in the rostral ventrolateral medulla mediates the sympathoexcitatory response to hyperinsulinemia.
Topics: Analysis of Variance; Animals; Blotting, Western; Disease Models, Animal; Excitatory Amino Acid Anta | 2010 |
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Crea | 2010 |
Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Diseas | 2010 |
Astroglia are a possible cellular substrate of angiotensin(1-7) effects in the rostral ventrolateral medulla.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Astrocytes; Biosens | 2010 |
Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arthritis, Experi | 2010 |
Losartan increases NO release in afferent arterioles during regression of L-NAME-induced renal damage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterioles; Blood Pressur | 2010 |
Different protective actions of losartan and tempol on the renal inflammatory response to acute sodium overload.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Blood Pressu | 2010 |
Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
Effect of losartan on vascular function in fructose-fed rats: the role of perivascular adipose tissue.
Topics: Acetylcholine; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Di | 2010 |
Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system.
Topics: Angiotensin I; Animals; Cells, Cultured; Chemokine CCL2; Collagen Type I; Connective Tissue Growth F | 2010 |
Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice.
Topics: Analysis of Variance; Animals; Diet, Sodium-Restricted; Disease Models, Animal; Hypertension; Immuno | 2010 |
Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrophy; Ceruletide; Colla | 2010 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticonvulsants; Behavior, Animal; Benzimidazoles; | 2010 |
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone | 2010 |
Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2010 |
Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticonv | 2010 |
Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Press | 2010 |
In dystrophic hamsters losartan affects control of ventilation and dopamine D1 receptor density.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Corpus Striatum; Cricetinae; Disease | 2010 |
Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries.
Topics: Acetylcholine; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bloo | 2010 |
Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Catalase; Combined Modality Therapy; Disease Model | 2010 |
Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.
Topics: Amides; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Mode | 2010 |
Mitigating effects of captopril and losartan on lung histopathology in a rat model of fat embolism.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Disease Models, Animal; Drug Therapy, | 2011 |
Losartan reduces mortality in a genetic model of heart failure.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Calsequestri | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.
Topics: Animals; Bromodeoxyuridine; Cardiomyopathy, Hypertrophic; Cell Proliferation; Disease Models, Animal | 2010 |
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.
Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; | 2010 |
The effect of anti-hypertensive drugs on the obstructive pancreatitis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2010 |
Chronic infusion of angiotensin receptor antagonists in the hypothalamic paraventricular nucleus prevents hypertension in a rat model of sleep apnea.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2011 |
Protective actions of des-aspartate-angiotensin I in mice model of CEES-induced lung intoxication.
Topics: Angiotensin I; Animals; Bronchoalveolar Lavage Fluid; Dinoprostone; Disease Models, Animal; Dose-Res | 2011 |
Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Atorvastatin; Base Sequence; Calcium C | 2010 |
Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies.
Topics: Administration, Oral; alpha-Cyclodextrins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2011 |
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling.
Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, New | 2011 |
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
Topics: Animals; Anthracenes; Aorta; Aortic Aneurysm; Diphenylamine; Disease Models, Animal; Disease Progres | 2011 |
Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2011 |
[Experimental study of (Pro)renin receptor siRNA inhibiting retinal neovascularization].
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Movement; Cell Proliferation; Disease Models, | 2011 |
Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Blood Pressure; | 2011 |
Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin.
Topics: Angiotensin II; Animals; Cholesterol; Disease Models, Animal; Doxorubicin; Endothelin-1; Fluorescent | 2011 |
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Topics: Acyl Coenzyme A; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Anticholest | 2011 |
Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cytochrome P-450 CYP1A1; Disease M | 2011 |
Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.
Topics: Aging; Analysis of Variance; Animals; Arterial Pressure; Diastole; Disease Models, Animal; Dose-Resp | 2012 |
Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anthelmintics; Disease Models, Animal; Drug Therap | 2011 |
Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: role for CAPON and Ang II.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anima | 2011 |
Mechanisms underlying altered extracellular nucleotide-induced contractions in mesenteric arteries from rats in later-stage type 2 diabetes: effect of ANG II type 1 receptor antagonism.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 1; Cyclooxy | 2011 |
Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pre | 2011 |
Pravastatin reduces Marfan aortic dilation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Dilatation, Pathologic; Di | 2011 |
Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiotonic Agents; Coronary Circulation; Disease Models, | 2012 |
Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blocker | 2011 |
Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Female; Ligation; Losartan | 2012 |
Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Animals; Bronchoal | 2011 |
Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2012 |
miR-29b participates in early aneurysm development in Marfan syndrome.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Apoptosis; Ap | 2012 |
Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Disease Models, Animal; Humans; Losarta | 2012 |
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, A | 2012 |
Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Coarctation; Benzazepines; Cell Membrane; C | 2012 |
Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antibodies; Benzimidazoles; Benzoates; C | 2012 |
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Colitis; Disease Models, Animal; Disease Progressi | 2012 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2012 |
Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antibodies, Monoclonal; Antibodi | 2012 |
Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoradiography; Baroreflex; Blood Pressure; Disea | 2012 |
Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Be | 2012 |
Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome.
Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Blood Pre | 2012 |
Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice.
Topics: Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2012 |
ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1.
Topics: AIDS-Associated Nephropathy; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Anima | 2012 |
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Be | 2012 |
Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice.
Topics: 3T3-L1 Cells; Adipocytes; Adiposity; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor B | 2012 |
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; | 2012 |
Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats.
Topics: Animals; Disease Models, Animal; Losartan; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Renal I | 2012 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasent | 2012 |
Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Disease Models, Animal; Fluores | 2012 |
Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Captopril; Cardiovascular S | 2012 |
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Biomarkers; Blood P | 2013 |
Angiotensin AT(1) receptor inhibition-induced apoptosis by RhoA GTPase activation and pERK1/2 signaling pathways in neonatal obstructive nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Di | 2012 |
Angiotensin II type 2 receptor-mediated inhibition of NaCl absorption is blunted in thick ascending limbs from Dahl salt-sensitive rats.
Topics: Absorption; Angiotensin II Type 2 Receptor Blockers; Animals; Disease Models, Animal; Hypertension; | 2012 |
The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
Topics: Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Collagen Type III; Disease Models, Animal | 2012 |
β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury.
Topics: Acute Coronary Syndrome; Acute Disease; Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 | 2012 |
Upregulation of junctional adhesion molecule-A is a putative prognostic marker of hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial | 2012 |
A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Ascorbic Acid; Biomarkers; Blood Pro | 2012 |
Oxidative stress exaggerates skeletal muscle contraction-evoked reflex sympathoexcitation in rats with hypertension induced by angiotensin II.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Afferent Pathways; Angiotensin II; Angiotens | 2013 |
The neuroprotective effect of losartan through inhibiting AT1/ASK1/MKK4/JNK3 pathway following cerebral I/R in rat hippocampal CA1 region.
Topics: Analysis of Variance; Animals; Brain Ischemia; CA1 Region, Hippocampal; Cell Death; Disease Models, | 2012 |
Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteries; Arter | 2013 |
Exercise training and losartan improve endothelial function in heart failure rats by different mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biological Factors; Disease Models, Animal; Dose-R | 2013 |
Intracerebroventricular losartan infusion modulates angiotensin II type 1 receptor expression in the subfornical organ and drinking behaviour in bile-duct-ligated rats.
Topics: Animals; Bile Ducts; Disease Models, Animal; Drinking; Drinking Behavior; Infusions, Intraventricula | 2013 |
Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Communication; Disease Models | 2013 |
Modulation of C16:0-ceramide in hypertrophied immature hearts by losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aortic Valve Stenosis; Cardiomeg | 2013 |
Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cyclospo | 2002 |
Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure.
Topics: Age Factors; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Bod | 2002 |
Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Diseas | 2002 |
Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2002 |
Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2002 |
The effects of sarmesin, an Angiotensin II analogue on seizure susceptibility, memory retention and nociception.
Topics: Angiotensin II; Animals; Avoidance Learning; Disease Models, Animal; Drug Combinations; Imidazoles; | 2003 |
Does losartan prevent cerebral edema? A preliminary study using a vascular compartment model.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Proteins; Brain Edema; Capillary Permeability; Cats | 2003 |
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2003 |
NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Blood Pressure; Disease Model | 2003 |
Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Bu | 2003 |
Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Disease | 2003 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2003 |
Losartan and atenolol on hypertension induced by adenosine receptor blockade.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 2 Receptor Blocker | 2003 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
Effects of losartan and enalapril at different doses on cardiac and renal interstitial matrix in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Collagen; Disease Models, Animal; Dos | 2003 |
The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1beta response in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Ani | 2004 |
Effect of losartan microinjections into the NTS on the cardiovascular components of chemically evoked reflexes in a rabbit model of acute heart ischemia.
Topics: Acute Disease; Animals; Capsaicin; Chemoreceptor Cells; Disease Models, Animal; Female; Losartan; Ma | 2003 |
Gender-specific genetic determinants of blood pressure and organ weight: pharmacogenetic approach.
Topics: Animals; Blood Pressure; Body Weight; Chromosomes, Mammalian; Crosses, Genetic; Disease Models, Anim | 2003 |
Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 2004 |
Effect of angiotensin II type 2 receptor blockade on activation of mitogen-activated protein kinases after ischemia-reperfusion in isolated working rat hearts.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiac O | 2003 |
Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon.
Topics: Allopurinol; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Capillaries; Captopr | 2004 |
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2004 |
[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Fibrosis; Losartan; Myoca | 2004 |
Evidence of the role of angiotensin AT(1) receptors in remote renal preconditioning of myocardium.
Topics: Angiotensin II; Animals; Blood Pressure; Body Temperature; Coronary Vessels; Disease Models, Animal; | 2004 |
Losartan-induced attenuation of blood pressure in L-NAME hypertensive rats is associated with reversal of the enhanced expression of Gi alpha proteins.
Topics: Adenylyl Cyclases; Animals; Antihypertensive Agents; Blood Pressure; Colforsin; Disease Models, Anim | 2004 |
[Relativity of nuclear factor-kappaB (P65/Rel-A) and angiotensin II type 1 receptor expression in early stage of lesions of adriamycin nephrosis in young rats and the effects of intervention].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibiot | 2004 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Ex | 2004 |
Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2004 |
Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure.
Topics: Animals; Atenolol; Disease Models, Animal; Kidney; Kidney Cortex; Kidney Failure, Chronic; Losartan; | 2004 |
Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system.
Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Biomarkers; Blood Pressure; Cyclic N-Ox | 2004 |
Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Disease Models, Animal; | 2004 |
Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Topics: Adenylyl Cyclases; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Enalap | 2004 |
Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Northern; Cyclosporine; Disease Models, | 2005 |
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Combined Modality Therapy; Disease | 2005 |
Morphological changes in experimental postischemic rat kidney. A pilot study.
Topics: Animals; Antihypertensive Agents; Basement Membrane; Blood Pressure; Disease Models, Animal; Ischemi | 2005 |
An extremely high dose of losartan affords superior renoprotection in the remnant model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Anima | 2005 |
[Myocardial remodeling after experimental acute myocardial infarction in rats. Effect of renin-angiotensin-aldosterone blockade].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease | 2005 |
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; K | 2005 |
Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2005 |
Histopathological and ultrastructural effects of Losartan on embryonic rat kidney.
Topics: Animals; Apoptosis; Disease Models, Animal; Epithelial Cells; Female; Glomerular Basement Membrane; | 2005 |
Regression of existing glomerulosclerosis by inhibition of aldosterone.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephri | 2005 |
Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role for oxidative stress.
Topics: Acetylcysteine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aort | 2006 |
Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Cardiovascular Sys | 2006 |
Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Choleste | 2006 |
Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Artery Thrombosis; Carotid | 2005 |
Renal vascular responses in an experimental model of preeclampsia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Coarctation; Blood Pressure | 2005 |
Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease | 2006 |
Increased vascular angiotensin II binding capacity and ET-1 release in young cardiomyopathic hamsters.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Binding, Competit | 2006 |
Medicine. Old drug, new hope for Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Clin | 2006 |
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta; Ao | 2006 |
Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Los | 2006 |
[Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl | 2006 |
Reduction of salt sensitivity in stroke-prone spontaneously hypertensive rats administered an AT1 receptor antagonist during suckling.
Topics: Albuminuria; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; An | 2006 |
Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE-/- mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Valve Stenosis; Atherosclerosis; Blood Pres | 2006 |
The role of angiotensin II in stress urinary incontinence: A rat model.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2007 |
Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor.
Topics: Adenoviridae; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Age | 2007 |
Increased sympathetic activity in rats submitted to chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Chronic Disease; Disease Models, A | 2007 |
Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice.
Topics: Albuminuria; Animals; Antihypertensive Agents; Benzamides; Diabetic Nephropathies; Disease Models, A | 2007 |
Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood | 2007 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Analysis of antihypertensive drugs in the heart of animal models: a proteomic approach.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Hea | 2007 |
Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arthritis, Rheumatoid; Carrageenan; Disease Models | 2007 |
Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodi | 2007 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica | 2007 |
Enhanced activity of ventricular Na+-HCO3- cotransport in pressure overload hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Disease Models, Animal; Heart Ve | 2007 |
Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Choline Deficiency; Disease Models, Animal; Fatty | 2007 |
Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Movement; Cell Proliferation; | 2007 |
Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Inflammatio | 2007 |
Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Angiotensin II Type 1 Receptor Blockers; Animals; Cy | 2007 |
Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiotonic Agents; | 2007 |
Losartan and its interaction with copper(II): biological effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Binding, Competitive; Cations, Divalent; Cell Prolif | 2007 |
Losartan attenuates ventilator-induced lung injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Apoptosis; Bronchoalveolar Lavage | 2008 |
Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship | 2007 |
Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; | 2007 |
Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2008 |
Effects of angiotensin II blockade on the development of autoimmune thyroiditis in nonobese diabetic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodie | 2007 |
Microvascular transport model predicts oxygenation changes in the infarcted heart after treatment.
Topics: Angiogenesis Inducing Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Computer Simulation; | 2007 |
ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin.
Topics: Angiotensin II; Animals; Apoptosis; Bradykinin; Bronchoalveolar Lavage Fluid; Captopril; Disease Mod | 2008 |
The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Pressure; D | 2008 |
[Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri | 2007 |
The role of angiotensin II receptor-1 blockade in the hypoxic pulmonary vasoconstriction response in newborn piglets.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Animals, Newborn | 2008 |
Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Aqueous Humor; Autoimmune Diseases; | 2008 |
Calcitonin gene-related Peptide-mediated depressor effect and inhibiting vascular hypertrophy of rutaecarpine in renovascular hypertensive rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Vessels; Calcitonin Ge | 2007 |
Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2008 |
Cardiovascular reactivity after blockade of angiotensin AT1 receptors in the experimental model of tilting test in conscious rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Disease | 2008 |
Persistent hypertension and progressive renal injury induced by salt overload after short term nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease Models, Animal; D | 2007 |
Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Cell Migration Inhibition; Diseas | 2007 |
Comparison of the cardioprotective effects of cardos and losartan in rats with experimental chronic cardiac insufficiency.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Cardiotonic Agents; Chronic Disease; D | 2007 |
Hyperinsulinemic rats are normotensive but sensitized to angiotensin II.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2008 |
Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Collagen; Combined Modality Therapy; Disease Model | 2008 |
Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2008 |
Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis.
Topics: Acidosis; Ammonia; Ammonium Chloride; Angiotensin II; Animals; Disease Models, Animal; Kidney Cortex | 2008 |
Meconium increases type 1 angiotensin II receptor expression and alveolar cell death.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosi | 2008 |
Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart.
Topics: Aldehydes; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzylamines; D | 2008 |
AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Female; Hypertension, Rena | 2008 |
Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease | 2008 |
Effects of long-term losartan and L-arginine treatment on haemodynamics, glomerular filtration, and SOD activity in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Abdominal; Arginin | 2008 |
Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bone Marrow Cells; Cell Differentiation; Disease M | 2008 |
Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; | 2008 |
Oestrogenic influence on brain AT1 receptor signalling on the thirst and sodium appetite in osmotically stimulated and sodium-depleted female rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Brain; C | 2008 |
Administration of angiotensin II in the paraventricular nucleus protects gastric mucosa from ischemia-reperfusion injury.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease M | 2008 |
Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cyclic N-Oxides; Cytokines; Disease Models, Animal | 2008 |
AT1 receptor participates in the cardiac hypertrophy induced by resistance training in rats.
Topics: Adaptation, Physiological; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blottin | 2008 |
Upregulation of interleukin-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Disease Models, A | 2008 |
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2008 |
Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1995 |
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inh | 1994 |
Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood | 1995 |
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; | 1994 |
Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Captopril; Cardiomyopathy, Dilated; D | 1995 |
Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1995 |
Alterations in glomerular dynamics in congenital, unilateral hydronephrosis.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Disease Models | 1994 |
EXP597, a nonpeptide angiotensin II receptor antagonist with high affinities for the angiotensin AT1 and AT2 receptor subtypes.
Topics: Administration, Oral; Adrenal Cortex; Adrenal Medulla; Angiotensin Receptor Antagonists; Animals; Ao | 1994 |
Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl | 1994 |
Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; | 1993 |
Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.
Topics: Anesthesia; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Coronar | 1993 |
Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1993 |
[Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihyperten | 1995 |
Survival after myocardial infarction in rats: captopril versus losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1996 |
Role of aldosterone in the remnant kidney model in the rat.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biph | 1996 |
The role of the renin-angiotensin system in cisplatin nephrotoxicity.
Topics: Angiotensin II; Animals; Antineoplastic Agents; Biphenyl Compounds; Blood Urea Nitrogen; Cisplatin; | 1995 |
Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits.
Topics: Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; | 1996 |
Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose | 1997 |
Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 1997 |
Actions of angiotensin and lisinopril on thalamic somatosensory neurons in normotensive, non-transgenic and hypertensive, transgenic rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; An | 1997 |
Interaction of angiotensin II and TGF-beta 1 in the rat remnant kidney.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Culture Techniques; Disease Models, Animal; Enzyme | 1997 |
Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model.
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Area Under Curve; Blood Pr | 1997 |
Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1997 |
Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 1997 |
Studies on nonpeptide angiotensin II receptor antagonists. IV. Synthesis and biological evaluation of 4-acrylamide-1H-imidazole derivatives.
Topics: Acrylamides; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Bl | 1998 |
Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Bosentan; Disease Models, | 1998 |
Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Disease Models, Animal; Hyperten | 1998 |
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Chronic Disease; Dihydropyridines; Disease | 1998 |
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Abdominal; Aortic | 1999 |
Downregulation of neuronal nitric oxide synthase in the rat remnant kidney.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Blotting, Western; Cell Nucleus; Cu | 1999 |
Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Platelets; Disease Models, Animal; Fibrinolytic Age | 1999 |
Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidepressive Agents; Ant | 1999 |
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhyt | 1999 |
Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats : possible role in renoprotection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Transformed; Disease Mo | 2000 |
Interaction between AT1 and alpha1-adrenergic receptors in cardiomyopathic hamsters.
Topics: Angiotensin I; Animals; Antihypertensive Agents; Aorta; Cardiomyopathies; Cricetinae; Disease Models | 2000 |
Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice.
Topics: Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; | 1999 |
Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2000 |
Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Diseases; Heart Ventricles; Hypertens | 2000 |
Angiotensin II infused intrarenally causes preglomerular vascular changes and hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Respo | 2000 |
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co | 2001 |
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co | 2001 |
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co | 2001 |
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co | 2001 |
The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure.
Topics: Acetamides; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Function, Left; Diasto | 2001 |
AT1 receptor antagonism enhances angiotensin-II-facilitated carrageenan-induced paw edema.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Acute and chronic alterations in blood pressure variability following experimental subarachnoid haemorrhage.
Topics: Animals; Blood Pressure; Disease Models, Animal; Epilepsies, Partial; Losartan; Male; Rats; Rats, Wi | 2001 |
Sexual dimorphism in the response of thoracic aorta from SHRs to losartan.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Disease Models, An | 2000 |
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2001 |
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu | 2001 |
Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Apolipoproteins E; Arteriosclerosi | 2001 |
The haemodynamic effects of losartan after right ventricle infarct in young pigs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Female; Heart Ventricles; | 2001 |
Structural changes in the kidney induced by coarctation hypertension.
Topics: Animals; Antihypertensive Agents; Aortic Coarctation; Body Weight; Disease Models, Animal; Heart Rat | 2001 |
Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |
Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Blood Pressure; Blotting | 2001 |
[In contrast to captopril and enalapril, losartan does not increase mortality of gerbils after carotid ligation].
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Su | 2001 |
Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Cardiomegaly; Circadian | 2001 |
Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2001 |
Effect of angiotensin type I-receptor blockade on left ventricular remodeling in pressure overload hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography; | 2001 |
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; B | 2001 |
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Disease Mode | 2001 |
Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure.
Topics: Angiotensins; Animals; Anti-Arrhythmia Agents; Calcium Signaling; Cardiomegaly; Cell Separation; Cel | 2002 |
Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.
Topics: Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Ar | 2002 |
Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood | 1996 |
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Capto | 2002 |
Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Disease Mo | 2002 |
Effects of renin-angiotensin system blockade in guinea pigs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Bradykinin; C | 1992 |
Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Disease Models, Animal; Dogs; Dose-Respon | 1991 |
Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure.
Topics: Administration, Oral; Angiotensin II; Animals; Body Weight; Captopril; Cardiac Output, Low; Complian | 1991 |
DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cerebrovascular Disorders; D | 1991 |